documents incorporated reference specified portions registrant 's proxy statement filed commission pursuant regulation connection registrant 's annual meeting stockholders held may incorporated reference part iii report based closing price per share june excludes shares registrant 's common stock held executive officers directors stockholders whose ownership exceeds registrant 's common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registrantgilead sciences inc annual report table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item mine safety disclosures part ii item market registrant 's common equity related stockholder matters issuer purchases equity securities item selected financial data item management 's discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules signatures rights various trademarks copyrights trade names used business including following gilead gilead sciences stribild complera eviplera truvada viread hepsera ambisome emtriva vistide letairis volibris ranexa cayston rapiscan atripla registered trademark belonging bristolmyers squibb gilead sciences llc lexiscan registered trademark belonging astellas us llc macugen registered trademark belonging eyetech inc sustiva registered trademark bristolmyers squibb pharma company tamiflu registered trademark belonging hoffmannla roche inc report also includes trademarks service marks trade names companiesthis annual report including section entitled management 's discussion analysis financial condition results operations contains forwardlooking statements regarding future events future results subject safe harbors created securities act amended securities act securities exchange act amended exchange act words expect anticipate target goal project hope intend plan believe seek estimate continue may could might variations words similar expressions intended identify forwardlooking statements addition statements statements historical fact forward looking statements including statements regarding overall trends operating cost revenue trends liquidity capital needs statements expectations beliefs future plans strategies anticipated events trends similar expressions based forwardlooking statements current expectations future events statements guarantees future performance involve risks uncertainties assumptions difficult predict actual results may differ materially suggested forwardlooking statements various reasons including identified risk factors beginning given risks uncertainties cautioned place undue reliance forward looking statements forwardlooking statements included report made date hereof except required federal securities laws rules regulations securities exchange commission sec undertake specifically decline obligation update statements publicly announce results revisions forwardlooking statements distribution report whether result new information future events changes assumptions otherwise part item business overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery experimental drug candidate seek improve care patients suffering lifethreatening diseases around world gilead 's primary areas focus include human immunodeficiency virus hiv liver diseases hepatitis b virus hbv hepatitis c virus hcv serious cardiovascular respiratory conditions oncologyinflammation headquartered foster city california operations north america europe asia continue add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategy highlights past year executed strategy bring bestinclass drugs market completed acquisition pharmasset inc pharmasset accelerated timeline develop first alloral hcv regimen entered agreement acquire ym biosciences inc ym biosciences closed february expands growing oncologyinflammation pipeline also expanded single tablet regimen product offerings treatment hiv launch stribild united states combines four medicines oncedaily single tablet regimen expanded worldwide access compleraeviplera available countries also advanced research development pipeline active phase clinical trials end filed marketing applications two components stribild elvitegravir cobicistat single agents hiv program substantial portion revenues derived six marketed hiv products continued forefront advancing hiv treatment development new single tablet regimens longterm goal ensure hiv patients option choose single tablet regimen right single tablet regimens allow patients adhere fully suppressive course therapy easily consistently critical successful management disease continue focus development new hiv medicines coformulations launch stribild united states compleraeviplera atripla three single tablet regimens available submitted marketing applications united states european union elvitegravir integrase inhibitor treatment hiv infection treatmentexperienced adults cobicistat pharmacoenhancing boosting agent increases blood levels allow oncedaily dosing certain hiv medicines us food drug administration fda set target review dates april prescription drug user fee act also obtained fda approval oncedaily oral truvada combination safer sex practices preexposure prophylaxis prep reduce risk hiv infection among uninfected adults truvada first antiretroviral approved prevention hiv infection adults also made important progress clinical development tenofovir alafenamide taf formerly known gs phase study showed taf efficacious onetenth dose viread provides potential safety advantages based results phase trial evaluating single tablet regimen taf elvitegravir cobicistat emtricitabine treatment hiv infection treatmentnave adults commenced earlier year agreement janssen rd ireland janssen also conducting phase trials evaluating single tablet regimen taf cobicistat darunavir emtricitabine treatment hiv infection hcv program january acquired pharmasset acquisition acquired sofosbuvir formerly known gs investigational nucleotide analog acts inhibit replication hcv product candidate currently phase phase clinical trials hcv therapeutic market continues vastly underserved due limitations available therapies small fraction individuals infected hcv diagnosed even smaller fraction patients treated prior may first protease inhibitors approved half patients responded standard care combination pegylated interferon pegifn ribavirin addition protease inhibitors standard care resulted incremental response rates patients genotype infection however regimen causes substantial side effects fatigue bone marrow suppression potentially debilitating rash anemia neuropsychiatric effects discontinuation rates triple therapy combinations significantly increased expect receive significant amount data clinical trials evaluating sofosbuvir alone combination direct acting antivirals hcvinfected individuals across genotypes initial new drug application nda sofosbuvir supported four phase studies named fission positron fusion neutrino fission study genotype treatment nave patients comparing weeks sofosbuvir ribavirin current standard care weeks treatment interferon ribavirin positron compares weeks treatment sofosbuvir ribavirin genotype interferon intolerantineligible patients placebo fusion study explores weeks duration treatment sofosbuvir ribavirin among genotype treatmentexperienced patients neutrino single arm study evaluating week course sofosbuvir interferon ribavirin genotype infectedpatients announced data four studies late first quarter anticipate filing regulatory approvals sofosbuvir second quarter expect initial indication weeks treatment sofosbuvir ribavirin treatmentnaive interferonintolerant experienced genotype patients weeks treatment sofosbuvir peg ifn ribavirin treatmentnaive genotype patients parallel also advancing fixeddose combination sofosbuvir ledipasvir formerly gs treatment genotype patients nda fixed dose combination sofosbuvir ledipasvir supported two clinical trials first study named ion evaluates fixeddose combination sofosbuvir ledipasvir without ribavirin either weeks treatmentnave genotype infected patients pending review results two week arms initial enrollment patients second quarter expect enroll additional patients ion study assess fixed dose combination sofosbuvir ledipasvir total individuals january also started screening patients second phase study named ion evaluates fixeddose combination ribavirin weeks without ribavirin weeks therapy among treatmentexperienced genotype hcv patients see risk factor entitled public announcement data clinical studies evaluating sofosbuvir fixed dose combination sofosbuvir ledipasvir hcvinfected patients likely cause significant volatility stock price oncologyinflammation last five years worked advance oncology franchise idelalisib pik delta inhibitor antibody formerly known gs advanced five phase trials compound evaluated treatment chronic lymphocytic leukemia indolent nonhodgkin 's lymphoma simtuzumab monoclonal antibody formerly known gs evaluated various phase trials treatment myelofibrosis colorectal cancer pancreatic cancer acquisition ym biosciences acquired momelotinib gs formerly known cyt momelotinib jak inhibitor evaluated phase clinical trials treatment myelofibrosis expect advance compound phase trials later products hivaids stribild elvitegravir mgcobicistat mgemtricitabine mgtenofovir disoproxil fumarate mg complete oncedaily single tablet regimen hiv infection treatmentnaive adults stribild combines four compounds one daily tablet approved fda august filed marketing authorization application stribild european medicines agency ema december expect receive approval european commission second quarter compleraeviplera oral formulation dosed day treatment hiv infection treatmentnave adults product marketed united states complera europe eviplera second complete single tablet regimen treatment hiv fixeddose combination antiretroviral medications viread tenofovir disoproxil fumarate emtriva emtricitabine janssen 's nonnucleoside reverse transcriptase inhibitor edurant rilpivirine atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg oral formulation dosed day treatment hiv infection adults atripla first oncedaily single tablet regimen hiv intended stand alone therapy combination antiretrovirals fixeddose combination antiretroviral medications viread emtriva bristol myerssquibb company 's non nucleoside reverse transcriptase inhibitor sustiva efavirenz truvada emtricitabine tenofovir disoproxil fumarate oral formulation dosed day part combination therapy treat hiv infection adults fixeddose combination antiretroviral medications viread emtriva fda also approved truvada combination safer sex practices reduce risk sexually acquired hiv infection adults high risk strategy called preexposure prophylaxis prep viread oral formulation nucleotide analog reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection patients years age older european commission also approved use viread combination antiretroviral agents treatment hiv infected pediatric patients aged less years nucleoside reverse transcriptase inhibitor resistance toxicities precluding use first line pediatric agents viread also approved treatment chronic hbv adults emtriva oral formulation nucleoside analog reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults united states europe emtriva also available oral solution approved part combination therapy treat hiv infection children liver disease viread oral formulation nucleotide analog reverse transcriptase inhibitor dosed day treatment chronic hbv adults compensated decompensated liver disease licensed glaxosmithkline inc gsk rights commercialize viread treatment chronic hbv china japan saudi arabia european commission approved use viread treatment chronic hbv infection adolescent patients aged less years compensated liver disease evidence immune active disease viread also approved treatment hiv infection patients years age older combination antiretroviral agents hepsera adefovir dipivoxil oral formulation nucleotide analog polymerase inhibitor dosed day treat chronic hbv patients years age older licensed gsk rights commercialize hepsera treatment chronic hbv asia latin america certain territories cardiovascular letairis ambrisentan oral formulation endothelin receptor antagonist era indicated treatment pulmonary arterial hypertension pah group patients class ii iii symptoms improve exercise capacity delay clinical worsening sublicensed gsk rights ambrisentan marketed gsk volibris ambrisentan pah territories outside united states ranexa ranolazine extendedrelease tablet treatment chronic angina licensed menarini international operations luxembourg sa rights ranexa territories outside united states lexiscanrapiscan regadenoson injection indicated use pharmacologic stress agent radionuclide myocardial perfusion imaging mpi test detects characterizes coronary artery disease patients unable undergo adequate exercise stress astellas us llc exclusive rights manufacture sell regadenoson name lexiscan united states subject obligations pay us royalties based sales lexiscan us rapidscan pharma solutions inc rps holds exclusive right manufacture sell regadenoson name rapiscan europe certain territories outside united states receive royalties astellas rps sales territories respiratory cayston aztreonam inhalation solution inhaled antibiotic treatment respiratory systems cystic fibrosis cf patients years age older pseudomonas aeruginosa p aeruginosa tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu approved treatment influenza children adults countries including united states japan european union tamiflu also approved prevention influenza children adults united states japan european union developed tamiflu f hoffmannla roche ltd together hoffmannla roche inc roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us royalties based percentage net sales tamiflu ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat serious invasive fungal infections caused various fungal species adults corporate partner astellas pharma us inc promotes sells ambisome united states canada promote sell ambisome europe australia new zealand vistide cidofovir injection antiviral injection treatment cytomegalovirus retinitis adult patients aids macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelated macular degeneration macugen developed eyetech inc eyetech using technology licensed us promoted united states valeant pharmaceuticals inc valeant acquired eyetech valeant holds exclusive rights manufacture sell macugen united states pfizer inc pfizer holds exclusive right manufacture sell macugen rest world receive royalties valeant pfizer based sales macugen worldwide sales antiviral products include products hivaids liver disease areas described billion billion billion represented total revenues sales products include letairis ranexa ambisome cayston billion billion million represented total revenues please see item management 's discussion analysis included annual report information regarding revenues commercialization distribution us international commercial sales operations marketing subsidiaries australia austria belgium canada czech republic denmark finland france germany greece hong kong ireland italy japan netherlands new zealand norway poland portugal russia south korea spain sweden switzerland turkey united kingdom united states products marketed commercial teams andor conjunction thirdparty distributors corporate partners commercial teams promote products direct field contact physicians hospitals clinics healthcare providers generally grant thirdparty distributors exclusive right promote product territory specified period time agreements distributors provide collaborative efforts distributor gilead obtaining maintaining regulatory approval product specified territory sell distribute stribild complera atripla truvada viread hepsera emtriva ranexa vistide united states exclusively wholesale channel product sales three large wholesalers cardinal health inc mckesson corp amerisourcebergen corp accounted total revenues years ended december combined basis wholesalers accounted approximately product sales united states approximately total worldwide revenues letairis cayston distributed exclusively specialty pharmacies specialty pharmacies dispense medications complex chronic conditions require high level patient education ongoing counseling sell distribute compleraeviplera atripla truvada viread hepsera emtriva ambisome asia australia canada europe latin america middle east new zealand either commercial teams thirdparty distributors corporate partners access developing world gilead access program established certain products treatment hiv chronic hbv visceral leishmaniasis available substantially reduced prices developing world gilead delivers medicines countries working regional business partners distribute brandname viread truvada prices based country 's ability pay represent little profit gilead also partnerships india based companies expand access generic versions hiv medications leastdeveloped countries world see work closely world health organization nongovernmental organizations provide ambisome treatment leishmaniasis preferential price resource limited settings support numerous clinical studies investigating role ambisome treat visceral cutaneous leishmaniasis developing countries collaborations organizations drugs neglected diseases initiative mdecins sans frontires also support clinical research studies aimed identifying best treatment course visceral leishmaniasis donated ambisome support clinical studies assessing combination therapies costeffectiveness multiple visceral leishmaniasis treatment interventions december signed partnership agreement world health organization donate vials ambisome five years donation used treat patients resourcelimited countries also support many clinical studies donation products help define best treatment strategies developing world countries example donated tenofovir centre aids programme research south africa caprisa microbicide trial assessed effectiveness safety tenofovirbased microbicide gel prevention hiv infection south african women also provide drugs number innovative international studies investigating whether viread truvada prevent hiv transmission among atrisk uninfected adults hiv prevention strategy called preexposure prophylaxis prep fda approval truvada became first agent indicated uninfected individuals reduce risk acquiring hiv sex also entered number collaborations related access products developing world include pharmachem technologies grand bahama ltd pharmachem pharmachem one commercial manufacturing partners established facility bahamas manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread one active pharmaceutical ingredients atripla truvada resource limited countries cooperative effort pharmachem grand bahama port authority aspen pharmacare holdings ltd aspen entered nonexclusive manufacturing distribution agreement aspen providing manufacture distribution viread truvada treatment hiv infection certain developing world countries included gilead access program amended agreement aspen amended agreement aspen retained right manufacture distribute viread truvada treatment hiv infection developing world countries aspen right purchase viread truvada unlabeled bottles us distribution countries also right manufacture viread truvada using active pharmaceutical ingredient purchased aspen suppliers approved us aspen also granted right manufacture distribute generic versions emtricitabine tenofovir disoproxil fumarate including versions tenofovir disoproxil fumarate combination emtricitabine treatment hiv infection aspen required pay us royalties net sales viread truvada well royalties net sales generic versions tenofovir disoproxil fumarate including versions tenofovir disoproxil fumarate combination generic versions emtricitabine manufactured distributed aspen licenses generic manufacturers entered nonexclusive license agreements indian generic manufacturers granting rights produce distribute generic versions tenofovir disoproxil fumarate treatment hiv infection low income countries around world includes india many low income countries gilead access program agreements require generic manufacturers meet certain national international regulatory quality standards include technology transfers enable expeditious production large volumes high quality generic versions tenofovir disoproxil fumarate addition agreements allow manufacture commercial quantities active pharmaceutical ingredient finished product expanded nonexclusive license agreements increase number countries included license also include rights stribild future product candidates elvitegravir investigational integrase inhibitor cobicistat pharmacoenhancing boosting agent increases blood levels allow oncedaily dosing certain hiv medicines expand access viread treatment hbv treatment developing countries also included nonexclusive license agreements ability manufacture distribute generic versions tenofovir disoproxil fumarate treatment hbv countries authorized sell generic versions tenofovir disoproxil fumarate hiv august announced new collaborations indian partners produce distribute generic emtricitabine developing world including single tablet regimens containing emtricitabine fixeddose combinations emtricitabine coformulated gilead hiv medicines merck entered agreement affiliate merck pursuant gilead merck provide atripla substantially reduced prices hiv infected patients developing countries africa caribbean latin america southeast asia agreement manufacture atripla using efavirenz supplied merck merck handles distribution product countries covered agreement international partnership microbicides ipm conrad entered agreement granted rights ipm conrad cooperating agency us agency international development committed improving reproductive health expanding contraceptive choices women men develop manufacture proven efficacious arrange distribution resource limited countries certain formulations tenofovir use topical microbicide prevent hiv infection medicines patent pool pool entered agreement pool organization established united nations increase global access highquality lowcost antiretroviral therapy sharing patents granted pool nonexclusive license identify generic pharmaceutical manufacturers india specialize highquality production generic medicines granted sublicenses indian manufacturers manufacture distribute generic versions antiretrovirals developing world sublicensees pool free develop combination products pediatric formulations hiv medicines also granted pool right grant sublicenses generic versions stribild product candidates elvitegravir cobicistat generic pharmaceutical manufacturers india distribution developing world janssen expanded agreement janssen formerly tibotec pharmaceuticals provide distribution compleraeviplera treatment hiv less developed countries enable commercialization generic versions product competition marketed products target number areas including viral cardiovascular respiratory fungal diseases many commercially available products treatment diseases many companies institutions making substantial investments developing additional products treat diseases products compete available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing hiv products hiv landscape becoming competitive complex treatment trends continue evolve growing number hiv drugs currently sold advanced stages clinical development competition current expected competitors may erode revenues receive sales hiv products branded hiv drugs available united states products primarily compete fixeddose combination products nucleotidenucleoside reverse transcriptase inhibitors nrti class including combivir lamivudinezidovudine epzicomkivexa abacavirlamivudine trizivir abacavirlamivudinezidovudine sold joint venture viiv established november gsk pfizer focused hiv therapies hiv products also compete broadly hiv products abbott laboratories inc boehringer ingelheim gmbh merck roche janssen bms 's videx ec didanosine ddi became first generic hiv product united states gsk 's retrovir zidovudine faces generic competition united states result launch generic zidovudine bms 's zerit stavudine faces generic competition united states result launch generic stavudine epivir lamivudine marketed viiv competitive emtricitabine active pharmaceutical ingredient emtriva component atripla truvada compleraeviplera stribild may compound patent covering epivir lamivudine expired united states europe generic lamivudine available united states spain portugal italy expect generic versions lamivudine launched countries within european union may generic version combivir lamivudine zidovudine approved recently launched united states addition late generic tenofovir also became available turkey resulted increase rebate viread turkey date significant impact generic didanosine zidovudine stavudine lamivudine generic version combivir generic tenofovir turkey price hiv products however price decreases hiv products may result longer term currently also expect competition generic version sustiva efavirenz component atripla available europe canada united states may negatively impact sales hiv products also expect launch dolutegravir integrase inhibitor fourth quarter gsk could impact sales hiv products liver disease products hbv products viread hepsera face significant competition existing expected therapies treating patients chronic hbv may erode revenues receive sales hbv products hbv products face competition baraclude entecavir oral nucleoside analog developed bms launched united states europe tyzekasebivo telbivudine oral nucleoside analog developed novartis pharmaceuticals corporation novartis sale united states european union china hbv products also compete epivirhbvzeffix lamivudine developed gsk collaboration shire pharmaceuticals group plc sold major countries throughout north south america europe asia viread hepsera treatment chronic hbv also compete established immunomodulatory therapies including introna interferon alfab sold schering plough corporation major countries throughout north south america europe asia pegasys pegylated interferon alfaa injectable drug similar introna sold roche treatment chronic hbv cardiovascular products letairis competes directly tracleer bosentan sold actelion pharmaceuticals us inc actelion indirectly adcirca tadalafil united therapeutics corporation ranexa competes predominantly generic compounds three distinct classes drugs treatment chronic angina united states including generic andor branded betablockers calcium channel blockers longacting nitrates addition surgical treatments interventions coronary artery bypass grafting percutaneous coronary intervention another option angina patients may perceived healthcare practitioners preferred methods treat cardiovascular disease underlies causes angina numerous marketed generic andor branded pharmacologic stress agents compete lexiscanrapiscan respiratory products cayston competes primarily tobi tobramycin inhalation solution inhaled medication sold novartis treatment cf patients whose lungs contain p aeruginosa bacterial infection tamiflu competes relenza zanamivir antiinfluenza drug sold gsk relenza neuraminidase inhibitor delivered orallyinhaled dry powder generic competitors include amantadine rimantadine oral tablets inhibit replication influenza virus biocryst pharmaceuticals inc developing injectable formulations peramivir influenza neuraminidase inhibitor treatment influenza currently approved japan south korea products ambisome faces strong competition several current expected competitors ambisome faces competition vfend voriconazole developed pfizer caspofungin product developed merck marketed cancidas united states caspofungin elsewhere ambisome also competes lipidbased amphotericin b products including abelcet amphotericin b lipid complex injection sold enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sold three rivers pharmaceuticals llc worldwide anfogen amphotericin b liposomal sold genpharma sa argentina bms numerous generic manufacturers sell conventional amphotericin b also competes ambisome aware least three lipid formulations claim similarity ambisome becoming available outside united states including possible entry formulations greece taiwan formulations may reduce market demand ambisome manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association vistide competes number drugs also treat cytomegalovirus retinitis including cytovene iv cytovene ganciclovir sold intravenous oral formulations respectively roche ocular implant bausch lomb incorporated valcyte valganciclovir also marketed roche foscavir foscarnet intravenous drug sold astrazeneca plc vitravene fomivirsen drug injected directly eye sold cibavision macugen competes primarily visudyne verteporfin injection sold novartis used connection photodynamic therapy lucentis ranibizumab sold genentech inc united states novartis territories outside united states number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs collaborative relationships part business strategy establish collaborations companies universities medical research institutions assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring products rights products technologies complementary business companies universities medical research institutions information regarding certain relationships including ongoing financial accounting impact business found item note consolidated financial statements included annual report form k commercial collaborations although currently number collaborations corporate partners govern manufacture sale distribution andor marketing products various territories worldwide following commercial collaborations significant us financial statement perspective significant ongoing collaboration activity exists bms entered collaboration arrangement bms develop commercialize single tablet regimen truvada bms 's sustiva united states combination approved use united states sold brand name atripla bms structured collaboration joint venture operate limited liability company named bristolmyers squibb gilead sciences llc consolidate bms granted royalty free sublicenses joint venture use respective company owned technologies return granted license joint venture use intellectual property results collaboration joint venture 's collaboration agreement amended allow joint venture sell atripla canada economic interests joint venture held us bms including share revenues outofpocket expenses based portion net selling price atripla attributable efavirenz truvada since net selling price truvada may change time relative net selling price efavirenz bms 's respective economic interests joint venture may vary annually since second quarter except limited number activities jointly managed parties longer coordinate detailing promotional activities united states parties reduced joint promotional efforts since launched complera august stribild august agreement continue terminated mutual agreement parties addition either party may terminate party 's participation collaboration within days launch least one generic version party 's single agent products double agent products nonterminating party right continue sell atripla obligated pay terminating party certain royalties threeyear period following effective date termination gilead sciences limited whollyowned subsidiary ireland bms entered collaboration agreement bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory parties formed limited liability company consolidate manufacture atripla distribution european territory using efavirenz purchases bms bms 's estimated net selling price efavirenz european territory starting first quarter except limited number activities jointly managed parties longer coordinate detailing promotional activities region december efavirenz purchased bms bms 's estimated net selling price efavirenz european territory included inventories consolidated balance sheets agreement terminate upon expiration lasttoexpire patent affords market exclusivity atripla one components european countries covered agreement addition either party may terminate agreement reason termination effective later december two calendar quarters notice termination nonterminating party right continue sell atripla obligated pay terminating party certain royalties threeyear period following effective date termination event nonterminating party decides sell atripla effective date termination date atripla withdrawn country date third party assumes distribution atripla whichever earlier gsk result acquisition myogen inc myogen assumed rights march license distribution supply agreements myogen gsk terms license agreement gsk exclusive rights market ambrisentan active pharmaceutical ingredient letairis name volibris pulmonary arterial hypertension territories outside united states license agreement received upfront payment million subject achievement specific milestones eligible receive total additional milestone payments million december received million potential milestone payments addition receive royalties based net sales volibris gsk territories gsk option negotiate us exclusive sublicense additional therapeutic uses volibris gsk territories term license agreement agreement continue conduct bear expense clinical development activities believe required obtain maintain regulatory approvals letairis volibris united states canada european economic area party may conduct additional development activities territories expense parties may agree jointly develop ambrisentan new indications licensed field party pay share external costs associated joint development agreement gsk 's obligation pay royalties us terminate countrybycountry basis earlier date generic equivalents sold country achieve certain percentage total prescriptions product plus generic equivalents fifteenth anniversary commercial launch country gsk may terminate agreement reason upon termination rights product would revert us either party may terminate agreement response material breach party janssen entered collaboration agreement janssen develop commercialize fixeddose combination truvada janssen 's rilpivirine combination approved united states european union sold brand name complera united states eviplera european union agreement janssen granted us exclusive license compleraeviplera worldwide excluding certain middle income developing world countries japan neither party restricted combining drugs drugs december recorded million approximately million reimbursable rd expenses incurred janssen development rilpivirine maximum amount reimbursable terms agreement responsible manufacturing compleraeviplera lead role registration distribution commercialization product licensed countries janssen exercised right codetail combination product countries gilead selling party july february amended collaboration agreement include distribution compleraeviplera rest world distribute product north america europe latin america except argentina mexico australia new zealand janssen distribute product regions including japan russia price product expected sum price truvada price rilpivirine purchased separately cost rilpivirine purchased us janssen compleraeviplera approximate market price rilpivirine less specified percentage major markets either party may terminate collaboration agreement compleraeviplera withdrawn market party materially breaches agreement may terminate agreement united states canada expiration last expire patent tenofovir disoproxil fumarate united states may terminate agreement country expiration last expire patent tenofovir disoproxil fumarate country european union janssen may terminate agreement united states canada expiration last expire patent rilpivirine united states may terminate agreement country expiration last expire patent rilpivirine country european union research collaborations currently number collaborations corporate partners govern research development rd certain compounds drug candidates research collaboration japan tobacco inc japan tobacco collaboration significant us financial statement perspective significant ongoing collaboration activity exists japan tobacco entered licensing agreement japan tobacco japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco would retain rights agreement responsible seeking regulatory approval territories required use diligent efforts commercialize product treatment hiv infection bear costs expenses associated commercialization efforts terms agreement paid upfront license fee million obligated make total potential milestone payments million upon achievement certain clinical regulatory commercial objectives additionally obligated pay royalties based net sales territories market product december made total milestone payments million agreement obligation pay royalties japan tobacco terminate productbyproduct basis patents providing exclusivity product expire later tenth anniversary commercial launch product may terminate agreement reason case license granted japan tobacco us would terminate either party may terminate agreement response material breach party research development research development philosophy strategy develop bestinclass drugs improve safety efficacy unmet medical needs intend continue committing significant resources research development opportunities business development activity product development efforts cover wide range medical conditions including hivaids liver diseases hbv hcv serious cardiovascular respiratory conditions inflammationoncology research scientists foster city fremont palo alto san dimas oceanside california branford connecticut seattle washington mississauga ontario engaged discovery development new molecules technologies hope lead approval new medicines addressing unmet needs development product candidates subject various risks uncertainties risks uncertainties include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain regulatory approvals result product candidates may never successfully commercialized drug development inherently risky many product candidates fail drug development process summary key product candidates corresponding current stages development additional information development pipeline visit website wwwgileadcom product candidates treatment hiv product candidates description marketing application pending stribild new drug application nda stribild oncedaily single tablet regimen elvitegravir cobicistat tenofovir disoproxil fumarate emtricitabine treatment hiv infection treatmentnave adults approved fda august filed marketing authorization application stribild european medicines agency december expect receive approval european commission second quarter cobicistat cobicistat pharmacoenhancing boosting agent increases blood levels allow oncedaily dosing certain hiv medicines approved component stribild united states evaluation standalone boosting agent certain hiv medicines treatmentnave patients may received validation ema marketing authorization application product june filed nda approval product single agent elvitegravir elvitegravir oral integrase inhibitor approved component stribild united states evaluated standalone agent hiv treatmentexperienced patients june submitted nda product received validation ema marketing authorization application also june filed nda product single agent product phase single tablet regimen tenofovir alafenamide single tablet regimen taf nucleotide reverse transcriptase inhibitor formerly known gs taf elvitegravir cobicistat emtricitabine elvitegravir cobicistat emtricitabine evaluated treatment hiv infection treatmentnave adults product phase single tablet regimen taf darunavir agreement janssen rd ireland entered single tablet regimen taf darunavir cobicistat emtricitabine cobicistat emtricitabine evaluated treatment hiv infection product candidates treatment liver disease product candidates description products phase sofosbuvir gs sofosbuvir nucleotide nsb inhibitor evaluation phase phase trials treatment hcv single tablet regimen sofosbuvir single tablet regimen sofosbuvir ledipasvir oral nsa inhibitor taken without ribavirin ledipasvir gs evaluation phase trials treatment hcv products phase gs gs oral ns protease inhibitor evaluated treatment hepatitis c gs gs nonnucleoside nsb polymerase inhibitor evaluation treatment hcv simtuzumab gs simtuzumab monoclonal antibody evaluated treatment liver fibrosis nonalcoholic steatohepatitis primary sclerosing cholangitis products phase gs gs pangenotypic nsa inhibitor evaluated treatment hcv gs gs oral tlr agonist evaluated treatment hbv hcv taf taf nucleoside reverse transcriptase inhibitor evaluation treatment hbv product candidates treatment cardiovascular diseases product candidates description product phase ranolazine ranolazine late sodium current inhibitor approved treatment chronic angina evaluated treatment incomplete revascularization postpercutaneous coronary intervention treatment type ii diabetes product phase ranolazine ranolazine also evaluated treatment paroxysmal atrial fibrillation product phase gs gs late sodium current inhibitor evaluated treatment ischemic heart disease arrhythmias product candidates treatment respiratory diseases product candidates description product phase aztreonam inhalation solution aztreonam inhalation solution evaluated treatment bronchiectasis product phase gs gs inhalable small molecule antiviral fusion inhibitor evaluated treatment respiratory syncytial virus simtuzumab simtuzumab monoclonal antibody evaluated treatment idiopathic pulmonary fibrosis product candidates treatment oncology diseasesinflammation product candidates description product phase idelalisib gs idelalisib pik delta inhibitor antibody evaluated treatment chronic lymphocytic leukemia indolent nonhodgkin 's lymphoma products phase momelotinib gscyt momelotinib gs formerly known cyt jak inhibitor evaluated treatment myelofibrosis simtuzumab simtuzumab monoclonal antibody evaluated treatment myelofibrosis colorectal cancer pancreatic cancer products phase gs gs pik delta inhibitor evaluated potential treatment lymphoid malignancies gs combination idelalisib gs syk inhibitor evaluated combination idelalisib potential treatment hematological malignancies total rd expenses billion compared billion billion addition internal discovery clinical development programs seek add portfolio products product acquisitions collaborations following table shows recent acquisitions year company therapeutic area cv therapeutics inc cardiovascular disorders cgi pharmaceuticals inc serious inflammatory diseases arresto biosciences inc fibrotic diseases cancer calistoga pharmaceuticals inc cancer inflammatory diseases pharmasset chronic hcv ym biosciences inc hematological immune cell disorders inflammatory diseases cancers largest transaction acquisition pharmasset january billion pharmasset clinicalstage pharmaceutical company located princeton new jersey committed discovering developing commercializing novel drugs treat viral infections pharmasset 's primary focus development oral therapeutics treatment hcv infection acquisition pharmasset gained ownership sofosbuvir currently phase trials treatment hcv see risk factor entitled public announcement data clinical studies evaluating sofosbuvir fixeddose combination sofosbuvir ledipasvir hcvinfected patients likely cause significant volatility stock price patents proprietary rights us european patent expiration number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows estimated expiration dates including patent term extension supplementary protection certificates andor pediatric exclusivity granted united states europe primary typically compound patents phase product candidates patents cover ranolazine compound instead discovered sustained release formulation ranolazine would achieve therapeutic plasma levels patents obtained formulations characteristic plasma levels achieve dates parentheses reflect estimated expiration date patents may issue currently pending applications estimated expiration dates include potential additional exclusivity eg patent term extension supplementary protection certificates pediatric exclusivity yet granted product candidates single tablet regimens estimated patent expiration date provided corresponds latest expiring compound patent one active ingredients single tablet regimen phase product candidates patent expiration product candidates treatment hiv us eu cobicistat elvitegravir single tablet regimen taf elvitegravir cobicistat emtricitabine product candidate treatment liver disease sofosbuvir treatment hepatitis c single tablet regimen sofosbuvir ledipasvir treatment hepatitis c product candidate treatment respiratory diseases aztreonam inhalation solution treatment bronchiectasis product candidate treatment cardiovascular diseases ranolazine treatment incomplete revascularization postpercutaneous coronary intervention treatment type ii diabetes product candidate treatment oncologyinflammation idelalisib treatment chronic lymphocytic leukemia indolent nonhodgkin 's lymphoma following table shows actual estimated expiration dates including patent term extension supplementary protection certificates andor pediatric exclusivity granted united states europe primary typically compound patents marketed products patents cover ranolazine compound instead discovered sustained release formulation ranolazine would achieve therapeutic plasma levels patents obtained formulations characteristic plasma levels achieve dates parentheses reflect estimated expiration date patents may issue currently pending applications expiration dates include potential additional exclusivity eg patent term extension supplementary protection certificates pediatric exclusivity product single tablet regimens eg truvada atripla complera stribild estimated patent expiration dates provided correspond latest expiring compound patent one active ingredients single tablet regimen products patent expiration us eu vistide hepsera ambisome macugen tamiflu letairis viread ranexa atripla cayston emtriva truvada lexiscan compleraeviplera stribild february gilead teva reached agreement principle settle ongoing patent litigation concerning four patents protect tenofovir disoproxil fumarate viread truvada atripla products agreement teva allowed launch generic version viread december settlement agreement must filed federal trade commission department justice review final patent protection certain challenges patents proprietary rights important business properly drafted enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology also rely trade secrets internal knowhow technological innovations agreements third parties develop maintain protect competitive position ability competitive depend success strategy patents covering active pharmaceutical ingredients stribild compleraeviplera atripla truvada viread emtriva hepsera letairis vistide lexiscan held third parties acquired exclusive rights patents agreements parties patents cover ranolazine compound active ingredient ranexa instead discovered sustained release formulation ranolazine would achieve therapeutic plasma levels patents obtained formulations characteristic plasma levels achieve patents cover active ingredients ambisome instead hold patents liposomal formulations compound also protect formulations trade secrets addition patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera asia major market therapies hbv indication hepsera developed may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions example extensions patents supplementary protection certificates many products granted united states number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain countries also important infringe valid patents proprietary rights others violate agreements grant proprietary rights us infringe valid patents violate agreements may prevented commercializing products using processes covered patents agreements may required obtain license third parties allow us use technology may unable obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware body patents may relate operation letairis education access program leap restricted distribution program designed support letairis patents claim sofosbuvir chemical entity metabolites however existence issued patents guarantee right practice patented technology commercialize patented product third parties may obtain rights patents may claim could used prevent attempt prevent us commercializing patented product candidates obtained pharmasset acquisition example aware patents patent applications owned parties might alleged cover use sofosbuvir parties successful obtaining valid enforceable patents establishing infringement patents could prevented selling sofosbuvir unless able obtain license patents license needed may available commercially reasonable terms gilead successor pharmasset party collaboration agreement roche develop psi cytidine analog prodrugs treatment chronic hcv infection collaborative research efforts agreement ended december roche later asked pharmasset consider whether roche may contributed inventorship sofosbuvir whether pharmasset complied confidentiality provisions collaboration agreement pharmasset advised us carefully considered issues raised roche believed issues without merit also considered issues reached conclusion roche recently contacted us asserting roche exclusive license sofosbuvir pursuant collaboration agreement roche alleges sofosbuvir prodrug uridine monophosphate analog prodrug psi therefore roche exclusive license believe roche 's claim without merit however roche successfully establish inventorship exclusive license rights sofosbuvir expected revenues earnings sale sofosbuvir could adversely affected patent applications confidential period time patent issued may know competitors filed patent applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete products addition competitors file patent applications covering technology may participate interferencederivation proceedings litigation determine right patent litigation interferencederivation proceedings unpredictable expensive even ultimately successful results operations may adversely affected events patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation examination proceedings regarding enforcement validity existing patents future patents could invalidate patents substantially reduce protection time time certain individuals entities may challenge patents example public patent foundation filed requests examination us patent trademark office pto challenging four patents related tenofovir disoproxil fumarate active ingredient atripla truvada compleraeviplera stribild viread pto granted requests pto confirmed patentability four patents time time may become involved disputes inventors patents example march jeremy clark former employee pharmasset acquired january inventor us patent filed demand arbitration lawsuit pharmasset dr raymond schinazi mr clark initially filed lawsuit pharmasset dr schinazi february seeking void assignment provision employment agreement assert ownership us patent claims metabolites sofosbuvir rg december court ordered stay litigation pending outcome arbitration proceeding required mr clark 's employment agreement instead proceeding arbitration mr clark filed two additional lawsuits september june subsequently dismissed court september mr clark filed motion seeking reconsideration court 's december order denied court december mr clark filed motion appoint special prosecutor february court issued order requiring mr clark enter arbitration risk dismissal case mr clark filed demand arbitration march arbitration panel set hearing date april predict outcome arbitration mr clark 's prior assignment patent pharmasset voided arbitration panel ultimately found owner patent determined infringed patent may required obtain license pay royalties mr clark commercialize sofosbuvir rg instances may required defend right patent invention interference proceeding pto interference administrative proceeding pto designed determine first invent subject matter claimed parties february received notice pto declared interference us patent idenix pharmaceuticals inc 's idenix pending patent application patent covers metabolites sofosbuvir rg idenix attempting claim class compounds including metabolites pending patent application course proceeding parties called upon submit evidence date conceived respective inventions interference determine first invent compounds therefore entitled patent claiming compounds administrative law judge determines idenix entitled patent claims determined infringed claims may required obtain license pay royalties idenix commercialize sofosbuvir rg determination judge appealed either party us federal district court june met idenix mandatory settlement discussions parties unable settle interference due widely divergent views strength respective positions whether need license idenix 's patents whether idenix needs license gilead patents develop manufacture pipeline products believe idenix application involved interference similar us foreign patents claiming compounds metabolites invalid result filed impeachment action canadian federal court invalidate idenix ca patent canadian patent corresponds idenix us patent idenix patent application subject interference filed similar legal action federal court norway seeking invalidate corresponding norwegian patent filed similar legal action federal court australia seeking invalidate corresponding australian patent may bring similar action countries idenix awarded patents compounds metabolites european countries japan china event patents issue expect challenge proceedings similar invoked canada norway australia pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products closely related developed developing addition certain countries africa asia including china provide effective enforcement patents thirdparty manufacturers able sell generic versions products countries litigation generic manufacturers part approval process products fda granted new chemical entity nce exclusivity period manufacturers ' applications approval generic versions product granted generic manufacturers may challenge patents protecting products granted exclusivity one year prior end exclusivity period generic manufacturers sought may continue seek fda approval similar identical drug anda application form typically used manufacturers seeking approval generic drug tenofovir disoproxil fumarate emtricitabine fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz example november received notice teva pharmaceuticals teva submitted anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine owned emory university licensed exclusively us invalid unenforceable andor infringed teva 's manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate december filed lawsuit teva infringement two emtricitabine patents march received notice teva submitted anda fda requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva challenged two emtricitabine patents may filed another lawsuit teva infringement two emtricitabine patents lawsuit consolidated lawsuit filed december january received notice teva submitted anda fda requesting permission manufacture market generic version viread notice teva challenged four tenofovir disoproxil fumarate patents protecting viread january also received notices teva amending andas related generic versions atripla truvada products notice related teva 's anda generic version atripla teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine two patents related efavirenz notice related teva 's anda generic version truvada teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine march filed lawsuits teva infringement four viread patents two additional emtricitabine patents march bristolmyers squibb company merck co inc filed lawsuit teva infringement patents related efavirenz filed lawsuits within requisite day period provided hatch waxman act stays preventing fda approval teva 's andas months court decision adverse patents month stay three teva andas expired july however result court 's scheduling orders teva prohibited launching risk upon expiration month stay february gilead teva reached agreement principle settle ongoing patent litigation concerning four patents protect tenofovir disoproxil fumarate viread truvada atripla products trial litigation scheduled begin february adjourned pending completion activities necessary finalize settlement agreement teva allowed launch generic version viread december settlement agreement must filed federal trade commission department justice review final november received notice teva submitted abbreviated new drug submission ands canadian ministry health requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate notice teva alleges three patents associated truvada invalid unenforceable andor infringed teva 's manufacture use sale generic version truvada january filed lawsuit teva seeking order prohibition approval ands december received notice teva submitted ands canadian ministry health requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva alleges three patents associated atripla two merck 's patents associated atripla invalid unenforceable andor infringed teva 's manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz february filed lawsuit teva seeking order prohibition approval ands july received notice lupin limited lupin submitted anda fda requesting permission manufacture market generic version truvada notice lupin alleges four patents associated emtricitabine four patents associated tenofovir disoproxil fumarate invalid unenforceable andor infringed lupin 's manufacture use sale generic version fixeddose combination emtricitabine tenofovir disoproxil fumarate august filed lawsuit lupin infringement patents july received notice cipla ltd submitted anda fda requesting permission manufacture market generic version emtriva generic version viread notices cipla alleges two patents associated emtricitabine invalid unenforceable andor infringed cipla 's manufacture use sale generic version emtricitabine four patents associated tenofovir disoproxil fumarate invalid unenforceable andor infringed cipla 's manufacture use sale generic version tenofovir disoproxil fumarate august filed lawsuits cipla infringement patents august received notice teva submitted ands canadian ministry health requesting permission manufacture market generic version tenofovir disoproxil fumarate notice teva alleges two patents associated viread invalid unenforceable andor infringed teva 's manufacture use sale generic version viread september filed lawsuit teva seeking order prohibition approval ands also august teva filed impeachment action canadian federal court seeking invalidation two canadian patents associated viread currently defending impeachment action october received notice lupin submitted anda fda requesting permission manufacture market generic version viread notice lupin alleges four patents associated tenofovir disoproxil fumarate invalid unenforceable andor infringed lupin 's manufacture use sale generic version tenofovir disoproxil fumarate october filed lawsuit lupin infringement patents ranolazine june received notice lupin submitted anda fda requesting permission manufacture market generic version sustained release ranolazine notice lupin alleges ten patents associated ranexa invalid unenforceable andor infringed lupin 's manufacture use sale generic version ranexa july filed lawsuit lupin infringement patents ranexa fda approve lupin 's anda receive court decision upon expiration court 's automatic stay july court scheduled trial begin april court finds none patents protect ranexa formulation infringed andor invalid lupin receives final approval product lupin able launch generic version ranexa product risk upon issuance decision adefovir disoproxil august received notice sigmapharm labs sigmapharm submitted anda fda requesting permission manufacture market generic adefovir dipivoxil notice sigmapharm alleges patents associated hepsera invalid unenforceable andor infringed sigmapharm 's manufacture use sale generic version hepsera september filed lawsuit sigmapharm infringement patents fda approve sigmapharm 's anda receive court decision upon expiration court 's automatic stay february court yet set trial date case anticipate trial occur mid upon expiry month stay february sigmapharm obtains final fda approval product fda may elect launch generic product risk infringing patents prior decision court one patents challenged sigmapharm also challenged ranbaxy inc ranbaxy pursuant notice received october patent challenged ranbaxy expires july option filing lawsuit time believe ranbaxy infringing patent tamiflu february received notice natco pharma ltd natco submitted anda fda requesting permission manufacture market generic oseltamivir phosphate notice natco alleges one patents associated tamiflu invalid unenforceable andor infringed natco 's manufacture use sale generic version tamiflu march f hoffmannla roche ltd filed lawsuit natco infringement one patents associated tamiflu december court issued ruling favor gilead roche patent invalid reasons stated natco 's notice letter predict ultimate outcome actions may spend significant resources enforcing defending patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states atripla truvada viread canada could substantially shortened patents covering one products invalidated fda canadian ministry health could approve requests manufacture generic version products united states canada respectively prior expiration date patents sale generic versions products hepsera earlier patent expiration would significant negative effect revenues results operations trade secrets also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions manufacturing raw materials manufacturing strategy contract third parties manufacture majority active pharmaceutical ingredients solid dose products also rely corporate partners manufacture certain products additionally lease manufacturing facilities san dimas california edmonton alberta canada cork ireland oceanside california manufacture certain products active pharmaceutical ingredients clinical commercial uses manufacturing products contract third parties manufacture certain products clinical commercial purposes including stribild compleraeviplera atripla truvada viread hepsera emtriva ranexa vistide use multiple thirdparty contract manufacturers manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread one active pharmaceutical ingredients stribild compleraeviplera atripla truvada emtricitabine active pharmaceutical ingredient emtriva one active pharmaceutical ingredients atripla truvada compleraeviplera stribild rely single third party manufacturer manufacture active pharmaceutical ingredient cayston exclusive manufacturer active pharmaceutical ingredients hepsera letairis vistide also rely thirdparty contract manufacturers tablet capsulate products example use multiple thirdparty contract manufacturers tablet stribild compleraeviplera atripla truvada viread hepsera ranexa emtriva encapsulation also completed thirdparty contract manufacturers rely single thirdparty supplier manufacture letairis tablets also manufacturing agreements many corporate partners roche third parties responsible manufacturing tamiflu agreement roche joint manufacturing committee composed representatives roche us opportunity review roche 's existing manufacturing capacity tamiflu global plans manufacturing tamiflu astellas us llc corporate partner lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan pari pharma gmbh responsible manufacturing device required administer cayston lungs patients device made single supplier single site future products continue develop additional manufacturing capabilities establish additional thirdparty suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities product approved commercial sale unable develop manufacturing capabilities internally contract large scale manufacturing third parties acceptable terms future products ability conduct large scale clinical trials meet customer demand commercial products adversely affected manufacturing facilities san dimas california manufacturing facility manufacture fill package solid dosage form products manufacture cayston ambisome san dimas facility depend single supplier active pharmaceutical ingredient cayston high quality cholesterol used manufacture ambisome also fill package solid dosage form products including stribild compleraeviplera atripla truvada viread emtriva ranexa finished forms label hepsera facilities san dimas exclusive supplier ambisome event disaster including earthquake equipment failure difficulty may unable replace manufacturing capacity timely manner may unable manufacture ambisome meet market needs fill package drug product stribild atripla truvada viread cayston finished forms label hepsera emtriva facilities cork ireland also perform quality control testing final labeling packaging ambisome final release many products european union elsewhere facility utilize cork ireland facility primarily solid dose tablet manufacturing certain antiviral products well product packaging activities distribute products european union international markets dublin ireland site edmonton alberta facility canada carry process research scaleup clinical development candidates manufacture active pharmaceutical ingredients investigational commercial products conduct chemical development activities improve existing commercial manufacturing processes also manufacture active pharmaceutical ingredients hepsera letairis vistide exclusively edmonton site although another supplier qualified make active pharmaceutical ingredient letairis oceanside california facility designed equipped produce biologic compounds toxicological phase phase clinical studies use facility process development manufacture simtuzumab investigational monoclonal antibody candidate development treatment certain cancers fibrotic diseases another antibody currently phase clinical trials thirdparty manufacturers thirdparty manufacturers corporate partners independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties cause delays clinical trials applications regulatory approval extent risks materialize affect performance obligations us financial results may adversely affected example due unexpected delays qualifying two new external sites expanding cayston manufacturing san dimas unable supply enough cayston fulfill projected demand february september suspended access patients new prescriptions cayston subject certain exceptions specific medical need exists result inability manufacture sufficient cayston meet demand amount revenues received sale cayston reduced believe technology use manufacture products proprietary products manufactured thirdparty contract manufacturers disclosed necessary aspects technology enable manufacture products us agreements thirdparty manufacturers intended restrict manufacturers using revealing technology certain thirdparty manufacturers comply restrictions addition thirdparty manufacturers could develop technology related work perform us may need manufacture products could required enter additional agreements thirdparty manufacturers want use technology allow another manufacturer use technology thirdparty manufacturer could refuse allow us use technology could demand terms use technology acceptable us regulation manufacturing process manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations thirdparty manufacturers corporate partners subject current good manufacturing practices extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda ema similar regulations effect countries manufacturing operations subject routine inspections regulatory agencies example january february fda conducted routine inspection san dimas california manufacturing distribution facility manufacture ambisome cayston package solid dosage form products conclusion inspection fda issued form inspectional observations stating concerns maintenance aseptic processing conditions manufacturing suite ambisome product environmental maintenance issues san dimas warehousing facility batch sampling timeliness completion annual product quality reports september san dimas manufacturing facility received warning letter fda detailing fda 's concerns ambisome manufacturing environment including control systems monitoring procedures prevent microbiological contamination preventative cleaning equipment maintenance referencing certain viread lots letter also stated concerns connected quality procedures controls investigation procedures generalized concern effectiveness san dimas quality unit carrying responsibilities november december fda reinspected san dimas facility reinspection closed additional form observations august fda notified us resolved issues raised fda warning letter access supplies materials need access certain supplies products manufacture products delivery material suppliers interrupted reason unable purchase sufficient quantities raw materials used manufacture products may unable ship certain products commercial supply supply product candidates development clinical trials example significant portion raw materials intermediates used manufacture hiv products stribild compleraeviplera atripla truvada viread emtriva supplied chinesebased companies result international trade dispute china united states actions chinese government would limit prevent chinese companies supplying materials would adversely affect ability manufacture supply hiv products meet market needs material adverse effect operating results seasonal operations backlog worldwide product sales reflect significant degree seasonality however royalty revenues represented approximately total revenues included tamiflu royalties affected seasonality royalty revenue recognize roche 's sales tamiflu impacted severity flu seasons product delivery response influenza pandemics part operate markets characterized short lead times absence significant backlogs believe backlog information material business whole government regulation operations activities subject extensive regulation numerous government authorities united states countries united states drugs subject rigorous fda regulation federal food drug cosmetic act federal state statutes regulations govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion products result regulations product development product approval processes expensive time consuming fda must approve drug sold united states general process approval follows preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug candidate 's potential benefits safety submit data fda investigational new drug ind application seeking approval test compound humans clinical trials fda accepts investigational new drug application drug candidate studied human clinical trials determine drug candidate safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug candidate given small number healthy human control subjects patients suffering indicated disease test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug candidate given limited patient population determine effect drug candidate treating disease best dose drug candidate possible side effects safety risks drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous phase clinical trials phase drug candidate appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials conducted longer term involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials fda approval process believe data phase clinical trials show adequate level safety efficacy submit appropriate filing usually form nda supplemental nda fda seeking approval sell drug candidate particular use fda may hold public hearing independent advisory committee expert advisors asks additional questions makes recommendations regarding drug candidate committee makes recommendation fda binding generally followed fda fda agrees compound met required level safety efficacy particular use allow us sell drug candidate united states use unusual however fda reject application believes drug candidate safe enough efficacious enough believe data submitted reliable conclusive point process development drug candidate stopped number reasons including safety concerns lack treatment benefit certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require phase nonregistrational studies explore scientific questions characterize safety efficacy commercial use drug fda may also require us provide additional data information improve manufacturing processes procedures facilities may require extensive surveillance monitor safety benefits product candidates determines filing contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards problems uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold united states facilities subject periodic regulatory inspection manufacturing facilities located california including oceanside san dimas facilities also must licensed state california compliance local regulatory requirements manufacturing facilities located canada including edmonton alberta facility facilities located near dublin cork ireland also must obtain local licenses permits compliance local regulatory requirements drugs treat serious life threatening diseases conditions adequately addressed existing drugs development program designed address unmet medical need may designated fast track candidates fda may eligible accelerated priority review drugs treatment hiv infection designated use us president 's emergency plan aids relief may also qualify expedited priority review atripla truvada viread complera received accelerated approval priority reviews drugs receiving accelerated approval must monitored postmarketing clinical trials order confirm safety benefits drug congress agree package tax federal spending proposals january absent congressional action automatic reduction federal spending sequestration take effect march sequestration acrossthe board cuts implemented expected effect operations governmental agencies including fda result fda may unable review approve new drug applications currently anticipated timelines significant delay timing anticipated product approvals may reduce anticipated future revenue earnings could negatively affect stock price drugs also subject extensive regulation outside united states european union centralized approval procedure authorizes marketing product countries european union includes major countries europe centralized approval procedure used approval one country european union used obtain approval another country european union one two simplified application processes mutual recognition procedure decentralized procedure rely principle mutual recognition receiving regulatory approval european registration procedures separate pricing reimbursement approvals also required countries european union also requirements approval manufacturing facilities products approved sale eu regulatory authorities pricing reimbursement successful commercialization products depends part availability governmental thirdparty payer reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services particularly new innovative products therapies resulted lower average selling prices significant portion sales majority products subject significant discounts list price rebate obligations united states state aids drug assistant programs adaps purchase significant portion hiv products rely federal supplemental federal state funding help fund purchases products given current economic downturn experienced shift payer mix patients previously covered private insurance move public reimbursement programs require rebates discounts us patients previously covered one public reimbursement program move another public reimbursement program requires greater rebates discounts us result shift revenue growth may lower prescription growth absent congressional action automatic reduction federal spending sequestration take effect march sequestration acrossthe board cuts implemented could potentially cut amount federal state funds support adap programs federal state funds available amounts sufficient support number patients rely adaps sales hiv products could negatively impacted would reduce revenues example first quarter state budget crisis florida led temporary movement patients previously covered florida 's adap industrysupported patient assistance programs prior quarters insufficiency federal state funds many states reduced eligibility criteria saw increase number patients state adap wait lists may see similar increases future periods result cut federal state adap support resulting sequestration patients enrolled adap generally receive product industrysupported patient assistance programs unable access treatment increased emphasis managed healthcare united states country regional pricing reimbursement controls european union put additional pressure product pricing reimbursement usage may adversely affect product sales profitability pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid healthcare reform pharmaceutical reimbursement policies pricing general europe success commercialized products product candidates may develop depend largely obtaining maintaining government reimbursement many european countries patients unlikely use prescription drugs reimbursed governments addition negotiating prices governmental authorities delay commercialization months reimbursement policies may adversely affect ability sell products profitable basis many international markets governments control prices prescription pharmaceuticals including implementation reference pricing price cuts rebates revenuerelated taxes profit control expect prices prescription pharmaceuticals decline life product volumes increase recently many countries european union increased amount discounts required products efforts could continue countries attempt manage healthcare expenditures especially light severe fiscal debt crises experienced many countries european union example june spain imposed incremental discount branded drugs august germany increased rebate prescription pharmaceuticals generic drugs come market may face price decreases products countries european union cost containment pressures european union could lead delays treatment patients also delay pricing approval could negatively impact commercialization new products government agencies also issue regulations guidelines directly applicable us products addition time time professional societies practice management groups private healthscience foundations organizations publish guidelines recommendations directed certain health care patient communities recommendations guidelines may relate matters product usage dosage route administration use related competing therapies consequently result increased decreased usage products example recent hiv treatment guidelines united states abroad endorsed earlier diagnosis treatment united states healthcare reform legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states march healthcare reform legislation adopted united states result required rebate discount products reimbursed paid various public payers including medicaid entities eligible purchase discounted products b drug pricing program public health service act adaps result legislation discounts rebates fees impacted us include minimum base rebate amount owed medicaid products reimbursed medicaid increased discounts rebates owe adaps public health service entities reimburse purchase products also increased required extend rebates patients receiving products medicaid managed care organizations required provide discount products sold patients medicare part donut hole along pharmaceutical manufacturers branded drug products required pay portion new industry fee also known pharmaceutical excise tax billion calculated based select government sales calendar year percentage total industry government sales amount industry fee imposed pharmaceutical industry whole increased billion additional increases next several years peak billion per year decrease billion thereafter amount industry fee increases product sales increase drug patents expire major drugs companies expect portion excise tax increase well estimate portion pharmaceutical excise tax approximately million compared approximately million excise tax tax deductible even though addressed healthcare reform legislation discussions continue federal level legislation would either allow require federal government directly negotiate price concessions pharmaceutical manufacturers set minimum requirements medicare part pricing addition state medicaid programs could request additional supplemental rebates products result increase federal base medicaid rebate private insurers could also use enactment increased rebates exert pricing pressure products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules health care fraud abuse laws antibribery laws subject various federal state laws pertaining health care fraud abuse including antikickback laws false claims laws antikickback laws make illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business including purchase prescription particular drug due breadth statutory provisions increasing attention given law enforcement authorities possible certain practices may challenged antikickback similar laws false claims laws generally prohibit anyone knowingly presenting causing presented false fraudulent claim payment federal certain state payers including medicare medicaid knowingly making using causing made used false record statement material false fraudulent claim sales marketing medical activities may subject scrutiny laws addition us foreign corrupt practices act similar worldwide antibribery laws generally prohibit companies intermediaries making improper payments purpose obtaining retaining business policies mandate compliance antibribery laws operate parts world experienced governmental corruption degree certain circumstances strict compliance antibribery laws may conflict local customs practices may require us interact doctors hospitals may state controlled manner different local custom despite training compliance program internal control policies procedures may protect us reckless criminal acts committed employees agents violations fraud abuse laws antibribery laws may punishable criminal andor civil sanctions including fines civil monetary penalties well possibility exclusion federal health care programs including medicare medicaid violations also lead imposition corporate integrity agreement similar government oversight program government allege convict us violating laws could disruption business material adverse effect results operations compulsory licenses number developing countries government officials interested groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread july brazilian patent authority rejected patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread highest level appeal available us within brazilian patent authority currently patent brazil brazilian government purchases supply tenofovir disoproxil fumarate generic manufacturers addition concerns cost availability tamiflu related potential avian flu pandemic hn influenza generated international discussions compulsory licensing tamiflu patents example canadian government considered allowing canadian manufacturers manufacture export active ingredient tamiflu eligible developing least developed countries canada 's access medicines regime furthermore roche issued voluntary licenses permit thirdparty manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense india 's hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override tamiflu patents roche issue additional voluntary licenses permit thirdparty manufacturing tamiflu developments could reduce royalties receive roche 's sales tamiflu certain countries permit enforcement patents thirdparty manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales employees january approximately fulltime employees believe good relations employees environment health safety voluntarily assessing publicly reporting greenhouse gas emissions water usage begun take action reduce emissions usage example established employee commuter programs evaluated energy efficiency buildings installed lowflow water fixtures various laws regulations implemented consideration mitigate effects climate change caused greenhouse gas emissions example california air resources board process drafting regulations meet state emissions targets based current information subject finalization proposed regulations believe primary risk related climate change risk increased energy costs however energy intensive business anticipate subject cap trade system mitigation measures would likely material capital expenditures results operations competitive position also subject federal state local regulations regarding workplace safety protection environment use hazardous materials chemicals viruses various radioactive compounds rd activities eliminate risk accidental contamination injury materials certain misuse accidents involving materials could lead significant litigation fines penalties implemented proactive programs reduce minimize risk hazardous materials incidents information subject information requirements exchange act therefore file periodic reports proxy statements information sec reports proxy statements information may obtained visiting public reference room sec f street ne washington dc calling sec sec sending electronic message sec publicinfosecgov sending fax sec addition sec maintains website wwwsecgov contains reports proxy information statements information regarding issuers file electronically mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section make available following filings soon reasonably practicable electronically filed furnished sec annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section exchange act filings available free charge upon request transactions iran discussed access developing world item business committed providing access certain hiv products developing world connection provided medical education related treatment hiv countries accordance commitment january nonus subsidiary gilead based greece greek sub sponsored hiv conference abu dhabi uae strategies treatment prevention hiv discussed third party distributor gilead north africa middle east including iran invited greek sub 's behalf doctors throughout region including four iranian doctors least two appear officials iranian national aids program gilead sciences europe limited reimbursed distributor travelrelated expenses four iranian doctors attend hiv conference expenses four iranian doctors totaled covered cost visa fees airline tickets transportation understand distributor turn transferred reimbursed amount iranian entity acts subdistributor iran neither distributor subdistributor affiliated gilead knowledge agencies instrumentalities otherwise controlled government iran sales products iran subdistributors made available part gilead access program sold notforprofit prices activities described involved nonus affiliates gilead occurred prior enactment iran threat reduction syria human rights act august subject usiran sanctions regime current intention engage activities described future directly pursuant nonus subsidiaries future time gilead including subsidiary engage activities would first obtain license us department treasury 's office foreign assets control rely applicable exemption usiran sanctions regime item risk factors evaluating business carefully consider following risks addition information annual report manifestation following risks could materially adversely affect business results operations financial condition note factors investors permitted private securities litigation reform act possible predict identify factors therefore consider following risks complete statement potential risks uncertainties face public announcement data clinical studies evaluating sofosbuvir fixeddose combination sofosbuvir ledipasvir hcvinfected patients likely cause significant volatility stock price development sofosbuvir alone combination ledipasvir delayed discontinued stock price could decline significantly expect receive significant amount data clinical trials evaluating sofosbuvir investigational nucleotide analog acquired purchase pharmasset inc pharmasset alone combination direct acting antivirals hepatitis c virus hcvinfected individuals across genotypes initial new drug application nda sofosbuvir supported four phase studies named fission positron fusion neutrino fission study genotype treatment nave patients comparing weeks sofosbuvir ribavirin current standard care weeks treatment interferon ribavirin february announced topline results fission study study met primary efficacy endpoint noninferiority sofosbuvir plus ribavirin pegylated interferon pegifn plus ribavirin found patients achieved sustained viral response svr sofosbuvir plus ribavirin treatment group versus pegifn plus ribavirin treatment group positron compares weeks treatment sofosbuvir ribavirin genotype interferon intolerantineligible patients placebo november announced topline results positron study study found patients achieved svr weeks completing therapy neutrino single arm study evaluates week course sofosbuvir interferon ribavirin genotype infectedpatients february announced topline results neutrino study study met primary efficacy endpoint superiority compared predefined historic control svr rate showed patients achieved svr weeks completing therapy fusion study explores weeks duration treatment sofosbuvir ribavirin genotype treatmentexperienced patients february announced topline results fusion study study met primary efficacy endpoint superiority compared predefined historic control svr rate showed patients week arm patients week arm achieved svr weeks completing therapy anticipate filing regulatory approvals sofosbuvir second quarter expect initial indication weeks treatment sofosbuvir ribavirin treatmentnaive interferonintolerant experienced genotype patients weeks treatment sofosbuvir peg ifn ribavirin treatmentnaive genotype patients parallel also advancing fixeddose combination sofosbuvir ledipasvir formerly gs treatment genotype patients nda fixed dose combination sofosbuvir ledipasvir supported two clinical trials first study named ion evaluates fixeddose combination sofosbuvir ledipasvir without ribavirin either weeks treatmentnave genotype infected patients pending review results two week arms initial enrollment patients second quarter expect enroll additional patients ion study assess fixed dose combination sofosbuvir ledipasvir total individuals january also started screening patients phase study named ion evaluating fixeddose combination ribavirin weeks without ribavirin weeks therapy among treatmentexperienced genotype hcv patients announcement data clinical studies evaluating sofosbuvir fixeddose combination sofosbuvir ledipasvir likely cause significant volatility stock price announcement negative unexpected data discontinuation development sofosbuvir fixeddose combination sofosbuvir ledipasvir delay anticipated timelines filing regulatory approval likely cause stock price decline significantly substantial portion revenues derived sales hiv products particularly atripla truvada unable maintain continue increasing sales products results operations may adversely affected currently dependent sales products treatment hiv infection particularly atripla truvada support existing operations hiv products contain tenofovir disoproxil fumarate andor emtricitabine belong nucleoside class antiviral therapeutics treatment paradigm hiv change causing nucleosidebased therapeutics fall favor unable maintain continue increasing hiv product sales results operations would likely suffer would likely need scale back operations including spending research development rd efforts year ended december atripla truvada product sales together billion total revenues may able sustain increase growth rate sales hiv products especially stribild compleraeviplera atripla truvada number reasons including limited following hiv products used longer period time many patients combination products additional studies conducted new issues respect safety resistance interactions drugs may arise could cause us provide additional warnings contraindications labels narrow approved indications halt sales product could reduce revenues hiv products mature private insurers government payers often reduce amount reimburse patients products increases pressure us reduce prices large part market hiv products consists patients already taking hiv drugs successful encouraging physicians change patients ' regimens include hiv products sales hiv products limited generic hiv products introduced major markets ability maintain pricing market share may affected fail commercialize new products expand indications existing products prospects future revenues may adversely affected introduce new products market increase sales existing products able increase maintain total revenues continue expand rd efforts drug development inherently risky many product candidates fail drug development process example january announced decision terminate phase clinical trial ambrisentan patients idiopathic pulmonary fibrosis ipf april announced decision terminate phase clinical trial aztreonam inhalation solution treatment cystic fibrosis cf patients burkholderia spp addition marketing application single tablet regimen elvitegravir cobicistat tenofovir disoproxil fumarate emtricitabine treatment hiv treatmentnave patient may approved european medicines agency ema foreign regulatory agencies new drug applications elvitegravir treatment hiv treatmentexperienced patients cobicistat pharmacoenhancing boosting agent may approved us food drug administration fda ema foreign regulatory authorities even marketing approval granted products may significant limitations use may unable file marketing applications new products including sofosbuvir fixeddose combination sofosbuvir ledipasvir currently anticipated timelines marketing approval products may granted congress agree package tax federal spending proposals january absent congressional action automatic reduction federal spending sequestration take effect march sequestration acrossthe board cuts implemented expected effect operations governmental agencies including fda result fda may unable review approve new drug applications currently anticipated timelines significant delay timing anticipated product approvals may reduce anticipated future revenue earnings could negatively affect stock price results operations adversely affected current potential future healthcare reforms legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states foreign jurisdictions march healthcare reform legislation adopted united states result required rebate discount products reimbursed paid various public payers including medicaid entities eligible purchase discounted products b drug pricing program public health service act aids drug assistance programs adaps result legislation discounts rebates fees impacted us include minimum base rebate amount owed medicaid products reimbursed medicaid increased discounts rebates owe adaps public health service entities reimburse purchase products also increased required extend rebates patients receiving products medicaid managed care organizations required provide discount products sold patients medicare part donut hole along pharmaceutical manufacturers branded drug products required pay portion new industry fee also known pharmaceutical excise tax billion calculated based select government sales calendar year percentage total industry government sales amount industry fee imposed pharmaceutical industry whole increased billion additional increases next several years peak billion per year decrease billion thereafter amount industry fee increases product sales increase drug patents expire major drugs companies expect portion excise tax increase well estimate portion pharmaceutical excise tax approximately million compared approximately million excise tax tax deductible even though addressed healthcare reform legislation discussions continue federal level legislation would either allow require federal government directly negotiate price concessions pharmaceutical manufacturers set minimum requirements medicare part pricing addition state medicaid programs could request additional supplemental rebates products result increase federal base medicaid rebate private insurers could also use enactment increased rebates exert pricing pressure products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental thirdparty payer reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services particularly new innovative products therapies resulted lower average selling prices significant portion sales majority products subject significant discounts list price rebate obligations united states state adaps purchase significant portion hiv products rely federal supplemental federal state funding help fund purchases products given current economic downturn experienced shift payer mix patients previously covered private insurance move public reimbursement programs require rebates discounts us patients previously covered one public reimbursement program move another public reimbursement program requires greater rebates discounts us result shift revenue growth may lower prescription growth absent congressional action automatic reduction federal spending sequestration take effect march sequestration acrossthe board cuts implemented could reduce amount federal state funds support adap programs federal state funds available amounts sufficient support number patients rely adaps sales hiv products could negatively impacted would reduce revenues example first quarter state budget crisis florida led temporary movement patients previously covered florida 's adap industrysupported patient assistance programs prior quarters insufficiency federal state funds many states reduced eligibility criteria saw increase number patients state adap wait lists may see similar increases future periods result reduction federal state adap support resulting sequestration patients enrolled adap generally receive product industrysupported patient assistance programs unable access treatment increased emphasis managed healthcare united states country regional pricing reimbursement controls european union put additional pressure product pricing reimbursement usage may adversely affect product sales profitability pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid healthcare reform pharmaceutical reimbursement policies pricing general europe success commercialized products product candidates may develop depend largely obtaining maintaining government reimbursement many european countries patients unlikely use prescription drugs reimbursed governments addition negotiating prices governmental authorities delay commercialization months reimbursement policies may adversely affect ability sell products profitable basis many international markets governments control prices prescription pharmaceuticals including implementation reference pricing price cuts rebates revenuerelated taxes profit control expect prices prescription pharmaceuticals decline life product volumes increase recently many countries european union increased amount discounts required products efforts could continue countries attempt manage healthcare expenditures especially light severe fiscal debt crises experienced many countries european union example june spain imposed incremental discount branded drugs august germany increased rebate prescription pharmaceuticals generic drugs come market may face price decreases products countries european union cost containment pressures european union could lead delays treatment patients also delay pricing approval could negatively impact commercialization new products approximately product sales occur outside united states currency fluctuations hedging expenses may cause earnings fluctuate could adversely affect stock price significant percentage product sales denominated foreign currencies primarily euro face exposure adverse movements foreign currency exchange rates us dollar strengthens foreign currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative value sales increases overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business use foreign currency exchange forward option contracts hedge percentage forecasted international sales primarily denominated euro also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid predict future fluctuations foreign currency exchange rate us dollar us dollar appreciates significantly certain currencies hedging program sufficiently offset effects appreciation results operations adversely affected stock price may decline additionally expenses recognize relation hedging activities also cause earnings fluctuate level hedging expenses recognize particular period impacted changes interest rate spreads foreign currencies hedge us dollar inability accurately estimate demand products well sales fluctuations result inventory levels held wholesalers pharmacies non retail customers make difficult us accurately forecast sales may cause earnings fluctuate could adversely affect financial results stock price approximately product sales united states three wholesalers cardinal health inc mckesson corp amerisourcebergen corp us wholesalers entered inventory management agreements make estimates determine end user demand may completely effective matching inventory levels actual end user demand result changes inventory levels held wholesalers cause operating results fluctuate unexpectedly sales wholesalers match end user demand addition inventory held retail pharmacies nonwholesale locations inventory management agreements control buying patterns adverse changes economic conditions factors may cause retail pharmacies reduce inventories products would reduce orders wholesalers consequently wholesalers ' orders us even end user demand changed example fourth quarter wholesalers increased inventory levels antiviral products first quarter wholesalers drew inventory inventory levels antiviral products moved lower end contractual boundaries set inventory management agreements inventory distribution channel fluctuates quarter quarter may continue see fluctuations earnings mismatch prescription demand products revenues addition nonretail sector united states includes government institutions including state adaps correctional facilities large health maintenance organizations tends even less consistent terms buying patterns often causes quarter quarter fluctuations necessarily mirror patient demand federal state budget pressures well annual grant cycles federal state adap funds may cause adap purchasing patterns reflect patient demand example first second quarters observed large nonretail purchases number state adaps exceeded patient demand believe purchases driven grant cycle federal adap funds early communication ryan white federal funds desire state adaps reduce patient wait lists led significant reduction adap purchasing third quarter also observed large nonretail purchases fourth quarter driven issues result expect continue experience fluctuations purchasing patterns nonretail customers may result fluctuations product sales revenues earnings future light global economic downturn budget crises faced many european countries observed variations purchasing patterns induced cost containment measures europe believe measures caused government agencies purchasers reduce inventory products distribution channels decreased revenues caused fluctuations product sales earnings may continue see trend future face significant competition face significant competition large pharmaceutical biotechnology companies substantially greater resources addition competitors products operated fields compete longer hiv products compete primarily products joint venture established glaxosmithkline inc gsk pfizer inc pfizer markets fixeddose combination products compete stribild compleraeviplera atripla truvada example lamivudine marketed joint venture competitive emtricitabine active pharmaceutical ingredient emtriva component compleraeviplera atripla truvada also face competition generic hiv products may compound patent covering epivir lamivudine expired united states generic lamivudine available united states spain portugal italy expect generic versions lamivudine launched countries within european union may generic version combivir lamivudine zidovudine approved recently launched united states addition late generic tenofovir also became available turkey resulted increase rebate viread turkey currently also expect competition generic version sustiva efavirenz component atripla available europe canada united states may negatively impact sales hiv products also expect launch dolutegravir integrase inhibitor fourth quarter gsk could impact sales hiv products viread hepsera treatment chronic hbv compete primarily products produced gsk bms novartis pharmaceuticals corporation novartis united states european union china ambisome compete primarily products produced merck co inc merck pfizer addition aware least three lipid formulations claim similarity ambisome becoming available outside united states including possible entry formulations greece taiwan formulations may reduce market demand ambisome furthermore manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association letairis competes directly product produced actelion pharmaceuticals us inc indirectly pulmonary arterial hypertension products united therapeutics corporation pfizer ranexa competes predominantly generic compounds three distinct classes drugs betablockers calcium channel blockers longacting nitrates treatment chronic angina united states cayston competes product marketed novartis tamiflu competes products sold gsk generic competitors addition number companies pursuing development technologies competitive existing products research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs significant safety issues arise marketed products product candidates future sales may reduced would adversely affect results operations data supporting marketing approvals products forming basis safety warnings product labels obtained controlled clinical trials limited duration cases postapproval use products used longer periods time many patients underlying health problems taking numerous medicines expect continue find new issues safety resistance drug interaction issues may require us provide additional warnings contraindications labels narrow approved indications could reduce market acceptance products product letairis approved fda june member class compounds called endothelin receptor antagonists eras pose specific risks including serious risks birth defects risks letairis available letairis education access program leap restricted distribution program intended help physicians patients learn risks associated product assure appropriate use product product used additional patients may discover new risks associated letairis may result changes distribution program additional restrictions use letairis may decrease demand product regulatory authorities moving towards active transparent pharmacovigilance making greater amounts standalone safety information directly available public websites means eg periodic safety update report summaries risk management plan summaries various adverse event data safety information without appropriate context expertise may misinterpreted lead misperception legal action may potentially cause product sales stock price decline serious safety resistance drug interaction issues arise marketed products sales products could limited halted us regulatory authorities results operations would adversely affected operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis maintain compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda ema comparable regulatory agencies countries continuing clinical trials stribild compleraeviplera atripla truvada viread hepsera emtriva letairis ranexa ambisome cayston currently approved additional uses anticipate file marketing approval additional countries additional indications products next several years products may fail receive marketing approvals timely basis marketed products manufacture sell products subject extensive regulation review discovery previously unknown problems marketed products problems manufacturing promotional activities may result restrictions products including withdrawal products market fail comply applicable regulatory requirements including related promotion manufacturing could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution example fda rules often required conduct postapproval clinical studies assess known serious risk signals serious risk identify unexpected serious risk implement risk evaluation mitigation strategy products could include medication guide patient package insert communication plan healthcare providers elements fda deems necessary assure safe use drug could include imposing certain restrictions distribution use product failure comply requirements imposed sponsor fda could result significant civil monetary penalties operating results may adversely affected results anticipated timelines clinical trials uncertain may support continued development product pipeline would adversely affect prospects future revenue growth required demonstrate safety efficacy products develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products product candidates fails achieve primary endpoint clinical trials safety issues arise results clinical trials otherwise inadequate support regulatory approval product candidates commercialization product candidate could delayed halted example january announced decision terminate phase clinical trial ambrisentan patients ipf april announced decision terminate phase clinical trial aztreonam inhalation solution treatment cf patients burkholderia spp addition may also face challenges clinical trial protocol design clinical trials product candidates pipeline delayed terminated prospects future revenue growth would adversely impacted example face numerous risks uncertainties product candidates including sofosbuvir fixeddose combination sofosbuvir ledipasvir treatment hepatitis c aztreonam inhalation solution treatment bronchiectasis ranolazine treatment incomplete revascularization postpercutaneous coronary intervention type ii diabetes idelalisib treatment chronic lymphocytic leukemia currently phase clinical trials could prevent completion development product candidates risks include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain fda regulatory body approvals result product candidates may never successfully commercialized may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline programs others pipeline completed timely basis prospects future revenue growth may adversely impacted addition clinical trials involving commercial products could raise new safety issues existing products could turn decrease revenues harm business due reliance thirdparty contract research organizations conduct clinical trials unable directly control timing conduct expense quality clinical trials extensively outsource clinical trial activities usually perform small portion startup activities inhouse rely independent third party contract research organizations cros perform clinical studies including document preparation site identification screening preparation prestudy visits training program management bioanalytical analysis many important aspects services performed us cros direct control dispute disruption relationship cros clinical trials may delayed moreover regulatory submissions rely quality validity clinical work performed thirdparty cros cros ' processes methodologies results determined invalid inadequate clinical data results related regulatory approvals could adversely impacted expenses associated clinical trials may cause earnings fluctuate could adversely affect stock price clinical trials required regulatory approval products well clinical trials required conduct approval expensive difficult accurately predict control amount timing expenses quarter quarter fda andor regulatory agencies may require clinical testing originally anticipated uneven unexpected spending programs including clinical trials necessary advance sofosbuvir fixeddose combination sofosbuvir ledipasvir product candidates treatment hcv oncology may cause operating results fluctuate quarter quarter volatility stock price depend relationships companies sales marketing performance development commercialization product candidates revenues failure maintain relationships poor performance companies disputes companies could negatively impact business rely number significant collaborative relationships major pharmaceutical companies sales marketing performance certain territories include collaborations bms atripla united states europe canada f hoffmannla roche ltd together hoffmannla roche inc roche tamiflu worldwide gsk ambrisentan territories outside united states countries rely international distributors sales truvada viread hepsera emtriva ambisome relationships also involve clinical development products partners reliance collaborative relationships poses number risks including risk unable control resources corporate partners devote programs products disputes may arise respect ownership rights technology developed corporate partners disagreements corporate partners could cause delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose pursue competing technologies devote fewer resources marketing products products development distributors corporate partners may unable pay us particularly light current economic conditions given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenues products could decline also rely collaborative relationships major pharmaceutical companies development commercialization certain product candidates gilead successor pharmasset party october collaboration agreement roche agreement granted roche rights develop psi cytidine analog prodrugs treatment chronic hcv infection collaborative research efforts agreement ended december roche later asked pharmasset consider whether roche may contributed inventorship sofosbuvir whether pharmasset complied confidentiality provisions collaboration agreement pharmasset advised us carefully considered issues raised roche believed issues without merit also considered issues reached conclusion roche recently contacted gilead asserting roche exclusive license sofosbuvir pursuant collaboration agreement roche alleges sofosbuvir prodrug uridine monophosphate analog prodrug psi therefore roche exclusive license believe roche 's claim without merit however roche successfully establish inventorship exclusive license rights sofosbuvir expected revenues earnings sale sofosbuvir could adversely affected april licensing agreement gsk gave gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major markets hepsera china japan taiwan south korea november entered agreement gsk provided gsk exclusive commercialization rights registration responsibilities viread treatment chronic hbv china october granted similar rights gsk japan saudi arabia success hepsera viread treatment chronic hbv territories depends almost entirely efforts gsk regard gsk promotes epivirhbvzeffix product competes hepsera viread treatment chronic hbv consequently gsk 's marketing strategy hepsera viread treatment chronic hepatitis b may influenced promotion epivirhbvzeffix receive royalties gsk equal percentage gsk 's net sales hepsera viread treatment chronic hbv well net sales gsk 's epivirhbvzeffix gsk fails devote sufficient resources succeed developing commercializing hepsera viread treatment chronic hbv territories potential revenues territories may substantially reduced addition cayston letairis distributed thirdparty specialty pharmacies pharmacies specializing dispensing medications complex chronic conditions may require high level patient education ongoing counseling use specialty pharmacies requires significant coordination sales marketing medical affairs regulatory affairs legal finance organizations involves risks including limited risks specialty pharmacies provide us accurate timely information regarding inventories patient data safety complaints effectively sell support cayston letairis devote resources necessary sell cayston letairis volumes within time frames expect able satisfy financial obligations us others cease operations also rely third party administer leap restricted distribution program designed support letairis third party provides information education prescribers patients risks letairis confirms insurance coverage investigates alternative sources reimbursement assistance ensures fulfillment risk management requirements mandated letairis fda coordinates controls dispensing patients third party specialty pharmacies failure third party specialty pharmacies distribute letairis perform expected may result regulatory action fda decreased letairis sales either would harm business cayston may taken patients using specific inhalation device delivers drug lungs patients ongoing distribution cayston entirely reliant upon manufacturer device example manufacturer could encounter issues regulatory agencies related device unable supply sufficient quantities device addition manufacturer may able provide adequate warranty support device distributed patients respect distribution drug device patients reliant capabilities specialty pharmacies example distribution channel drug device complicated requires coordination reimbursement approval processes associated drug device similarly complex device manufacturer unable obtain reimbursement approval receives approval lowerthanexpected price sales cayston may adversely affected previously described issues may limit sales cayston would adversely affect financial results success depend significant degree ability protect patents intellectual property rights domestically internationally may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology patents proprietary rights important business success depend significant degree ability obtain patents licenses patent rights preserve trade secrets defend infringement efforts invalidate patents operate without infringing property others properly drafted enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents patent applications confidential period time patent issued result may know competitors filed patent applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete products addition competitors file patent applications covering technology may participate interferencederivation proceedings litigation determine right patent litigation interferencederivation proceedings unpredictable expensive even ultimately successful results operations may adversely affected events time time certain individuals entities may challenge patents example public patent foundation filed requests reexamination us patent trademark office pto challenging four patents related tenofovir disoproxil fumarate active ingredient stribild compleraeviplera atripla truvada viread pto granted requests pto confirmed patentability four patents time time may become involved disputes inventors patents example march jeremy clark former employee pharmasset acquired january inventor us patent filed demand arbitration lawsuit pharmasset dr raymond schinazi mr clark initially filed lawsuit pharmasset dr schinazi february seeking void assignment provision employment agreement assert ownership us patent claims metabolites sofosbuvir rg december court ordered stay litigation pending outcome arbitration proceeding required mr clark 's employment agreement instead proceeding arbitration mr clark filed two additional lawsuits september june subsequently dismissed court september mr clark filed motion seeking reconsideration court 's december order denied court december mr clark filed motion appoint special prosecutor february court issued order requiring mr clark enter arbitration risk dismissal case mr clark filed demand arbitration march arbitration panel set hearing date april predict outcome arbitration mr clark 's prior assignment patent pharmasset voided arbitration panel ultimately found owner patent determined infringed patent may required obtain license pay royalties mr clark commercialize sofosbuvir rg patents cover ranolazine compound active ingredient ranexa instead discovered sustained release formulation ranolazine would achieve therapeutic plasma levels patents obtained formulations characteristic plasma levels achieve patents cover active ingredients ambisome addition patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera asia major market therapies hbv indication hepsera developed may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions supplementary protection certificates countries generic manufacturers sought may continue seek fda approval market generic versions products anda application form typically used manufacturers seeking approval generic drug see description anda litigation legal proceedings beginning risk factor entitled litigation generic manufacturers reduced may continue reduce earnings unsuccessful lawsuits original claims patents may narrowed invalidated beginning success depends large part ability operate without infringing upon patents proprietary rights third parties infringe valid patents others may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware body patents may relate operation leap restricted distribution program designed support letairis patents claim sofosbuvir chemical entity metabolites however existence issued patents guarantee right practice patented technology commercialize patented product third parties may obtain rights patents may claim could used prevent attempt prevent us commercializing patented product candidates obtained pharmasset acquisition example aware patents patent applications owned parties might alleged cover use sofosbuvir parties successful obtaining valid enforceable patents establishing infringement patents could prevented selling sofosbuvir unless able obtain license patents license needed may available commercially reasonable terms instances may required defend right patent invention interference proceeding pto interference administrative proceeding pto designed determine first invent subject matter claimed parties february received notice pto declared interference us patent idenix pharmaceuticals inc 's idenix pending patent application patent covers metabolites sofosbuvir rg idenix attempting claim class compounds including metabolites pending patent application course proceeding parties called upon submit evidence date conceived respective inventions interference determine first invent compounds therefore entitled patent claiming compounds administrative law judge determines idenix entitled patent claims determined infringed claims may required obtain license pay royalties idenix commercialize sofosbuvir rg determination judge appealed either party us federal court june met idenix mandatory settlement discussions parties unable settle interference due widely divergent views strength respective positions whether need license idenix 's patents whether idenix needs license gilead patents develop manufacture pipeline products believe idenix application involved interference similar us foreign patents claiming compounds metabolites invalid result filed impeachment action canadian federal court invalidate idenix ca patent canadian patent corresponds idenix us patent idenix patent application subject interference filed similar legal action federal court norway seeking invalidate corresponding norwegian patent filed similar legal action federal court australia seeking invalidate corresponding australian patent may bring similar action countries idenix awarded patents compounds metabolites european countries japan china event patents issue expect challenge proceedings similar invoked canada norway australia furthermore use significant proprietary technology rely unpatented trade secrets proprietary knowhow protect certain aspects production technologies trade secrets may become known independently discovered competitors manufacturing problems including thirdparty manufacturers corporate partners could cause inventory shortages delay product shipments regulatory approvals may adversely affect results operations order generate revenue products must able produce sufficient quantities products satisfy demand many products result complex manufacturing processes manufacturing process pharmaceutical products also highly regulated regulators may shut manufacturing facilities believe comply regulations products either manufactured facilities thirdparty manufacturers corporate partners depend third parties perform manufacturing activities effectively timely basis majority solid dose products addition roche either third parties responsible manufacturing tamiflu thirdparty manufacturers corporate partners subject current good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda ema similar regulations effect countries thirdparty manufacturers corporate partners independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties cause delays clinical trials applications regulatory approval extent risks materialize affect performance obligations us financial results may adversely affected addition thirdparty manufacturers corporate partners may able produce products one limited number facilities therefore limited manufacturing capacity certain products example due unexpected delays qualifying two new external sites expanding cayston manufacturing san dimas unable supply enough cayston fulfill projected demand february september suspended access patients new prescriptions cayston subject certain exceptions specific medical need exists result inability manufacture sufficient cayston meet demand amount revenues received sale cayston reduced manufacturing operations subject routine inspections regulatory agencies example january february fda conducted routine inspection san dimas manufacturing facility exclusively manufacture cayston ambisome conclusion inspection fda issued form inspectional observations stating concerns maintenance aseptic processing conditions manufacturing suite ambisome product environmental maintenance issues san dimas warehousing facility batch sampling timeliness completion annual product quality reports september san dimas manufacturing facility received warning letter fda detailing fda 's concerns ambisome manufacturing environment including control systems monitoring procedures prevent microbiological contamination preventative cleaning equipment maintenance referencing certain viread lots letter also stated concerns connected quality procedures controls investigation procedures generalized concern effectiveness san dimas quality unit carrying responsibilities november december fda reinspected san dimas facility reinspection closed additional form observations august fda notified us resolved issues raised fda warning letter ability successfully manufacture commercialize cayston depend upon ability manufacture multiproduct facility aztreonam active pharmaceutical ingredient cayston monobactam gramnegative antibiotic manufacture cayston san dimas california third parties multiproduct manufacturing facilities historically fda permitted manufacture monobactams multiproduct manufacturing facilities however assurance fda continue allow practice currently singleproduct facility dedicated manufacture cayston engaged contract manufacturer singleproduct facility cayston fda prohibits manufacture monobactam antibiotics like aztreonam multiproduct manufacturing facilities future may able procure singleproduct manufacturing facility timely manner would adversely affect commercial supplies cayston anticipated financial results attributable product may able obtain materials supplies necessary conduct clinical trials manufacture sell products would limit ability generate revenues need access certain supplies products conduct clinical trials manufacture products light global economic downturn increased difficulty purchasing certain raw materials used manufacturing process unable purchase sufficient quantities materials find suitable alternate materials timely manner development efforts product candidates may delayed ability manufacture products would limited would limit ability generate revenues suppliers key components materials must named nda filed fda ema regulatory authority product candidate seeking marketing approval significant delays occur qualification new supplier required even manufacturer qualified regulatory authority manufacturer must continue expend time money effort area production quality control ensure full compliance gmp manufacturers subject regular periodic inspections regulatory authorities following initial approval result inspections regulatory authority determines equipment facilities laboratories processes comply applicable regulations conditions product approval regulatory authority may suspend manufacturing operations manufacturing operations single suppliers products suspended may unable generate sufficient quantities commercial clinical supplies product meet market demand would turn decrease revenues harm business addition delivery material suppliers interrupted reason may unable ship certain products commercial supply supply products development clinical trials addition products materials utilize operations made one facility example manufacture ambisome exclusively facilities san dimas california event disaster including earthquake equipment failure difficulty may unable replace manufacturing capacity timely manner may unable manufacture ambisome meet market needs cayston dependent two different thirdparty singlesource suppliers first aztreonam active pharmaceutical ingredient cayston manufactured single supplier single site second administered lungs patients device made single supplier single site disruptions delays single suppliers could adversely affect ability supply cayston sure alternative suppliers identified timely manner see risk factor entitled ability successfully manufacture commercialize cayston depend upon ability manufacture multiproduct facility addition depend single supplier highquality cholesterol used manufacture ambisome also rely single source active pharmaceutical ingredient hepsera letairis vistide tableting letairis astellas us llc markets lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan problems single suppliers depend may negatively impact development commercialization efforts significant portion raw materials intermediates used manufacture hiv products stribild compleraeviplera atripla truvada viread emtriva supplied chinesebased companies result international trade dispute china united states actions chinese government would limit prevent chinese companies supplying materials would adversely affect ability manufacture supply hiv products meet market needs material adverse effect operating results litigation generic manufacturers reduced may continue reduce earnings unsuccessful lawsuits original claims patents may narrowed invalidated generic versions products could launched prior patent expiry part approval process products fda granted new chemical entity nce exclusivity period manufacturers ' applications approval generic versions product granted generic manufacturers may challenge patents protecting products granted exclusivity one year prior end exclusivity period generic manufacturers sought may continue seek fda approval similar identical drug anda application form typically used manufacturers seeking approval generic drug received notices generic manufacturers submitted andas manufacture generic version atripla truvada viread hepsera ranexa tamiflu united states atripla truvada viread canada expect begin trial generic manufacturers february gilead teva reached agreement principle settle ongoing patent litigation concerning four patents protect tenofovir disoproxil fumarate viread truvada atripla products trial litigation adjourned pending completion activities necessary finalize settlement agreement teva allowed launch generic version viread december settlement agreement must filed federal trade commission department justice review final trial related ten patents associated ranexa scheduled begin april anticipate trial related two patents related hepsera begin mid trial related two patents protecting emtricitabine patent atripla scheduled begin october predict ultimate outcome actions may spend significant resources enforcing defending patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states atripla truvada viread canada could substantially shortened patents covering one products invalidated fda canadian ministry health could approve requests manufacture generic version products united states canada respectively prior expiration date patents sale generic versions products hepsera earlier patent expiration would significant negative effect revenues results operations face credit risks southern european customers may adversely affect results operations european product sales governmentowned supported customers southern europe specifically greece italy portugal spain historically continue subject significant payment delays due government funding reimbursement practices resulted may continue result days sales outstanding significantly higher countries due average length time accounts receivable remain outstanding december accounts receivable countries totaled approximately million million past due greater days million past due greater days follows thousands december greater greater days past due days past due italy spain portugal greece total historically receivable balances certain publiclyowned hospitals accumulate period time subsequently settled large lump sum payments pattern also experienced pharmaceutical companies sell directly hospitals significant changes occur reimbursement practices european governments government funding becomes unavailable may able collect amounts due us customers results operations would adversely affected collected million past due accounts receivable customers based spain portugal included million proceeds onetime factoring arrangement sold receivables spain greek government settled substantially outstanding receivables subject bond settlement zerocoupon bonds trade discount face value march greek government restructured sovereign debt impacted holders greek bonds result recorded million loss revenues gross margin could reduced imports countries products available lower prices prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported countries lower price markets cases pharmaceutical products sold steeply discounted prices developing world reexported european countries could resold much higher prices happens products particularly truvada viread agreed make available substantially reduced prices countries participating gilead access program atripla merck distributes substantially reduced prices hiv infected patients developing countries agreement revenues would adversely affected addition established partnerships thirteen indian generic manufacturers distribute highquality lowcost generic versions tenofovir disoproxil fumarate developing world countries including india generic versions medications licenses reexported united states europe markets outside countries revenues would adversely affected addition purchases products countries selling prices relatively low resale countries selling prices relatively high may adversely impact revenues gross margin may cause sales fluctuate quarter quarter example european union required permit products purchased one country sold another country purchases products countries selling prices relatively low resale countries selling prices relatively high affect inventory level held wholesalers cause relative sales levels various countries fluctuate quarter quarter reflect actual consumer demand given quarter quarterly fluctuations may impact earnings could adversely affect stock price harm business expensive litigation government investigations reduced may continue reduce earnings involved number litigation investigation disputerelated matters require us expend substantial internal financial resources expect matters continue require high level internal financial resources foreseeable future matters reduced continue reduce earnings please see description department justice investigation interference litigation proceedings idenix contract arbitration jeremy clark legal proceedings beginning outcome lawsuits lawsuits may brought us investigation investigations may initiated inherently uncertain adverse developments outcomes result significant expenses monetary damages penalties injunctive relief us could significantly reduce earnings cash flows harm business countries may required grant compulsory licenses products face generic competition products number developing countries government officials interested groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread july brazilian patent authority rejected patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread highest level appeal available us within brazilian patent authority currently patent brazil brazilian government purchases supply tenofovir disoproxil fumarate generic manufacturers addition concerns cost availability tamiflu related potential avian flu pandemic hn influenza generated international discussions compulsory licensing tamiflu patents example canadian government considered allowing canadian manufacturers manufacture export active ingredient tamiflu eligible developing least developed countries canada 's access medicines regime furthermore roche issued voluntary licenses permit thirdparty manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense india 's hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override tamiflu patents roche issue additional voluntary licenses permit thirdparty manufacturing tamiflu developments could reduce royalties receive roche 's sales tamiflu certain countries permit enforcement patents thirdparty manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales changes royalty revenue disproportionately affect pretax income earnings per share gross margins portion revenues derived royalty revenues recognized collaboration agreements third parties royalty revenues impact pretax income earnings per share gross margins disproportionately contributions revenues increase decrease royalty revenue could material could significantly impact operating results example roche 's tamiflu sales unpredictable variability due strong relationship seasonal influenza global pandemic planning efforts tamiflu royalties increased sharply first quarter primarily result pandemic planning initiatives worldwide tamiflu royalties since second quarter decreased due declining pandemic planning initiatives worldwide periods royalty revenue tamiflu increase see disproportionate increase pretax income earnings per share gross margins similarly periods royalty tamiflu decrease see disproportionate decrease pretax income earnings per share gross margins may face significant liability resulting products may covered insurance successful claims could materially reduce earnings testing manufacturing marketing use commercial products well product candidates development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others recent years coverage availability costeffective product liability insurance decreased may unable maintain sufficient coverage product liabilities may arise addition cost defend lawsuits pay damages product liability claims may exceed coverage unable maintain adequate coverage claims exceed coverage financial condition ability clinically test product candidates market products adversely impacted addition negative publicity associated claims regardless merit may decrease future demand products impair financial condition business disruptions natural manmade disasters may harm future revenues worldwide operations could subject business interruptions stemming natural manmade disasters may selfinsured corporate headquarters fremont locations together house majority research development activities san dimas oceanside manufacturing facilities located california seismically active region carry earthquake insurance significant recovery time could required resume operations financial condition operating results could materially adversely affected event major earthquake changes effective income tax rate could reduce earnings various factors may favorable unfavorable effects income tax rate factors include limited interpretations existing tax laws changes tax laws rates portion nondeductible pharmaceutical excise tax accounting stock options sharebased payments mergers acquisitions future levels rd spending changes accounting standards changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings resolution federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant could negative impact net income income tax returns audited federal state foreign tax authorities currently examination internal revenue service tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions resolution one exposures reporting period could material impact results operations period fail attract retain highly qualified personnel may unable successfully develop new product candidates conduct clinical trials commercialize product candidates future success depend large part continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical testing governmental regulation commercialization face competition personnel companies universities public private research institutions government entities organizations competition qualified personnel biopharmaceutical field intense limited pool qualified potential employees recruit may able attract retain quality personnel acceptable terms unsuccessful recruitment retention efforts business may harmed item b unresolved staff comments applicable item properties lease facilities foster city fremont palo alto san dimas california house manufacturing warehousing rd activities addition also lease facilities branford connecticut seattle washington house administrative rd activities order expand corporate headquarters completed purchase office building located velocity way foster city associated real property international headquarters include commercial medical administrative facilities located leased london area united kingdom manufacturing facility cork ireland primarily use solid dose tablet manufacturing antiviral products well product packaging activities also lease facility cork used shared services lease facilities dublin area ireland house distribution activities manufacturing facility edmonton alberta canada primarily use conduct process research scaleup clinical development candidates manufacturing active pharmaceutical ingredients investigational commercial products chemical development activities improve existing commercial manufacturing processes also manufacturing facility oceanside california designed equipped produce biologic compounds toxicological phase phase clinical studies use facility process development manufacture simtuzumab investigational monoclonal antibody candidate development treatment certain cancers fibrotic diseases another antibody leased additional facilities house commercial medical administrative activities australia austria belgium canada czech republic france germany greece hong kong ireland italy netherlands poland portugal russia spain south korea sweden switzerland turkey united kingdom also lease office shanghai china provide sourcing manufacturing support primarily related commercial purchases active pharmaceutical ingredients believe existing properties including owned leased sites good condition suitable conduct business believe capital resources sufficient purchase lease construct additional facilities required meet expected longterm growth needs item legal proceedings litigation generic manufacturers tenofovir disoproxil fumarate emtricitabine fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz november received notice teva pharmaceuticals teva submitted abbreviated new drug application anda us drug administration fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine owned emory university licensed exclusively us invalid unenforceable andor infringed teva 's manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate december filed lawsuit us district court new york teva infringement two emtricitabine patents march received notice teva submitted anda fda requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva challenged two emtricitabine patents may filed another lawsuit us district court new york teva infringement two emtricitabine patents lawsuit consolidated lawsuit filed december january received notice teva submitted anda fda requesting permission manufacture market generic version viread notice teva challenged four tenofovir disoproxil fumarate patents protecting viread january also received notices teva amending andas related generic versions atripla truvada products notice related teva 's anda generic version atripla teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine two patents related efavirenz notice related teva 's anda generic version truvada teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine march filed lawsuits teva infringement four viread patents two additional emtricitabine patents march bristolmyers squibb company merck co inc filed lawsuit teva infringement patents related efavirenz filed lawsuits within requisite day period provided hatch waxman act stays preventing fda approval teva 's andas months district court decision adverse patents month stay three teva andas expired july however result court 's scheduling orders teva prohibited launching risk upon expiration month stay gilead teva reached agreement principle settle ongoing patent litigation concerning four patents protect tenofovir disoproxil fumarate viread truvada atripla products trial litigation scheduled begin february adjourned pending completion activities necessary finalize settlement agreement teva allowed launch generic version viread december settlement agreement must filed federal trade commission department justice review final november received notice teva submitted abbreviated new drug submission ands canadian ministry health requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate notice teva alleges three patents associated truvada invalid unenforceable andor infringed teva 's manufacture use sale generic version truvada january filed lawsuit teva canadian federal court seeking order prohibition approval ands december received notice teva submitted ands canadian ministry health requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva alleges three patents associated atripla two merck 's patents associated atripla invalid unenforceable andor infringed teva 's manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz february filed lawsuit teva canadian federal court seeking order prohibition approval ands july received notice lupin limited lupin submitted anda fda requesting permission manufacture market generic version truvada notice lupin alleges four patents associated emtricitabine four patents associated tenofovir disoproxil fumarate invalid unenforceable andor infringed lupin 's manufacture use sale generic version fixeddose combination emtricitabine tenofovir disoproxil fumarate august filed lawsuit lupin us district court new york infringement patents july received notice cipla ltd submitted anda fda requesting permission manufacture market generic version emtriva generic version viread notice cipla alleges two patents associated emtricitabine invalid unenforceable andor infringed cipla 's manufacture use sale generic version emtricitabine four patents associated tenofovir disoproxil fumarate invalid unenforceable andor infringed cipla 's manufacture use sale generic version tenofovir disoproxil fumarate august filed lawsuits cipla us district court new york infringement patents august received notice teva submitted ands canadian ministry health requesting permission manufacture market generic version tenofovir disoproxil fumarate notice teva alleges two patents associated viread invalid unenforceable andor infringed teva 's manufacture use sale generic version viread september filed lawsuit teva canadian federal court seeking order prohibition approval ands also august teva filed impeachment action canadian federal court seeking invalidation two canadian patents associated viread currently defending impeachment action october received notice lupin submitted anda fda requesting permission manufacture market generic version viread notice lupin alleges four patents associated tenofovir disoproxil fumarate invalid unenforceable andor infringed lupin 's manufacture use sale generic version tenofovir disoproxil fumarate october filed lawsuit lupin us district court new york infringement patents ranolazine june received notice lupin submitted anda fda requesting permission manufacture market generic version sustained release ranolazine notice lupin alleges ten patents associated ranexa invalid unenforceable andor infringed lupin 's manufacture use sale generic version ranexa july filed lawsuit lupin us district court new jersey infringement patents ranexa fda approve lupin 's anda receive district court decision upon expiration court 's automatic stay july court scheduled trial begin april court finds none patents protect ranexa formulation infringed andor invalid lupin receives final approval product lupin able launch generic version ranexa product risk upon issuance decision adefovir disoproxil fumarate august received notice sigmapharm labs sigmapharm submitted anda fda requesting permission manufacture market generic adefovir dipivoxil notice sigmapharm alleges patents associated hepsera invalid unenforceable andor infringed sigmapharm 's manufacture use sale generic version hepsera september filed lawsuit sigmapharm us district court new jersey infringement patents fda approve sigmapharm 's anda receive district court decision upon expiration court 's automatic stay february court yet set trial date case anticipate trial occur mid upon expiry month stay february sigmapharm obtains final fda approval product fda may elect launch generic product risk infringing patents prior decision court one patents challenged sigmapharm also challenged ranbaxy inc ranbaxy pursuant notice received october patent challenged ranbaxy expires july option filing lawsuit time believe ranbaxy infringing patent tamiflu february received notice natco pharma ltd natco submitted anda fda requesting permission manufacture market generic oseltamivir phosphate notice natco alleges one patents associated tamiflu invalid unenforceable andor infringed natco 's manufacture use sale generic version tamiflu march f hoffmannla roche ltd filed lawsuit natco us district court new jersey infringement one patents associated tamiflu december court issued ruling favor gilead roche patent invalid reasons stated natco 's notice letter predict ultimate outcome actions may spend significant resources enforcing defending patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states atripla truvada viread canada could substantially shortened patents covering one products invalidated fda canadian ministry health could approve requests manufacture generic version products united states canada respectively prior expiration date patents sale generic versions products hepsera earlier patent expiration would significant negative effect revenues results operations department justice investigation june received subpoena us attorney 's office northern district california requesting documents related manufacture related quality distribution practices complera atripla truvada viread emtriva hepsera letairis cooperating continue cooperate governmental inquiry interference proceedings litigation idenix pharmaceuticals inc february received notice us patent trademark office pto declared interference us patent idenix pharmaceuticals inc 's idenix pending patent application interference administrative proceeding pto designed determine first invent subject matter claimed parties patent covers metabolites sofosbuvir rg idenix attempting claim class compounds including metabolites pending patent application course proceeding parties called upon submit evidence date conceived respective inventions interference determine first invent compounds therefore entitled patent claiming compounds administrative law judge determines idenix entitled patent claims determined infringed claims may required obtain license pay royalties idenix commercialize sofosbuvir rg determination pto appealed either party us federal court june met idenix mandatory settlement discussions parties unable settle interference due widely divergent views strength respective positions whether need license idenix 's patents whether idenix needs license gilead patents develop manufacture pipeline products believe idenix application involved interference similar us foreign patents claiming compounds metabolites invalid result filed impeachment action canadian federal court invalidate idenix ca patent canadian patent corresponds idenix us patent idenix patent application subject interference filed similar legal action federal court norway seeking invalidate corresponding norwegian patent filed similar legal action federal court australia seeking invalidate corresponding australian patent may bring similar action countries idenix awarded patents compounds metabolites european countries japan china event patents issue expect challenge proceedings similar invoked canada norway australia contract arbitration march jeremy clark former employee pharmasset inc pharmasset acquired january inventor us patent filed demand arbitration lawsuit pharmasset dr raymond schinazi mr clark initially filed lawsuit pharmasset dr schinazi alabama district court february seeking void assignment provision employment agreement assert ownership us patent claims metabolites sofosbuvir rg december court ordered stay litigation pending outcome arbitration proceeding required mr clark 's employment agreement instead proceeding arbitration mr clark filed two additional lawsuits september june subsequently dismissed court september mr clark filed motion seeking reconsideration court 's december order denied court december mr clark filed motion appoint special prosecutor february alabama court issued order requiring mr clark enter arbitration risk dismissal case mr clark filed demand arbitration march arbitration panel set hearing date april predict outcome arbitration mr clark 's prior assignment patent pharmasset voided arbitration panel ultimately found owner patent determined infringed patent may required obtain license pay royalties mr clark commercialize sofosbuvir rg matters party various legal actions arose ordinary course business believe legal actions material adverse impact consolidated business financial position results operations item mine safety disclosures applicable part ii item market registrant 's common equity related stockholder matters issuer purchases equity securities common stock traded nasdaq global select market symbol gild following table sets forth high low intraday sale prices per share common stock nasdaq global select market periods indicated prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low first quarter second quarter third quarter fourth quarter first quarter second quarter third quarter fourth quarter february shares common stock outstanding held approximately stockholders record include shares held broker bank nominee paid cash dividends common stock since inception expect retain earnings primarily use operation expansion business therefore anticipate paying cash dividends near future effort continue return value stockholders minimize dilution stock issuances january board directors board authorized threeyear billion stock repurchase program commenced september upon completion may stock repurchase program december repurchased billion common stock january stock repurchase program spent total million repurchase retire million shares common stock average purchase price per share suspend share repurchases first half order focus debt repayment see item note consolidated financial statements included annual report information regarding stock repurchase programs performance graph following graph compares total stockholder returns past five years two indices standard poor 's stock index labeled sp index nasdaq biotechnology index labeled nbi index total return index assumes reinvestment dividends paid companies included indices calculated december year composite member sp index nbi index intend use indices comparators stock performance purposes following graph going forward composite member sp index required applicable regulations use index comparator believe nbi index relevant comparator since composed peer companies linesofbusiness similar stockholder return shown graph necessarily indicative future performance make endorse predictions future stockholder returns comparison cumulative total return investment past five years section soliciting material deemed filed sec incorporated reference filings securities act exchange act whether made date hereof irrespective general incorporation language filing shows cumulative return investment assuming investment common stock nbi index sp index december issuer purchases equity securities december repurchased billion common stock january threeyear billion stock repurchase program spent total million repurchase retire million shares common stock average purchase price per share suspend share repurchases first half order focus debt repayment see item note consolidated financial statements included annual report information regarding stock repurchase programs table summarizes stock repurchase activity three months ended december thousands except per share amounts total number maximum fair shares purchased value shares part publicly may yet total number average price announced purchased shares purchased paid per share program program october october november november december december total january announced board authorized threeyear billion stock repurchase program expires january difference total number shares purchased total number shares purchased part publicly announced programs due shares common stock withheld us employee restricted stock awards order satisfy applicable tax withholding obligations item selected financial data gilead sciences inc selected consolidated financial data thousands except per share data year ended december consolidated statement income data total revenues total costs expenses income operations provision income taxes net income attributable gilead net income per share attributable gilead common stockholdersbasic shares used per share calculationbasic net income per share attributable gilead common stockholdersdiluted shares used per share calculationdiluted december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm obligations convertible senior notes senior unsecured notes credit facility retained earnings total stockholders ' equity recorded million million stockbased compensation research development rd expenses selling general administrative expenses respectively related acquisition pharmasset recorded million impairment charges rd expense related certain inprocess research development iprd assets acquired cgi pharmaceuticals inc recorded million impairment charges rd expense related certain iprd assets acquired cv therapeutics inc cv therapeutics completed acquisition assets navitas assets llc related cicletanine business aggregate purchase price million recorded iprd expense net income per share number shares used per share calculations periods presented reflect twoforone stock split form stock dividend effective january completed acquisition pharmasset recognized consideration transferred billion primarily recorded intangible assets financed transaction approximately billion cash hand billion bank debt issued january billion senior unsecured notes issued december completed acquisition cv therapeutics recognized consideration transferred billion primarily recorded intangible assets borrowed million fiveyear revolving credit facility credit agreement issued billion principal amount senior unsecured notes registered offerings issued billion principal amount convertible senior notes private placement item management 's discussion analysis financial condition results operations following management 's discussion analysis financial condition results operations mda intended help reader understand results operations financial condition mda provided supplement read conjunction audited consolidated financial statements accompanying notes consolidated financial statements disclosures included annual report including disclosures item risk factors consolidated financial statements prepared accordance us generally accepted accounting principles presented us dollars management overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery experimental drug candidate seek improve care patients suffering lifethreatening diseases around world gilead 's primary areas focus include human immunodeficiency virus hiv liver diseases hepatitis b virus hbv hepatitis c virus hcv serious cardiovascular respiratory conditions oncologyinflammation headquartered foster city california operations north america europe asia continue add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategy product portfolio comprised stribild compleraeviplera atripla truvada viread hepsera emtriva letairis ranexa ambisome cayston vistide us international commercial sales operations marketing subsidiaries north america europe asia addition also sell distribute certain products corporate partners royaltypaying collaborative agreements business highlights continue advance pipeline across therapeutic areas believe combination existing internal research programs recent acquisitions partnerships allow us continue bring innovative therapies individuals living unmet medical needs summary key accomplishments completed billion acquisition pharmasset inc pharmasset acquired lead compound known sofosbuvir nucleotide analog evaluated treatment hcv infection accelerated timeline develop first alloral hcv regimen result acquisition expanded worldwide access compleraeviplera available countries expanded research development rd pipeline active phase clinical studies end submitted marketing applications united states european union elvitegravir integrase inhibitor treatment hiv infection treatmentexperienced adults cobicistat pharmacoenhancing boosting agent increases blood levels allow oncedaily dosing certain hiv medicines us food drug administration fda set target review dates april prescription drug user fee act obtained fda approval launched stribild third single tablet regimen treatment hiv united states announced acquisition ym biosciences ym closed february expand growing oncologyinflammation pipeline obtained fda approval oncedaily oral truvada combination safer sex practices preexposure prophylaxis prep reduce risk hiv infection among uninfected adults outlook operating objectives include increasing market share commercial products continuing strengthen pipeline internally developed andor externally inlicensed purchased opportunities strengthening key alliances rd perspective continue advancing growing product pipeline focus progressing efforts towards filing marketing applications sofosbuvir treatment hcv developing additional innovative hiv single tablet regimens advancing new product candidates treatment oncology inflammation diseases result expect move forward number important latestage clinical studies related hiv hcv oncology inflammation commercial perspective number initiatives promote continued growth franchises hiv area scientific support earlier diagnosis treatment along use single tablet regimens remains compelling medically practically anticipation receiving regulatory approval sofosbuvir begin build commercial organization support expected launch product launched stribild single tablet regimen treatment hiv united states expect continued strong uptake stribild united states marketing application stribild currently reviewed european medicines agency approved expect make product available second quarter hbv area continue support educational promotional activities focused asian communities united states highlighting need screen diagnose link patients care cardiovascular area continue efforts raise awareness gilead pulmonary arterial hypertension cardiology communities mindful conditions current macroeconomic environment could affect ability achieve goals factors could affect business include changes legislation may delay impact funding adaps united states continuation worsening economic conditions certain key markets particularly europe patent expirations competitive products launch generic competitors continued government pricing pressures internationally potential volatility foreign currency exchange rates continue monitor conditions adjust business processes appropriate attempt mitigate risks business believe successes experienced enabled us continue build financially sound business model allow us continue expand commercial rd activities maintain quality compliance continue grow business remain focused profitable revenue growth prudent expense management believe enable solid execution operating objectives financial highlights total revenues grew billion driven strong underlying demand products total product sales billion increase due primarily growth antiviral franchise increased billion compared prior year sales letairis ranexa ambisome together surpassed billion mark reaching billion increase compared prior year royalty revenues collaborations corporate partners million increase compared prior year rd expenses increased billion progressed invested expansion product pipeline continued investing phase clinical studies particularly liver disease oncology selling general administrative sga expenses billion increase million reflective ongoing growth business increase pharmaceutical excise tax resulting us healthcare reform net income billion per diluted share decrease billion per diluted share primarily due continued progression investment product pipeline increase effective tax rate resulting shift geographic mix earnings expiration federal research tax credit increase acquisitionrelated expenses receive tax benefit december cash cash equivalents marketable securities totaled billion decrease billion december january completed pharmasset acquisition financed approximately billion cash hand billion senior unsecured notes issued december billion bank debt issued january generated billion operating cash flows used repay approximately billion debt financing repurchase retire shares common stock million results operations total revenues total revenues include product sales royalty revenues contract revenues total revenues billion billion billion increases total revenues driven growth product sales product sales total product sales billion increase total product sales billion primarily driven continued growth sales antiviral products including atripla truvada compleraeviplera increase also reflected sales growth products primarily letairis ranexa ambisome reached billion compared million total product sales increased compared billion primarily driven growth atripla truvada product sales generated outside united states result face exposure adverse movements foreign currency exchange rates primarily euro used foreign currency exchange forward contracts hedge percentage foreign currency exposure foreign currency exchange net hedges unfavorable impact million revenues compared favorable impact million revenues compared product sales united states increased billion compared billion primarily driven higher underlying demand antiviral products launch stribild august product sales therapeutic areas also contributed growth letairis sales totaled million increase compared ranexa sales totaled million increase compared ambisome sales totaled million increase compared product sales europe increased billion compared billion primarily driven higher underlying demand antiviral franchise antiviral product sales europe totaled billion increase compared billion primarily driven sales atripla truvada foreign currency exchange net hedges unfavorable impact million european product sales compared total product sales expected grow realize full year impact sales stribild continued growth compleraeviplera products cardiovascular franchise believe growth could tempered uncertainty around timing approval us federal budget possibility automatic reduction federal spending sequestration march unavailability delay aids drug assistance programs adap funding challenging economic environment europe results also subject continued potential volatility foreign currency exchange rates following table summarizes period period changes product sales thousands change change antiviral products atripla truvada viread compleraeviplera stribild hepsera emtriva total antiviral products letairis ranexa ambisome total product sales antiviral products antiviral product sales increased compared compared atripla atripla sales driven primarily sales volume growth united states atripla sales driven primarily sales volume growth europe united states atripla sales accounted total antiviral product sales respectively efavirenz component atripla gross margin zero comprised billion billion billion atripla sales respectively truvada truvada sales driven primarily sales volume growth united states truvada sales driven primarily sales volume growth europe united states truvada sales accounted total antiviral product sales respectively compleraeviplera sales compleraeviplera increased primarily due sales volume growth united states complera approved united states august eviplera approved european union november stribild stribild approved united states august product sales products include letairis ranexa ambisome increased due primarily sales volume growth since label update march sales letairis continued grow result higher enrollments increasing ambisome product sales united states canada relate solely sales ambisome astellas pharma us inc recorded manufacturing cost royalty revenues following table summarizes period period changes royalty revenues thousands change change royalty revenues royalty revenues increased compared driven primarily higher royalty revenues glaxosmithkline japan tobacco astellas partially offset lower tamiflu royalties roche since second quarter tamiflu royalties decreasing due decline flu planning initiatives worldwide significant source royalty revenues sales tamiflu roche royalty revenues declined compared due primarily lower tamiflu royalties roche tamiflu royalties roche contributed million million million total royalty revenues respectively recognize royalties tamiflu sales roche quarter following quarter corresponding sales occur cost goods sold product gross margin following table summarizes period period changes product sales thousands cost goods sold thousands product gross margin change change total product sales cost goods sold product gross margin product gross margin consistent product gross margin product gross margin decrease compared due primarily annual selling price adjustment percentage share atripla paid partner efavirenz component research development expenses change change research development manage rd expenses identifying rd activities anticipate performed given period prioritizing efforts based scientific data probability successful development market potential available human capital resources considerations continually review rd pipeline status development necessary reallocate resources among rd portfolio believe best support future growth business rd expenses summarized consist primarily clinical studies performed contract research organizations cros materials supplies licenses fees milestone payments collaboration arrangements personnel costs including salaries benefits stockbased compensation overhead allocations consisting various support facilitiesrelated costs following table provides breakout rd expenses major cost type thousands clinical studies outside services personnel expenses facilities costs iprd impairment charges total compared clinical studies outside services increased million due progression expansion phase studies particularly liver disease oncology personnel expenses increased million due higher headcount support product pipeline study progression compared clinical studies outside services increased million due study progression liver disease hiv new investments oncology inflammation new inlicense agreements milestones ongoing collaborations personnel expenses increased million due higher headcount facilities costs increased million support ongoing growth business increase partially offset million decrease iprd impairment charges recorded million impairment charges related certain iprd assets acquired cgi pharmaceuticals inc cgi impairment charges result changes anticipated market share related syk compound recorded million impairment charges related certain iprd assets acquired cv therapeutics inc majority impairment charge related gs program product candidate phase clinical studies treatment diabetes hypertriglyceridemia terminated fourth quarter due unfavorable results pharmacokinetics pharmacodynamics tests demonstrated limited effectiveness compound patients expect rd expenses increase levels due continued investment internal collaborative rd efforts advancement product pipeline driven primarily progression phase clinical studies liver disease oncology areas selling general administrative expenses change change selling general administrative sga expenses relate sales marketing finance human resources legal administrative activities expenses primarily comprised facilities overhead costs outside marketing advertising legal expenses general administrative costs compared sga expenses increased million increase due primarily million increase costs associated growth business include personnel headcountrelated expenses million increase stockbased compensation expenses primarily resulting acquisition pharmasset increase million pharmaceutical excise tax resulting us healthcare reform increase partially offset reduction bad debt provisions million included gain million related sale accounts receivables balances spain second quarter compared sga expenses increased million due primarily increased contract legal professional services million pharmaceutical excise tax million increased compensation benefits expenses million result higher headcount support expanding commercial activities promotional costs million driven expanding sales marketing activities bad debt provisions million associated slower collections southern european countries expect sga expenses increase support expansion business including prelaunch activities preparation anticipated nda filing sofosbuvir first half increase pharmaceutical excise tax also expect bad debt provisions return historical levels included significant collections past due accounts receivable spain portugal expect occur interest expense compared interest expense increased million increase due primarily additional debt issued connection acquisition pharmasset included billion senior unsecured notes issued december billion bank debt issued january compared interest expense increased million increase interest expense due primarily issuance convertible senior notes billion july issuance senior unsecured notes billion march issuance senior unsecured notes billion december increase partially offset maturity convertible senior notes due may aggregate principal balance million income expense net income expense net net expense million compared income million million respectively decrease income expense net compared due primarily decreased interest income resulting lower cash marketable securities balances yields million loss greek bonds related greece 's restructuring sovereign debt first quarter increase income expense net compared driven primarily favorable net foreign currency exchange impact increase interest income partially offset increase costs related hedging activities provision income taxes provision income taxes billion million billion respectively effective tax rate differed us federal statutory rate due primarily tax credits certain operating earnings nonus subsidiaries considered indefinitely reinvested partially offset state taxes stockbased compensation expense related pharmasset acquisition contingent consideration expense related certain acquisitions receive tax benefit provide us income taxes undistributed earnings foreign operations intended indefinitely reinvested foreign subsidiaries effective tax rate differed us federal statutory rate due primarily tax credits certain operating earnings nonus subsidiaries considered indefinitely reinvested partially offset state taxes nondeductible pharmaceutical excise tax effective tax rate differed us federal statutory rate due primarily tax credits certain operating earnings nonus subsidiaries considered indefinitely reinvested partially offset state taxes january us congress passed american taxpayer relief act retroactively reinstated federal research tax credit result income tax provision first quarter include discrete tax benefit related federal research tax credit reduce effective tax rate quarter lesser extent annual effective tax rate acquisition pharmasset january completed acquisition pharmasset publiclyheld clinicalstage pharmaceutical company committed discovering developing commercializing novel drugs treat viral infections pharmasset 's primary focus development oral therapeutics treatment hcv infection pharmasset 's lead compound known sofosbuvir formally known gs nucleotide analog january evaluated phase phase clinical studies treatment hcv infection across genotypes believe acquisition pharmasset provides us opportunity complement existing hcv portfolio helps advance effort develop alloral regimens treatment hcv acquired outstanding shares common stock pharmasset per share cash tender offer subsequent merger terms agreement plan merger entered november aggregate cash payment acquire outstanding shares common stock billion financed transaction approximately billion cash hand billion senior unsecured notes issued december billion bank debt issued january pharmasset acquisition accounted business combination results operations pharmasset included consolidated statement income since january date acquired approximately outstanding shares common stock pharmasset cash consideration transferred result obtained effective control pharmasset acquisition completed january time pharmasset became whollyowned subsidiary gilead integrated operations track earnings results product candidate therapeutic area maintain separate earnings results acquired pharmasset business following table summarizes components cash paid acquire pharmasset thousands total consideration transferred stockbased compensation expense total cash paid billion cash payment consisted billion cash payment outstanding common stockholders well million cash payment option holders pharmasset stock option plans billion cash payment outstanding common stockholders million cash payment vested option holders pharmasset stock option plans accounted consideration transferred remaining million cash payment accounted stockbased compensation expense resulting accelerated vesting pharmasset employee options immediately prior acquisition following table summarizes acquisition date fair values assets acquired liabilities assumed consideration transferred thousands identifiable intangible assets cash cash equivalents assets acquired liabilities assumed net total identifiable net assets goodwill total consideration transferred identifiable intangible assets acquired intangible assets primarily comprised sofosbuvir inprocess research development iprd compound estimated fair value billion date acquisition fair value determined using probabilityweighted income approach discounts expected future cash flows present value estimated net cash flows discounted using discount rate based estimated weightedaverage cost capital companies profiles similar pharmasset rate comparable estimated internal rate return acquisition represents rate market participants would use value intangible asset projected cash flows based key assumptions estimates revenues operating profits related project considering stage development acquisition date time resources needed complete development approval product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing product candidate obtaining marketing approval fda regulatory agencies risks related viability potential alternative treatments future target markets intangible assets related iprd projects considered indefinitelived assets amortized completion abandonment associated rd efforts goodwill million goodwill represents excess consideration transferred fair values assets acquired liabilities assumed attributable synergies expected combining rd operations pharmasset 's none goodwill expected deductible income tax purposes stockbased compensation expense stockbased compensation expense recognized accelerated vesting employee options immediately prior acquisition reported consolidated statement income follows thousands year ended december research development expense selling general administrative expense total stockbased compensation expense costs costs incurred connection acquisition include thousands year ended december transaction costs eg investment advisory legal accounting fees bridge financing costs restructuring costs total costs following table summarizes costs line item consolidated statement income costs recognized thousands year ended december research development expense selling general administrative expense interest expense total costs liquidity capital resources believe existing capital resources supplemented cash flows generated operating activities well cash flow financing activities adequate satisfy capital needs foreseeable future cash cash equivalents marketable securities decreased significantly completed acquisition pharmasset january following table summarizes cash cash equivalents marketable securities working capital cash flow activities end periods presented thousands december cash cash equivalents marketable securities working capital year ended december cash provided used operating activities investing activities financing activities cash cash equivalents marketable securities cash cash equivalents marketable securities totaled billion december decrease billion december primarily due acquisition pharmasset billion january generated billion cash flows operations cash cash equivalents marketable securities totaled billion december increase billion december increase primarily attributable issuance senior unsecured notes total net proceeds billion cash provided operations billion increase partially offset billion used repurchase common stock stock repurchase programs million used repay convertible senior notes due may million used acquisitions arresto biosciences inc calistoga pharmaceuticals inc billion net proceeds related senior unsecured notes issued december billion additional bank debt issued january used fund billion acquisition pharmasset total cash cash equivalents marketable securities december approximately billion generated operations foreign jurisdictions intended use foreign operations rely unrepatriated earnings source funds domestic business expect sufficient cash flow borrowing capacity united states fund domestic operational strategic needs working capital working capital billion december decrease billion working capital december primarily attributable billion cash used pharmasset acquisition increase shortterm debt billion related current portion bank debt issued finance pharmasset acquisition current portion convertible senior notes due may working capital billion december increase billion working capital december increase primarily attributable increase billion cash cash equivalents shortterm marketable securities resulting billion net issuance senior unsecured notes december sales longterm marketable securities anticipation acquisition pharmasset cash provided operating activities cash provided operating activities billion primarily related net income billion adjusted noncash items million depreciation amortization expenses million stockbased compensation expenses million net cash inflow related changes operating assets liabilities million tax benefits employee stock plans cash provided operating activities billion primarily related net income billion adjusted noncash items million depreciation amortization expenses million net cash inflow related changes operating assets liabilities million stockbased compensation expenses cash provided operating activities billion primarily related net income billion adjusted noncash items million depreciation amortization expenses million stockbased compensation expenses million iprd impairment expenses million tax benefits employee stock plans partially offset million net cash outflow related changes operating assets liabilities cash provided used investing activities cash used investing activities billion consisting primarily billion used acquisition pharmasset net stockbased compensation expense cash acquired million net purchases marketable securities million capital expenditures related primarily purchase office building million million increase construction progress associated new facilities headquarters support ongoing growth business cash provided investing activities billion consisting billion net proceeds related sales marketable securities connection acquisition pharmasset partially offset million used acquisitions arresto calistoga million capital expenditures cash used investing activities billion driven billion net purchases marketable securities million used acquisition cgi million capital expenditures cash provided used financing activities cash provided financing activities million driven primarily net proceeds billion issuance bank debt conjunction pharmasset acquisition proceeds million issuances common stock employee stock plans million proceeds received related convertible note hedges cash proceeds partially offset billion used repay debt financing year million used repurchase common stock stock repurchase programs including commissions upcoming maturity may convertible notes suspending share repurchase activity first half cash provided financing activities billion driven primarily issuance billion senior unsecured notes billion raised december partially fund pharmasset acquisition net issuance costs million proceeds issuances common stock employee stock plans cash proceeds partially offset billion used repurchase common stock stock repurchase programs including commissions million used repay convertible senior notes due may cash used financing activities billion driven primarily billion used repurchase common stock stock repurchase programs million used purchase note hedges related convertible senior notes due may may cash outflows partially offset billion net proceeds issuance notes million proceeds issuances common stock employee stock plans million proceeds sale warrants related notes longterm obligations bank debt january conjunction acquisition pharmasset entered fiveyear billion revolving credit facility credit agreement five year revolving credit agreement million shortterm revolving credit facility credit agreement shortterm revolving credit agreement billion term loan facility term loan credit agreement borrowed aggregate principal amount billion follows million fiveyear revolving credit agreement million shortterm revolving credit agreement billion term loan credit agreement upon close acquisition fully repaid billion outstanding debt term loan credit agreement shortterm revolving credit agreement time agreements terminated fiveyear revolving credit agreement contains customary representations warranties affirmative negative financial maintenance covenants events default loan bears interest either eurodollar rate plus applicable margin ii base rate plus applicable margin defined credit agreement may reduce commitments may prepay loan whole part time without premium penalty fiveyear revolving credit agreement inclusive million swing line loan subfacility million letter credit subfacility december million letters credit outstanding fiveyear revolving credit agreement fiveyear revolving credit agreement terminate amounts owed agreement shall due payable january convertible senior notes senior unsecured notes portion convertible notes due may converted repaid million principal balance also paid million cash related conversion spread notes represents conversion value excess principal amount received million cash convertible note hedges related notes december issued senior unsecured notes registered offering aggregate principal amount billion partially fund acquisition pharmasset pay interest notes fixed annual rates ranging also convertible senior notes due may matured repaid aggregate principal balance million also paid million cash related conversion spread matured notes represent conversion value excess principal amount received million cash related convertible note hedges warrants related convertible senior notes due may expired august march issued senior unsecured notes due april registered offering aggregate principal amount billion notes pay interest fixed annual rate december debttoebitda ratio x repaid billion debt financing plan continue repay debt decrease debttoebitda ratio following summary borrowings various financing arrangements thousands interest december type borrowing description issue date due date rate convertible senior may notes april may convertible senior may notes july may convertible senior may notes july may senior unsecured april notes march april senior unsecured december notes december december senior unsecured december notes december december senior unsecured december notes december december senior unsecured december notes december december credit facility fiveyear revolver january january variable total debt net less current portion total longterm debt net believe existing capital resources supplemented cash generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including limited following commercial performance current future products progress scope rd efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities administrative expenses possibility acquiring additional manufacturing capabilities office facilities possibility acquiring companies new products costs associated settlement conversion convertible senior notes related warrants establishment additional collaborative relationships companies costs associated defense settlement adverse results litigation government investigations may future require additional funding could form proceeds equity debt financings funding required guarantee available us favorable terms critical accounting policies estimates judgments discussion analysis financial condition results operations based consolidated financial statements prepared accordance us generally accepted accounting principles preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate estimates including related revenue recognition allowance doubtful accounts valuation intangible assets contingent consideration liabilities resulting business combination tax provision base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements revenue recognition product sales recognize revenues product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectability reasonably assured record estimated reductions revenues government rebates medicaid reimbursements customer incentives cash discounts prompt payment distributor fees expected returns expired products estimates deducted gross product sales time revenues recognized reductions gross product sales government rebates significantly impact reported net product sales based upon certain estimates require complex significant judgment management government rebates allowances accrued government rebates estimate reductions revenues governmentmanaged medicaid programs well certain qualifying federal state foreign government programs reimbursement portions retail price prescriptions filled covered programs reductions settled either us invoiced directly chargebacks wholesalers government rebates invoiced directly us recorded accrued government rebates consolidated balance sheets qualified programs purchase products wholesalers lower contractual government price wholesalers charge back us difference acquisition cost lower contractual government price record allowances accounts receivable although may pay rebates countries outside united states date payments made foreign governments represented significant portion total government rebates government programs united states estimate sales allowances based contractual terms historical utilization rates new information regarding changes programs ' regulations guidelines would impact amount actual rebates expectations regarding future utilization rates programs channel inventory data obtained major us wholesalers accordance inventory management agreements us government rebates chargebacks billion billion billion respectively representing total gross product sales respectively deducted gross product sales believe methodology use estimate sales allowances government price reductions reasonable appropriate given current facts circumstances however actual results may differ based current information available us actual government rebates claimed periods varied less estimates recorded periods december accrued us government rebates million million respectively accrued government rebates allowance government chargebacks million million respectively recorded accounts receivable following table summarizes aggregate activity us government rebates allowance accrued government rebate accounts balance deducted balance beginning charged end year expense accruals year year ended december government rebates allowances accrued government rebates activity related sales activity related sales prior total year ended december government rebates allowances accrued government rebates activity related sales activity related sales prior total allowance doubtful accounts maintain allowance doubtful accounts estimated losses resulting inability customers make required payments allowance based analysis several factors including limited contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding geographic region review local economic environment potential impact government funding reimbursement practices financial condition customers economic environment operate deteriorate resulting inability make payments additional allowances may required believe allowance doubtful accounts adequate however significant deterioration factors could materially change expectations may result increase allowance doubtful accounts december allowance doubtful accounts million million respectively valuation intangible assets contingent consideration liabilities resulting business combination conjunction business combinations recorded intangible assets primarily related iprd projects recorded contingent consideration liabilities payable upon achievement specified development regulatory approval salesbased milestone events identifiable intangible assets contingent consideration liabilities measured respective fair values acquisition date models used valuing intangible assets contingent consideration liabilities require use significant estimates assumptions including limited estimates revenues operating profits related products product candidates probability success unapproved product candidates considering stages development time resources needed complete development approval product candidates life potential commercialized products associated risks including inherent difficulties uncertainties developing product candidate obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets intangible assets indefinite useful lives reviewed annually impairment facts circumstances suggest carrying value assets may recoverable revalue contingent consideration obligations quarter following acquisition record increases decreases fair value rd expense within consolidated statement income increases decreases fair value indefinitelived intangible assets contingent consideration liabilities result updates assumptions expected timing probability achieving specified milestones changes projected revenues changes discount rates significant judgment employed determining assumptions acquisition date subsequent period updates assumptions could significant impact results operations given period actual results may differ estimates december total intangible assets billion billion respectively contingent consideration liabilities million million respectively tax provision estimate income tax provision including deferred tax assets liabilities based significant management judgment evaluate realization portion deferred tax assets quarterly basis record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance expect realize deferred tax assets previously recorded valuation allowance reduce valuation allowance period determination first made various factors may favorable unfavorable effects income tax rate factors include limited interpretations existing tax laws changes tax laws rates portion nondeductible pharmaceutical excise tax accounting stock options sharebased payments mergers acquisitions future levels rd spending changes accounting standards changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings resolution federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant could negative impact net income record liabilities related uncertain tax positions accordance guidance clarifies accounting uncertainty income taxes recognized enterprise 's financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return believe uncertain tax positions currently pending material adverse effect consolidated financial statements although adverse resolution one uncertain tax positions period could material impact results operations period december total federal state foreign unrecognized tax benefits million million respectively total unrecognized tax benefits million million december respectively recognized would reduce effective tax rate period recognition december believe reasonably possible unrecognized tax benefits significantly change next months expect clarification irs tax authorities regarding uncertain tax positions file federal state foreign income tax returns many jurisdictions united states abroad federal income tax purposes statute limitations open onwards certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years california income tax purposes statute limitations open onwards income tax returns audited federal state foreign tax authorities currently examination irs tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions balance sheet arrangements balance sheet arrangements defined item aii regulation sk contractual obligations contractual obligations consist debt obligations operating leases capital commitments purchase obligations active pharmaceutical ingredients inventoryrelated items clinical trials contracts following table summarizes significant enforceable legally binding obligations future commitments obligations related contracts likely continue regardless fact certain obligations may cancelable december thousands payments due period less one contractual obligations total year years years years longterm debt operating lease obligations capital commitments purchase obligations clinical trials total longterm debt obligations include future interest payments based fixed rates convertible senior notes due may may may respectively longterm debt obligations also include future interest payments based fixed rates senior unsecured notes due december december april december december respectively december aggregate carrying values convertible notes senior unsecured notes billion billion respectively december firm capital project commitments approximately million primarily relating facilities improvement projects december firm purchase commitments related active pharmaceutical ingredients certain inventoryrelated items amounts include minimum purchase requirements actual purchases expected significantly exceed amounts addition committed make potential future milestone payments third parties part licensing collaboration development arrangements payments agreements generally become due payable upon achievement certain developmental regulatory andor commercial milestones achievement milestones neither probable reasonably estimable contingencies recorded consolidated balance sheets included table december several clinical studies various clinical trial phases significant clinical trial expenditures cros although material contracts cros cancelable historically cancelled contracts amounts reflect commitments based existing contracts reflect future modifications terminations existing contracts anticipated potential new contracts total gross unrecognized tax benefit liabilities million december believe reasonably possible unrecognized tax benefits significantly change next months expect clarification irs tax authorities regarding uncertain tax positions unrecognized tax benefits included longterm income taxes payable noncurrent deferred tax assets consolidated balance sheet included table recent accounting pronouncement july financial accounting standards board issued new accounting guidance intended simplify testing indefinitelived intangible assets impairment entities allowed option first perform qualitative assessment impairment indefinitelived intangible assets determine whether quantitative assessment necessary guidance effective impairment tests performed interim annual periods fiscal years beginning september early adoption permitted elected early adopt guidance december material impact consolidated financial statements item quantitative qualitative disclosures market risk exposed market risks may result changes foreign currency exchange rates interest rates credit risks reduce certain risks enter various types foreign currency interest rate derivative hedging transactions follow investment guidelines monitor outstanding receivables part risk management program foreign currency exchange risk operations include manufacturing sales activities united states canada ireland well sales activities countries outside united states including europe asia result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes foreign currency exchange rates us dollar various foreign currencies significant euro us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business product sales denominated foreign currencies partially mitigate impact changes currency exchange rates net cash flows foreign currency denominated sales may enter foreign currency exchange forward option contracts also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid general market risks contracts offset corresponding gains losses transactions hedged december open foreign currency forward contracts notional amounts billion billion respectively hypothetical adverse movement foreign currency exchange rates compared us dollar relative exchange rates december would resulted reduction fair value contracts approximately million date realized would negatively affect earnings remaining life contracts hypothetical adverse movement foreign currency exchange rates compared us dollar relative exchange rates december would resulted reduction fair value contracts approximately million date realized would negatively affect earnings remaining life contracts analysis consider impact hypothetical changes foreign currency exchange rates would anticipated transactions foreign currency sensitive instruments designed offset interest rate risk portfolio availableforsale marketable securities fixed variable rate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based credit rating maturity industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates interestgenerating assets fixed interestbearing liabilities december dollars thousands expected maturity total fair value thereafter total december assets available forsale debt securities average interest rate liabilities longterm debt average interest rate december issued senior unsecured notes due december registered offering notes pay interest fixed annual rates ranging march issued senior unsecured notes due april registered offering notes pay interest fixed annual rate july issued convertible senior notes due may may private placement pursuant rule securities act amended notes due may may issued par bear interest rates respectively may converted shares common stock subject certain circumstances april issued convertible senior notes due may private placement pursuant rule securities act amended notes issued par bear interest rates may converted shares common stock subject certain circumstances first quarter connection acquisition pharmasset entered credit agreements subject variable interest rates portion interest expense related variable interest totaled million credit risk subject credit risk portfolio cash equivalents marketable securities investment policy limit amounts invested securities credit rating maturity industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales majority trade accounts receivable arises product sales united states europe second quarter received payment million past due accounts receivable customers based spain included amount proceeds onetime factoring arrangement sold receivables carrying value million net allowance doubtful accounts received proceeds million recorded gain million resulting primarily reversal related allowance doubtful accounts gain recorded offset sga expenses consolidated statement income subsequent transaction continuing involvement transferred receivables derecognized time sale december accounts receivable southern europe specifically greece italy portugal spain totaled approximately million million past due greater days million past due greater days december accounts receivable southern europe specifically greece italy portugal spain totaled approximately billion million past due greater days million past due greater days date experienced significant losses respect collection accounts receivable believe allowance doubtful accounts adequate december item financial statements supplementary data financial statements required item set forth beginning annual report incorporated herein reference item changes disagreements accountants accounting financial disclosure applicable item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness disclosure controls procedures defined rule ae securities exchange act amended exchange act controls procedures company designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified securities exchange commission 's rules forms information accumulated communicated company 's management including chief executive officer chief financial officer appropriate allow timely decisions regarding required disclosure based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective december b management 's report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af exchange act internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including chief executive officer chief financial officer conducted evaluation effectiveness internal control financial reporting based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission coso based evaluation concluded internal control financial reporting effective december independent registered public accounting firm ernst young llp audited consolidated financial statements included annual report issued report internal control financial reporting december report audit internal control financial reporting appears c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting report independent registered public accounting firm board directors stockholders gilead sciences inc audited gilead sciences inc 's internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso criteria gilead sciences inc 's management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying management 's report internal control financial reporting responsibility express opinion company 's internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion company 's internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles company 's internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition company 's assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion gilead sciences inc maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states consolidated financial statements gilead sciences inc report dated february expressed unqualified opinion thereon ernst young llp redwood city california february item b information applicable part iii item directors executive officers corporate governance information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed securities exchange commission pursuant regulation connection annual meeting stockholders proxy statement headings nominees directors standing reelection board committees meetings executive officers section beneficial ownership reporting compliance written code ethics applies directors employees including executive officers including without limitation principal executive officer principal financial officer principal accounting officer controller persons performing similar functions code ethics available website httpwwwgileadcom investors section corporate governance changes waivers code ethics disclosed website intend satisfy disclosure requirement item form k regarding amendment waiver provision code ethics disclosing information website item executive compensation information required item incorporated reference sections proxy statement headings executive compensation compensation committee interlocks insider participation compensation committee report compensation nonemployee board members item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference sections proxy statement headings security ownership certain beneficial owners management securities authorized issuance equity compensation plans item certain relationships related transactions director independence information required item incorporated reference sections proxy statement headings nominees directors standing reelection certain relationships related party transactions item principal accountant fees services information required item incorporated reference section proxy statement heading principal accountant fees services part iv item exhibits financial statement schedules following documents filed part annual report index list consolidated financial statements report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements comprehensive income consolidated statements stockholders ' equity consolidated statements cash flows notes consolidated financial statements schedule ii included report schedules omitted required required information included financial statements notes thereto exhibits following exhibits filed herewith incorporated reference item exhibits exhibit footnote exhibit number description document agreement plan merger among registrant apex merger sub inc cv therapeutics inc dated march agreement plan merger among registrant merger sub pharmasset inc dated november restated certificate incorporation registrant amended may amended restated bylaws registrant amended restated may reference made exhibit exhibit indenture related convertible senior notes due notes registrant wells fargo bank national association trustee including form convertible senior note due dated april indenture related convertible senior notes due notes registrant wells fargo bank national association trustee including form convertible senior note due dated july indenture related convertible senior notes due notes registrant wells fargo bank national association trustee including form convertible senior note due dated july indenture related senior notes dated march registrant wells fargo national association trustee first supplemental indenture related senior notes dated march registrant wells fargo national association trustee including form senior notes second supplemental indenture related senior notes dated december registrant wells fargo national association trustee including form note form note form note form note confirmation otc convertible note hedge related notes dated april amended restated april registrant bank america na confirmation otc warrant transaction dated april amended restated april registrant bank america na warrants expiring confirmation otc convertible note hedge related notes dated july registrant goldman sachs co confirmation otc convertible note hedge related notes dated july registrant jpmorgan chase bank national association confirmation otc convertible note hedge related notes dated july registrant goldman sachs co confirmation otc convertible note hedge related notes dated july registrant jpmorgan chase bank national association confirmation otc warrant transaction dated july registrant goldman sachs co warrants expiring confirmation otc warrant transaction dated july registrant jpmorgan chase bank national association warrants expiring confirmation otc warrant transaction dated july registrant goldman sachs co warrants expiring confirmation otc warrant transaction dated july registrant jpmorgan chase bank national association warrants expiring confirmation otc additional convertible note hedge related notes dated august registrant goldman sachs co confirmation otc additional convertible note hedge related notes dated august registrant jpmorgan chase bank national association confirmation otc additional convertible note hedge related notes dated august registrant goldman sachs co confirmation otc additional convertible note hedge related notes dated august registrant jpmorgan chase bank national association confirmation otc additional warrant transaction dated august registrant goldman sachs co warrants expiring confirmation otc additional warrant transaction dated august registrant jpmorgan chase bank national association warrants expiring confirmation otc additional warrant transaction dated august registrant goldman sachs co warrants expiring confirmation otc additional warrant transaction dated august registrant jpmorgan chase bank national association warrants expiring amendment confirmation otc convertible note hedge related notes dated august registrant goldman sachs co amendment confirmation otc convertible note hedge related notes dated august registrant jpmorgan chase bank national association amendment confirmation otc convertible note hedge related notes dated august registrant goldman sachs co amendment confirmation otc convertible note hedge related notes dated august registrant jpmorgan chase bank national association amendment confirmation otc additional convertible note hedge related notes dated august registrant goldman sachs co amendment confirmation otc additional convertible note hedge related notes dated august registrant jpmorgan chase bank national association amendment confirmation otc additional convertible note hedge related notes dated august registrant goldman sachs co amendment confirmation otc additional convertible note hedge related notes dated august registrant jpmorgan chase bank national association year revolving credit facility credit agreement among registrant gilead biopharmaceutics ireland corporation borrowers bank america na administrative agent swing line lender lc issuer certain lenders parties thereto barclays capital syndication agent goldman sachs bank usa jpmorgan chase bank na royal bank canada wells fargo bank na codocumentation agents dated january parent guaranty agreement year revolving credit facility dated january registrant gilead sciences inc stock option plan amended january form option agreements used stock option plan gilead sciences inc nonemployee directors ' stock option plan amended january form option agreement used gilead sciences inc nonemployee directors ' stock option plan gilead sciences inc equity incentive plan amended may form employee stock option agreement used equity incentive plan grants prior february form employee stock option agreement used equity incentive plan grants made february april form employee stock option agreement used equity incentive plan grants commencing may form employee stock option agreement used equity incentive plan grants commencing february form employee stock option agreement used equity incentive plan subsequent year grants form nonemployee director stock option agreement used equity incentive plan grants prior form nonemployee director option agreement used equity incentive plan initial grants made form nonemployee director option agreement used equity incentive plan annual grants made may form nonemployee director option agreement used equity incentive plan annual grants commencing may form restricted stock unit issuance agreement used equity incentive plan annual grants nonemployee directors commencing may form restricted stock award agreement used equity incentive plan annual grants certain nonemployee directors prior may form performance share award agreement used equity incentive plan grants certain executive officers made form performance share award agreement used equity incentive plan grants certain executive officers made form performance share award agreement used equity incentive plan grants certain executive officers made form performance share award agreement used equity incentive plan grants certain executive officers made form restricted stock unit issuance agreement used equity incentive plan grants certain executive officers made prior may form restricted stock unit issuance agreement used equity incentive plan grants certain executive officers commencing may form restricted stock unit issuance agreement used equity incentive plan servicebased vesting certain executive officers commencing november form restricted stock unit issuance agreement used equity incentive plan servicebased vesting certain executive officers commencing gilead sciences inc employee stock purchase plan amended restated november gilead sciences inc international employee stock purchase plan adopted november gilead sciences inc deferred compensation planbasic plan document gilead sciences inc deferred compensation planadoption agreement addendum gilead sciences inc deferred compensation plan gilead sciences inc deferred compensation plan amended restated october gilead sciences inc severance plan amended january gilead sciences inc corporate bonus plan amended restated gilead sciences inc code section bonus plan base salaries named executive officers offer letter dated april registrant robin washington form indemnity agreement entered registrant directors executive officers form employee proprietary information invention agreement entered registrant certain officers key employees form employee proprietary information invention agreement entered registrant certain officers key employees revised september amended restated collaboration agreement among registrant gilead holdings llc bristolmyers squibb company er squibb sons llc bristolmyers squibb gilead sciences llc dated september commercialization agreement gilead sciences limited bristolmyers squibb company dated december amendment agreement dated october registrant institute organic chemistry biochemistry iocb rega stichting vzw rega together following exhibits license agreement dated december registrant iocb rega license agreement license agreement dated october registrant iocb rega october license agreement license agreement dated december registrant iocb rega december license agreement amendment agreement registrant iocbrega dated december amending license agreement december license agreement sixth amendment agreement license agreement iocbrega registrant dated august amending october license agreement december license agreement development license agreement among registrant f hoffmannla roche ltd hoffmannla roche inc dated september first amendment supplement dated november development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc dated september second amendment dated december development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc dated september third amendment dated october development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc dated september exclusive license agreement registrant successor triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university dated may royalty sale agreement among registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july amended restated license agreement registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july license agreement japan tobacco inc registrant dated march first amendment license agreement japan tobacco inc registrant dated may second amendment license agreement japan tobacco inc registrant dated may third amendment license agreement japan tobacco inc registrant dated july fourth amendment license agreement japan tobacco inc registrant dated july license agreement registrant successor myogen inc abbott deutschland holding gmbh dated october license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc dated march first amendment license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc dated july amendment license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc dated november amendment license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc dated june amendment license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc dated december license collaboration agreement among registrant gilead sciences limited janssen rd ireland formerly tibotec pharmaceuticals dated july second amendment license collaboration agreement among registrant gilead sciences limited janssen rd ireland formerly tibotec pharmaceuticals dated july master clinical commercial supply agreement gilead world markets limited registrant patheon inc dated january tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated july addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated may addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated december addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated february tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited ampac fine chemicals llc dated november restated amended toll manufacturing agreement gilead sciences limited registrant nycomed gmbh formerly altana pharma oranienburg gmbh dated november emtricitabine manufacturing supply agreement gilead sciences limited evonik degussa gmbh formerly known degussa ag dated june amendment emtricitabine manufacturing supply agreement gilead sciences limited evonik degussa gmbh formerly known degussa ag dated april purchase sale agreement joint escrow instructions electronics imaging inc registrant dated july amendment dated october purchase sale agreement joint escrow instructions electronics imaging inc registrant dated july subsidiaries registrant consent independent registered public accounting firm power attorney reference made signature certification chief executive officer required rule aa rule da securities exchange act amended certification chief financial officer required rule aa rule da securities exchange act amended certifications chief executive officer chief financial officer required rule ab rule db section chapter title united states code usc following materials registrant 's annual report year ended december formatted extensible business reporting language xbrl includes consolidated balance sheets december ii consolidated statements income years ended december iii consolidated statements comprehensive income years ended december iv consolidated statements stockholders ' equity years ended december v consolidated statements cash flows years ended december vi notes consolidated financial statements filed exhibit registrant 's current report form k filed march incorporated herein reference filed exhibit registrant 's current report form k filed november incorporated herein reference filed exhibit registrant 's current report form k filed may incorporated herein reference filed exhibit registrant 's current report form k filed april incorporated herein reference filed exhibit registrant 's current report form k filed august incorporated herein reference filed exhibit registrant 's current report form k filed april incorporated herein reference filed exhibit registrant 's current report form k filed december incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's current report form k filed january incorporated herein reference filed exhibit registrant 's registration statement form filed january incorporated herein reference filed exhibit registrant 's registration statement form amended incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's current report form k filed may incorporated herein reference filed exhibit registrant 's current report form ka filed february incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended march incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended march incorporated herein reference filed exhibit registrant 's current report form k first filed december incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended march incorporated herein reference filed exhibit registrant 's registration statement form filed december incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference information included registrant 's current report form k filed february incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's annual report fiscal year ended march incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit triangle pharmaceuticals inc 's quarterly report form qa filed november incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended march incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit myogen inc 's registration statement form amended originally filed august incorporated herein reference filed exhibit cv therapeutics inc 's registration statement form amended originally filed april incorporated herein reference filed exhibit cv therapeutics inc 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's current report form k filed august incorporated herein reference filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference agreement plan merger merger agreement contains representations warranties registrant apex merger sub inc cv therapeutics inc made solely specific dates representations warranties made solely purposes merger agreement may subject important qualifications limitations agreed registrant apex merger sub inc cv therapeutics inc moreover representations warranties may accurate complete specified date may subject standard materiality provided merger agreement used purpose allocating risk among registrant apex merger sub inc cv therapeutics inc rather establishing matters facts agreement plan merger pharmasset merger agreement contains representations warranties registrant merger sub pharmasset inc made solely specific dates representations warranties made solely purposes pharmasset merger agreement may subject important qualifications limitations agreed registrant merger sub pharmasset inc moreover representations warranties may accurate complete specified date may subject standard materiality provided pharmasset merger agreement used purpose allocating risk among registrant merger sub pharmasset inc rather establishing matters facts management contract compensatory plan arrangement certification accompanies relates deemed filed securities exchange commission incorporated reference filing registrant securities act amended securities exchange act amended whether made date irrespective general incorporation language contained filing xbrl information filed herewith certain confidential portions exhibit omitted means marking portions asterisk mark exhibit filed separately secretary sec without mark pursuant registrant 's application requesting confidential treatment rule b securities exchange act amended gilead sciences inc consolidated financial statements years ended december contents report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements comprehensive income consolidated statements stockholders ' equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm board directors stockholders gilead sciences inc audited accompanying consolidated balance sheets gilead sciences inc december related consolidated statements income comprehensive income stockholders ' equity cash flows three years period ended december audits also included financial statement schedule listed index item financial statements schedule responsibility company 's management responsibility express opinion financial statements schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statements referred present fairly material respects consolidated financial position gilead sciences inc december consolidated results operations cash flows three years period ended december conformity us generally accepted accounting principles also opinion related financial statement schedule considered relation basic financial statements taken whole presents fairly material respects information set forth therein also audited accordance standards public company accounting oversight board united states gilead sciences inc 's internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion thereon ernst young llp redwood city california february gilead sciences inc consolidated balance sheets thousands except per share amounts december assets current assets cash cash equivalents shortterm marketable securities accounts receivable net allowances december respectively inventories deferred tax assets prepaid taxes prepaid expenses current assets total current assets property plant equipment net longterm portion prepaid royalties longterm deferred tax assets longterm marketable securities intangible assets net goodwill longterm assets total assets liabilities stockholders equity current liabilities accounts payable accrued government rebates accrued compensation employee benefits income taxes payable accrued liabilities deferred revenues current portion longterm debt obligations net total current liabilities longterm deferred revenues longterm debt net longterm income taxes payable longterm obligations commitments contingencies note stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share shares authorized shares issued outstanding december respectively additional paidin capital accumulated comprehensive income loss retained earnings total gilead stockholders equity noncontrolling interest total stockholders equity total liabilities stockholders equity number shares periods presented reflects twoforone stock split form stock dividend declared december took effect january see accompanying notes gilead sciences inc consolidated statements income thousands except per share amounts year ended december revenues product sales royalty revenues contract revenues total revenues costs expenses cost goods sold research development expenses selling general administrative expenses total costs expenses income operations interest expense income expense net income provision income taxes provision income taxes net income net loss attributable noncontrolling interest net income attributable gilead net income per share attributable gilead common stockholdersbasic shares used per share calculationbasic net income per share attributable gilead common stockholdersdiluted shares used per share calculationdiluted net income per share number shares used per share calculations periods presented reflect twoforone stock split form stock dividend declared december took effect january see accompanying notes gilead sciences inc consolidated statements comprehensive income thousands year ended december net income comprehensive income loss net foreign currency translation gain loss availableforsale securities net unrealized gain loss net tax impact year ended december respectively reclassifications net income net tax impact year ended december respectively net change cash flow hedges net unrealized gain loss net tax impact year ended december respectively reclassification net income net tax impact year ended december respectively net change comprehensive income loss comprehensive income comprehensive loss attributable noncontrolling interest comprehensive income attributable gilead see accompanying notes gilead sciences inc consolidated statements stockholders ' equity thousands gilead stockholders ' equity common stock accumulated additional total paidin comprehensive retained noncontrolling stockholders ' shares amount capital income loss earnings interest equity balance december contributions noncontrolling interest net income loss comprehensive income net tax issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans stockbased compensation purchases convertible note hedges sale warrants deferred tax assets convertible note hedges equity portion convertible notes net issuance costs repurchases common stock balance december distributions noncontrolling interest net income loss comprehensive income net tax issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans stockbased compensation repurchases common stock balance december contributions noncontrolling interest net income loss comprehensive loss net tax issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans stockbased compensation repurchases common stock balance december common stock shares periods presented reflect twoforone stock split form stock dividend declared december took effect january see accompanying notes gilead sciences inc consolidated statements cash flows thousands year ended december operating activities net income adjustments reconcile net income net cash provided operating activities depreciation expense amortization expense stockbased compensation expense inprocess research development impairment charges excess tax benefits stockbased compensation tax benefits employee stock plans deferred income taxes changes operating assets liabilities accounts receivable net inventories prepaid expenses assets accounts payable income taxes payable accrued liabilities deferred revenues net cash provided operating activities investing activities purchases marketable securities proceeds sales marketable securities proceeds maturities marketable securities purchases investments acquisitions net cash acquired capital expenditures net cash provided used investing activities financing activities proceeds debt financing net issuance costs proceeds convertible note hedges proceeds sale warrants proceeds issuances common stock purchases convertible note hedges repurchases common stock repayments debt financing repayments longterm obligations excess tax benefits stockbased compensation contributions distributions noncontrolling interest net cash provided used financing activities effect exchange rate changes cash net change cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period supplemental disclosure cash flow information interest paid net amounts capitalized income taxes paid see accompanying notes gilead sciences inc notes consolidated financial statements organization summary significant accounting policies overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery experimental drug candidate seek improve care patients suffering lifethreatening diseases around world gilead 's primary areas focus include human immunodeficiency virus hiv liver diseases hepatitis b virus hbv hepatitis c virus hcv serious cardiovascular respiratory conditions various oncologyinflammation continue add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategy product portfolio comprised atripla truvada viread compleraeviplera stribild hepsera emtriva letairis ranexa ambisome cayston vistide us international commercial sales operations marketing subsidiaries north america europe asia addition also sell distribute certain products corporate partners royaltypaying collaborative agreements basis presentation accompanying consolidated financial statements include accounts gilead whollyowned subsidiaries joint ventures bristolmyers squibb company bms primary beneficiary record noncontrolling interest consolidated financial statements reflect bms 's interest joint ventures intercompany transactions eliminated consolidated financial statements include results companies acquired us date acquisition applicable reporting periods january completed twoforone stock split form stock dividend stockholders record january declared december accordingly share per share amounts periods presented consolidated financial statements notes adjusted retroactively reflect stock split additionally certain prior period amounts within consolidated financial statements related notes reclassified conform current presentation significant accounting policies estimates judgments preparation consolidated financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis management evaluates significant accounting policies estimates base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates revenue recognition product sales recognize revenue product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectability reasonably assured upon recognition revenue product sales provisions made government rebates medicaid reimbursements customer incentives cash discounts prompt payment distributor fees expected returns expired products appropriate items deducted gross product sales government rebates estimate reductions revenues governmentmanaged medicaid programs well certain qualifying federal state foreign government programs based contractual terms historical utilization rates new information regarding changes programs ' regulations guidelines would impact amount actual rebates expectations regarding future utilization rates programs us product sales channel inventory data obtained major us wholesalers accordance inventory management agreements government rebates invoiced directly us recorded accrued government rebates consolidated balance sheets qualified programs purchase products wholesalers lower contractual government price wholesalers charge back us difference acquisition cost lower contractual government price record allowances accounts receivable cash discounts estimate cash discounts based contractual terms historical utilization rates expectations regarding future utilization rates distributor fees inventory management agreements significant us wholesalers pay wholesalers fee primarily compliance certain contractually determined covenants maintenance agreed upon inventory levels distributor fees based contractually determined fixed percentage sales product returns provide customers general right product return permit returns product damaged defective received customer case product sold united states certain countries outside united states product expired accept returns product expire within six months expired one year expiration dates estimates expected returns expired products based primarily ongoing analysis historical return patterns royalty revenues royalty revenue sales products generally recognized received generally quarter following quarter corresponding sales occur royalty revenue sales lexiscan ambisome astellas us llc astellas pharma us inc respectively recognized month following month corresponding sales occur contract revenues revenue nonrefundable upfront license fees milestone payments development collaboration obligation supply product recognized performance occurs obligations completed accordance specific terms obligations arrangements revenue recognized obligation fulfilled ratably development manufacturing period revenue associated substantive atrisk milestones recognized based upon achievement milestones set forth respective agreements advance payments received excess amounts earned classified deferred revenue consolidated balance sheets shipping handling costs shipping handling costs incurred inventory purchases product shipments recorded cost goods sold consolidated statements income research development expenses rd expenses consist primarily personnel costs including salaries benefits stockbased compensation clinical studies performed contract research organizations cros materials supplies licenses fees milestone payments collaboration arrangements overhead allocations consisting various support facilitiesrelated costs charge rd costs including clinical study costs expense incurred clinical study costs significant component rd expenses clinical studies performed thirdparty cros monitor levels performance significant contract including extent patient enrollment activities communications cros accrue costs clinical studies performed cros service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cros material cro contracts terminable us upon written notice generally liable actual services completed cro certain noncancelable expenses incurred point termination amounts paid advance related uncompleted services refunded us contract terminated advertising expenses expense costs advertising including promotional expenses incurred advertising expenses million million million net income per share attributable gilead common stockholders following table reconciliation numerator denominator used calculation basic diluted net income per share attributable gilead common stockholders thousands year ended december numerator net income attributable gilead denominator weightedaverage shares common stock outstanding used calculation basic net income per share attributable gilead common stockholders effect dilutive securities stock options equivalents conversion spread related may notes conversion spread related may notes conversion spread related may notes conversion spread related may notes warrants related convertible notes weightedaverage shares common stock outstanding used calculation diluted net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding period diluted net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding dilutive securities outstanding period potential dilutive shares common stock resulting assumed exercise outstanding stock options performance shares assumed exercise warrants relating convertible senior notes due may may notes may may notes may may notes collectively convertible notes determined treasury stock method principal amount convertible notes settled cash conversion spread relating convertible notes included calculation diluted net income per share attributable gilead common stockholders common stock resulting assumed settlement conversion spread convertible notes dilutive effect average market price common stock period exceeds conversion prices may notes may notes may notes respectively convertible senior notes due may may notes matured related warrants expired result considered impact period outstanding net income per share calculations common stock resulting assumed settlement conversion spread may notes dilutive effect average market price common stock period exceeded conversion price average market price common stock exceeded conversion price may notes dilutive effect included accompanying table warrants related may notes dilutive effect average market price common stock period exceeded warrants exercise price average market price common stock exceed exercise price warrants related may notes therefore warrants dilutive effect net income per share periods average market price common stock exceeded conversion price may notes dilutive effects included accompanying table portion may notes converted result considered impact period outstanding average market price common stock exceeded conversion prices may notes may notes dilutive effect included accompanying table average market price common stock exceed conversion prices may notes may notes therefore notes dilutive effect net income per share periods warrants relating may notes may notes may notes dilutive effect average market price common stock period exceeds warrants exercise prices respectively average market price common stock exceeded warrants ' exercise price relating may notes dilutive effect included accompanying table average market price common stock exceed warrants ' exercise prices relating may notes may notes therefore warrants dilutive effect net income per share period average market prices common stock exceed warrants exercise prices relating convertible notes therefore warrants dilutive effect net income per share periods stock options purchase approximately million million million weightedaverage shares common stock outstanding respectively included computation diluted net income per share attributable gilead common stockholders effect antidilutive stockbased compensation sharebased payments employees directors recognized consolidated statements income based fair values benefit tax deductions excess recognized compensation cost reported consolidated statements cash flows financing activity calculated pool excess tax benefits recorded part additional paidin capital apic cash cash equivalents consider highly liquid investments insignificant interest rate risk original maturity three months less purchase date cash equivalents eligible instruments investment policy included cash equivalents include commercial paper money market funds overnight repurchase agreements repos major banks authorized dealers bank obligations marketable nonmarketable securities determine appropriate classification marketable securities consist primarily debt securities variable rate demand obligations time purchase reevaluate designation balance sheet date marketable securities considered availableforsale carried estimated fair values reported either cash equivalents shortterm marketable securities longterm marketable securities unrealized gains losses availableforsale securities excluded net income reported accumulated comprehensive income loss separate component stockholders ' equity income expense net includes interest dividends amortization purchase premiums discounts realized gains losses sales securities otherthantemporary declines fair value securities cost securities sold based specific identification method regularly review investments otherthantemporary declines fair value review includes consideration cause impairment including creditworthiness security issuers number securities unrealized loss position severity duration unrealized losses whether intent sell securities whether likely required sell securities recovery amortized cost basis determine decline fair value investment accounting basis decline otherthantemporary reduce carrying value security hold record loss amount decline result entering collaborations time time may hold investments nonpublic companies record nonmarketable securities cost longterm assets less amounts otherthantemporary impairment regularly review securities indicators impairment investments nonmarketable securities material periods presented concentrations risk subject credit risk portfolio cash equivalents marketable securities investment policy limit amounts invested securities credit rating maturity industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales majority trade accounts receivable arises product sales united states europe received payment million past due accounts receivable customers based spain included amount proceeds onetime factoring arrangement sold receivables carrying value million net allowance doubtful accounts received proceeds million recorded gain million resulting primarily reversal related allowance doubtful accounts gain recorded offset selling general administrative sga expenses consolidated statement income subsequent transaction continuing involvement transferred receivables derecognized time sale december accounts receivable southern europe specifically greece italy portugal spain totaled approximately million million greater days past due million greater days past due date experienced significant losses respect collection accounts receivable believe allowance doubtful accounts adequate december certain raw materials components utilize operations obtained single suppliers certain raw materials utilize operations made one facility since suppliers key components raw materials must named new drug application nda filed us food drug administration fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship commercial products supply product candidates clinical trials accounts receivable trade accounts receivable recorded net allowances wholesaler chargebacks related government rebate programs cash discounts prompt payment sales returns doubtful accounts estimates wholesaler chargebacks government rebates cash discounts sales returns based contractual terms historical trends expectations regarding utilization rates programs estimates allowance doubtful accounts determined based existing contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding geographic region review local economic environment potential impact government funding reimbursement practices historically amounts uncollectible accounts receivable written insignificant consistent management 's expectations inventories inventories recorded lower cost market cost determined firstin firstout basis periodically review composition inventories order identify obsolete slowmoving otherwise unsaleable items unsaleable items observed alternate uses inventory record writedown net realizable value period impairment first recognized future commercialization considered probable future economic benefit expected realized based management 's judgment capitalize prelaunch inventory costs prior regulatory approval number factors taken consideration including current status regulatory approval process potential impediments approval process safety efficacy anticipated research development initiatives could impact indication compound used viability commercialization marketplace trends december amount prelaunch inventory consolidated balance sheets significant property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straight line method repairs maintenance costs expensed incurred estimated useful lives years follows description estimated useful life buildings improvements laboratory manufacturing equipment office computer equipment leasehold improvements shorter useful life lease term office computer equipment includes capitalized software unamortized capitalized software costs million million consolidated balance sheets december respectively leasehold improvements capitalized leased equipment amortized shorter lease term asset 's useful life amortization capitalized leased equipment included depreciation expense capitalized interest construction inprogress included property plant equipment interest capitalized significant goodwill intangible assets goodwill represents excess consideration transferred estimated fair value assets acquired liabilities assumed business combination intangible assets indefinite useful lives related purchased inprocess research development iprd projects measured respective fair values acquisition date amortize goodwill intangible assets indefinite useful lives test goodwill indefinite lived intangible assets impairment annual basis annual tests become aware events changes would indicate reduction fair value assets carrying amounts intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts period assets considered indefinitelived amortized tested impairment annual basis well annual tests become aware events changes would indicate reduction fair value iprd projects respective carrying amounts development complete generally occurs regulatory approval market product obtained associated assets would deemed finitelived would amortized based respective estimated useful lives point time intangible assets finite useful lives amortized estimated useful lives intangible assets finite useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable impairment longlived assets carrying value longlived assets reviewed regular basis existence facts circumstances internally externally may suggest impairment specific potential indicators impairment include significant decrease fair value asset significant change extent manner asset used significant physical change asset significant adverse change legal factors business climate affects value asset adverse action assessment fda another regulator accumulation costs significantly excess amount originally expected acquire construct asset operating cash flow losses combined history operating cash flow losses projection forecast demonstrates continuing losses associated income producing asset indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset asset group eventual disposition carrying amount asset asset group excess carrying value asset asset group estimated fair value recognized impairment loss valuation contingent consideration resulting business combination connection certain acquisitions may required pay future consideration contingent upon achievement specified development regulatory approval salesbased milestone events record contingent consideration resulting business combination fair value acquisition date quarter thereafter revalue obligations record increases decreases fair value rd expense within consolidated statement income time related product candidate receives marketing approval increases decreases fair value contingent consideration liabilities result updates assumptions expected timing probability achieving specified milestones changes projected revenues changes discount rates significant judgment employed determining assumptions acquisition date subsequent period updates assumptions could significant impact results operations given period actual results may differ estimates foreign currency translation transactions contracts operations nonus entities recorded functional currency entity financial reporting purposes functional currency entity currency environment entity primarily generates expends cash results operations nonus dollar functional currency entities translated functional currencies us dollars using average currency rate month approximates results would obtained using actual currency rates dates individual transactions assets liabilities translated using currency rates end period adjustments resulting translating financial statements foreign entities us dollar excluded determination net income recorded component comprehensive income loss separate component stockholders ' equity transaction gains losses recorded income expense net consolidated statements income net transaction losses totaled million million million respectively hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward option contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions limit risk counterparties contracts may unable perform also limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes hedge net investment foreign subsidiaries fair value financial instruments financial instruments consist principally cash cash equivalents marketable securities accounts receivable foreign currency exchange forward option contracts accounts payable shortterm longterm debt cash cash equivalents marketable securities foreign currency exchange contracts hedge accounts receivable forecasted sales reported respective fair values consolidated balance sheets carrying value fair value convertible notes billion billion respectively december carrying value fair value convertible notes billion billion respectively december issued senior unsecured notes due april april notes registered offering aggregate principal amount billion carrying value fair value april notes million billion respectively december carrying value fair value april notes million billion respectively december also issued senior unsecured notes due december december notes december december notes december december notes december december notes aggregate principal amount billion carrying value fair value notes billion billion respectively december carrying value fair value notes billion billion respectively december fair values convertible notes senior unsecured notes determined using level inputs based quoted market values remaining financial instruments reported consolidated balance sheets amounts approximate current fair values income taxes income tax provision computed liability method deferred tax assets liabilities determined based difference financial statement tax basis assets liabilities using enacted tax rates effect year differences expected reverse significant estimates required determining provision income taxes estimates based interpretations existing tax laws regulations various factors may favorable unfavorable effects income tax rate factors include limited interpretations existing tax laws changes tax laws rates portion nontax deductible pharmaceutical excise tax accounting stock options sharebased payments mergers acquisitions future levels rd spending changes accounting standards changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings resolution federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant could negative impact consolidated net income record liabilities related uncertain tax positions accordance guidance clarifies accounting uncertainty income taxes recognized enterprise 's financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return believe uncertain tax positions currently pending material adverse effect consolidated financial statements although adverse resolution one uncertain tax positions period could material impact results operations period recent accounting pronouncement july financial accounting standards board issued new accounting guidance intended simplify testing indefinitelived intangible assets impairment entities allowed option first perform qualitative assessment impairment indefinitelived intangible assets determine whether quantitative assessment necessary guidance effective impairment tests performed interim annual periods fiscal years beginning september early adoption permitted elected early adopt guidance december material impact consolidated financial statements fair value measurements determine fair value financial nonfinancial assets liabilities using fair value hierarchy establishes three levels inputs may used measure fair value follows level inputs include quoted prices active markets identical assets liabilities level inputs include observable inputs level inputs quoted prices similar assets liabilities quoted prices identical similar assets liabilities markets active inputs observable corroborated observable market data substantially full term asset liability marketable securities review trading activity pricing measurement date sufficient quoted pricing identical securities available use market pricing observable market inputs similar securities obtained various thirdparty data providers inputs either represent quoted prices similar assets active markets derived observable market data level inputs include unobservable inputs supported little market activity significant fair value underlying asset liability level assets liabilities include whose fair value measurements determined using pricing models discounted cash flow methodologies similar valuation techniques significant management judgment estimation following table summarizes assets liabilities recorded fair value respective fair value classification level input within fair value hierarchy defined thousands december december level level level total level level level total assets debt securities us treasury securities money market funds certificates deposit us government agencies securities municipal debt securities nonus government securities corporate debt securities residential mortgage asset backed securities student loanbacked securities total debt securities equity securities derivatives liabilities contingent consideration derivatives level inputs estimate fair values government related debt corporate debt residential mortgage assetbacked securities taking consideration valuations obtained thirdparty pricing services pricing services utilize industry standard valuation models including income marketbased approaches significant inputs observable either directly indirectly estimate fair value inputs include reported trades brokerdealer quotes similar securities issuer credit spreads benchmark securities prepaymentdefault projections based historical data observable inputs substantially foreign currency derivatives contracts maturities primarily month time horizon counterparties minimum credit rating equivalent standard poor 's moody 's investors service inc fitch inc estimate fair values contracts taking consideration valuations obtained thirdparty valuation service utilizes incomebased industry standard valuation model significant inputs observable either directly indirectly inputs include foreign currency rates london interbank offered rates libor swap rates inputs applicable commonly quoted intervals level inputs assets measured fair value using level inputs comprised auction rate securities greek bonds within availableforsale investment portfolio policy recognize transfers level classification actual date event change circumstances caused transfer december held assets measured using level inputs following table provides rollforward changes fair value assets measured using level inputs thousands year ended december fair value beginning period total realized unrealized gains losses included income expense net comprehensive income loss net sales marketable securities transfers level fair value end period auction rate securities underlying assets auction rate securities consisted student loans although auction rate securities would typically measured using level inputs failure auctions lack market activity liquidity experienced since beginning required securities measured using level inputs fair value auction rate securities determined using discounted cash flow model considered projected cash flows issuing trusts underlying collateral expected yields projected cash flows estimated based underlying loan principal bonds outstanding payout formulas weightedaverage life cash flows projected considered collateral composition securities related historical projected prepayments third quarter sold remaining portfolio auction rate securities result sale received total proceeds million resulted million loss recognized income expense net consolidated statement income december auction rate securities recorded longterm marketable securities consolidated balance sheets greek government bonds greek government agreed settle majority aged outstanding accounts receivable zerocoupon bonds expected trade discount face value estimated fair value greek zerocoupon bonds using level inputs due current lack market activity liquidity discount rates used fair value model bonds based credit default swap rates march greek government restructured sovereign debt impacted holders greek bonds result recorded million loss related debt restructuring part income expense net consolidated statement income exchanged greek governmentissued bonds new securities liquidated first quarter december greek governmentissued bonds recorded shortterm longterm marketable securities consolidated balance sheet contingent consideration liabilities connection certain acquisitions may required pay future consideration contingent upon achievement specified development regulatory approval salesbased milestone events estimate fair value contingent consideration liabilities acquisition date reporting period thereafter using probabilityweighted income approach reflects probability timing future payments fair value measurement based significant level inputs anticipated timelines probability achieving development regulatory approval salesbased milestone events projected revenues resulting probabilityweighted cash flows discounted using creditrisk adjusted interest rates reporting period thereafter revalue obligations performing review assumptions listed record increases decreases fair value contingent consideration obligations rd expense within consolidated statements income time related product candidate receives marketing approval absence significant changes key assumptions quarterly determination fair values contingent consideration obligations would primarily reflect passage time significant judgment employed determining level inputs fair value measurements acquisition date subsequent period updates assumptions could significant impact results operations given period actual results may differ estimates example significant increases probability achieving milestone projected revenues would result significantly higher fair value measurement significant decreases estimated probability achieving milestone projected revenues would result significantly lower fair value measurement significant increases discount rate anticipated timelines would result significantly lower fair value measurement significant decreases discount rate anticipated timelines would result significantly higher fair value measurement potential contingent consideration payments resulting development regulatory approval based milestones related cgi pharmaceuticals inc cgi calistoga pharmaceuticals acquisitions range payment none milestones achieved estimated maximum million undiscounted accrued million december million december potential future payments resulting acquisition arresto biosciences inc arresto relate royalty obligations future sales specified salesbased milestones achieved following table provides rollforward contingent consideration liabilities recorded part longterm obligations consolidated balance sheets thousands year ended december balance beginning period additions new acquisitions net changes valuation balance end period availableforsale securities following table summary availableforsale debt equity securities recorded cash cash equivalents marketable securities consolidated balance sheets first quarter liquidated portion investment portfolio partially fund acquisition pharmasset inc pharmasset completed january estimated fair values availableforsale securities generally based prices obtained commercial pricing services thousands december december gross gross gross gross amortized unrealized unrealized estimated amortized unrealized unrealized estimated cost gains losses fair value cost gains losses fair value debt securities us treasury securities money market funds certificates deposit us government agencies securities municipal debt securities nonus government securities corporate debt securities residential mortgage assetbacked securities student loan backed securities total debt securities equity securities total following table summarizes classification availableforsale debt equity securities consolidated balance sheets thousands december december cash cash equivalents shortterm marketable securities longterm marketable securities total cash cash equivalents table exclude cash million million december respectively following table summarizes portfolio availableforsale debt securities contractual maturity thousands december december amortized cost fair value amortized cost fair value less one year greater one year less five years greater five years less ten years greater ten years total conform current presentation reclassified billion amortized cost fair value balances december greater ten years less one year contractual maturity following table summarizes gross realized gains losses related sales marketable securities thousands year ended december gross realized gains sales gross realized losses sales cost securities sold determined based specific identification method following table summarizes availableforsale debt securities continuous unrealized loss position deemed otherthan temporarily impaired thousands less months months greater total gross gross gross unrealized estimated unrealized estimated unrealized estimated losses fair value losses fair value losses fair value december debt securities us treasury securities us government agencies securities municipal debt securities nonus government securities corporate debt securities certificates deposit residential mortgage asset backed securities student loanbacked securities total december debt securities us treasury securities us government agencies securities municipal debt securities nonus government securities corporate debt securities certificates deposit residential mortgage asset backed securities student loanbacked securities total december held total securities respectively unrealized loss position based review securities believe otherthantemporary impairments securities december intend sell securities likely required sell securities recovery amortized cost basis derivative financial instruments operate foreign countries exposes us market risk associated foreign currency exchange rate fluctuations us dollar various foreign currencies significant euro order manage risk may hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward option contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions limit risk counterparties contracts may unable perform also limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes hedge net investment foreign subsidiaries hedge exposure foreign currency exchange rate fluctuations certain monetary assets liabilities foreign subsidiaries denominated nonfunctional currency derivative instruments use hedge exposure designated hedges result changes fair value recorded income expense net consolidated statements income hedge exposure foreign currency exchange rate fluctuations forecasted product sales denominated nonfunctional currency derivative instruments use hedge exposure designated cash flow hedges maturity dates months less upon executing hedging contract quarterly thereafter assess prospective hedge effectiveness using regression analysis calculates change cash flow result hedge instrument monthly basis assess retrospective hedge effectiveness using dollar offset approach exclude time value effectiveness testing recognize changes time value hedge income expense net effective component hedge recorded unrealized gain loss hedging instrument accumulated comprehensive income oci within stockholders ' equity hedged forecasted transaction occurs hedge dedesignated unrealized gains losses reclassified product sales majority gains losses related hedged forecasted transactions reported accumulated oci december reclassified product sales within months cash flow effects derivatives contracts three years ended december included within net cash provided operating activities consolidated statements cash flows notional amounts foreign currency exchange contracts outstanding billion billion december respectively following table summarizes information fair values derivative instruments consolidated balance sheets thousands december asset derivatives liability derivatives classification fair value classification fair value derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities total derivatives designated hedges total derivatives december asset derivatives liability derivatives classification fair value classification fair value derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities total derivatives designated hedges total derivatives following table summarizes effect foreign currency exchange contracts consolidated statements income thousands year ended december derivatives designated hedges net gains losses recognized oci effective portion net gains losses reclassified accumulated oci product sales effective portion gains losses recognized income expense net ineffective portion amounts excluded effectiveness testing derivatives designated hedges net gains losses recognized income expense net material amounts recorded income expense net years ended december result discontinuance cash flow hedges balance accumulated comprehensive income loss net taxes reported consolidated balance sheets consists following components thousands december net unrealized gain loss availableforsale securities net unrealized gain loss cash flow hedges cumulative foreign currency translation adjustment accumulated comprehensive income loss acquisitions pharmasset inc january completed acquisition pharmasset publiclyheld clinicalstage pharmaceutical company committed discovering developing commercializing novel drugs treat viral infections pharmasset 's primary focus development oral therapeutics treatment hcv infection pharmasset 's lead compound known sofosbuvir formally referred gs nucleotide analog january evaluated phase phase clinical studies treatment hcv infection across genotypes believe acquisition pharmasset provides us opportunity complement existing hcv portfolio helps advance effort develop alloral regimens treatment hcv acquired outstanding shares common stock pharmasset per share cash tender offer subsequent merger terms agreement plan merger entered november aggregate cash payment acquire outstanding shares common stock billion financed transaction approximately billion cash hand billion senior unsecured notes issued december billion bank debt issued january pharmasset acquisition accounted business combination results operations pharmasset included consolidated statement income since january date acquired approximately outstanding shares common stock pharmasset cash consideration transferred result obtained effective control pharmasset acquisition completed january time pharmasset became whollyowned subsidiary gilead integrated operations track earnings results product candidate therapeutic area maintain separate earnings results acquired pharmasset business following table summarizes components cash paid acquire pharmasset thousands total consideration transferred stockbased compensation expense total cash paid billion cash payment consisted billion cash payment outstanding common stockholders well million cash payment option holders pharmasset stock option plans billion cash payment outstanding common stockholders million cash payment vested option holders pharmasset stock option plans accounted consideration transferred remaining million cash payment accounted stockbased compensation expense resulting accelerated vesting pharmasset employee options immediately prior acquisition following table summarizes acquisition date fair values assets acquired liabilities assumed consideration transferred thousands identifiable intangible assets cash cash equivalents assets acquired liabilities assumed net total identifiable net assets goodwill total consideration transferred identifiable intangible assets acquired intangible assets primarily comprised sofosbuvir iprd compound estimated fair value billion date acquisition fair value asset determined using probabilityweighted income approach discounts expected future cash flows present value estimated net cash flows discounted using discount rate based estimated weightedaverage cost capital companies profiles similar pharmasset rate comparable estimated internal rate return acquisition represents rate market participants would use value intangible asset projected cash flow sofosbuvir based key assumptions estimates revenues operating profits related project considering stage development acquisition date time resources needed complete development approval product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing product candidate obtaining marketing approval fda regulatory agencies risks related viability potential alternative treatments future target markets intangible assets related iprd projects considered indefinitelived assets completion abandonment associated rd efforts goodwill million goodwill represents excess consideration transferred fair values assets acquired liabilities assumed attributable synergies expected combining rd operations pharmasset 's none goodwill expected deductible income tax purposes stockbased compensation expense stockbased compensation expense recognized accelerated vesting employee options immediately prior acquisition reported consolidated statement income follows thousands year ended december research development expense selling general administrative expense total stockbased compensation expense costs costs incurred connection acquisition include thousands year ended december transaction costs eg investment advisory legal accounting fees bridge financing costs restructuring costs total costs following table summarizes costs line item consolidated statement income costs recognized thousands year ended december research development expense selling general administrative expense interest expense total costs pro forma information following unaudited pro forma information presents combined results operations gilead pharmasset acquisition pharmasset completed january adjustments give effect pro forma events directly attributable acquisition unaudited pro forma results reflect operating efficiencies potential cost savings may result consolidation operations gilead pharmasset accordingly unaudited pro forma results presented informational purposes necessarily indicative actual results operations combined company would acquisition occurred beginning period presented indicative future results operations thousands year ended december total revenues net income attributable gilead unaudited pro forma consolidated results include nonrecurring pro forma adjustments assume acquisition occurred january stock based compensation expenses million incurred included net income attributable gilead year ended december costs million incurred year ended december included net income attributable gilead year ended december calistoga pharmaceuticals inc february entered agreement acquire calistoga million plus potential payments million based achievement certain milestones transaction closed april time calistoga became whollyowned subsidiary calistoga privatelyheld biotechnology company based seattle washington focused development medicines treat cancer inflammatory diseases acquisition provided us portfolio proprietary compounds selectively target isoforms phosphoinositide kinase pik lead product candidate idelalisib formerly referred gs firstinclass specific inhibitor pik delta isoform pik delta preferentially expressed leukocytes involved variety inflammatory autoimmune diseases hematological cancers acquisition accounted business combination calistoga 's results operations since april included consolidated statement income significant acquisitiondate fair value total consideration transferred acquire calistoga million consisted cash paid prior closing million contingent consideration million following table summarizes fair values assets acquired liabilities assumed april thousands iprd net liabilities assumed total identifiable assets goodwill total consideration transferred iprd intangible assets associated iprd projects relate idelalisib product candidate management determined estimated acquisitiondate fair value intangible assets related iprd million estimated fair value determined using income approach discounts expected future cash flows present value estimated fair value using present value discount rate considers estimated weightedaverage cost capital companies profiles substantially similar calistoga well acquirer 's estimated weightedaverage cost capital believe appropriate given unique characteristics acquisition included competitive bidding process rate comparable estimated internal rate return acquisition represents rate market participants would use value intangible assets projected cash flows iprd projects based key assumptions estimates revenues operating profits related project considering stage development acquisition date time resources needed complete development approval product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing product candidate obtaining marketing approval fda regulatory agencies risks related viability potential alternative treatments future target markets intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts goodwill excess consideration transferred fair values assigned assets acquired liabilities assumed million represents goodwill amount resulting calistoga acquisition management believes goodwill mainly represents synergies expected combining rd operations well acquiring calistoga 's assembled workforce intangible assets qualify separate recognition consider calistoga acquisition material business combination therefore disclosed pro forma results operations required material business combinations arresto biosciences inc december entered agreement acquire arresto million plus potential future payments based achievement certain sales targets transaction closed january time arresto became whollyowned subsidiary arresto privatelyheld developmentstage biotechnology company based palo alto california focused developing antibodies potential treatment fibrotic diseases cancer lead product acquisition arresto simtuzumab formerly referred gs humanized monoclonal antibody mab targeting human lysyl oxidaselike loxl protein addition ongoing phase study simtuzumab patients advanced solid tumors time acquisition phase study also initiated evaluate simtuzumab patients idiopathic pulmonary fibrosis acquisition accounted business combination arresto 's results operations since january included consolidated statement income significant acquisitiondate fair value total consideration transferred acquire arresto million consisted cash paid prior closing million contingent consideration million following table summarizes fair values assets acquired liabilities assumed january thousands iprd deferred tax assets deferred tax liabilities net liabilities assumed total identifiable net assets goodwill total consideration transferred iprd intangible assets associated iprd projects relate simtuzumab product candidate management determined estimated acquisitiondate fair value intangible assets related iprd million estimated fair value determined using income approach discounts expected future cash flows present value estimated fair value using present value discount rate based estimated weightedaverage cost capital companies profiles substantially similar arresto comparable estimated internal rate return acquisition represents rate market participants would use value intangible assets projected cash flows iprd projects based key assumptions estimates revenues operating profits related project considering stage development acquisition date time resources needed complete development approval product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing product candidate obtaining marketing approval fda regulatory agencies risks related viability potential alternative treatments future target markets intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts goodwill excess consideration transferred fair values assigned assets acquired liabilities assumed million represents goodwill amount resulting arresto acquisition management believes goodwill mainly represents synergies expected combining rd operations well acquiring arresto 's assembled workforce intangible assets qualify separate recognition consider arresto acquisition material business combination therefore disclosed pro forma results operations required material business combinations cgi pharmaceuticals inc june entered agreement acquire cgi million cash consisting million upfront payment million contingent consideration payable based achievement clinical development milestones transaction closed july time cgi became whollyowned subsidiary cgi privatelyheld development stage pharmaceutical company based branford connecticut primarily focused small molecule chemistry protein kinase biology lead preclinical compound cgi 's library proprietary small molecule kinase inhibitors targets spleen tyrosine kinase syk could unique applications treatment serious inflammatory diseases including rheumatoid arthritis cgi acquisition accounted business combination results operations cgi since july included consolidated statements income significant acquisitiondate fair value total consideration transferred acquire cgi million consisted cash paid prior closing million contingent consideration million following table summarizes fair values assets acquired liabilities assumed july thousands iprd deferred tax assets deferred tax liabilities net liabilities assumed total identifiable net assets goodwill total consideration transferred iprd intangible assets associated iprd projects relate preclinical syk product candidate management estimated acquisitiondate fair value intangible assets related iprd million estimated fair value determined using income approach discounts expected future cash flows present value estimated fair value using present value discount rate based estimated weightedaverage cost capital companies profiles substantially similar cgi comparable estimated internal rate return cgi 's operations represents rate market participants would use value intangible assets projected cash flows iprd project based key assumptions estimates revenues operating profits related project considering stage development time resources needed complete development approval product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing drug compound obtaining marketing approval fda regulatory agencies risks related viability potential alternative treatments future target markets intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts fourth quarter recorded million impairment charges rd expense related syk iprd asset acquired cgi impairment charges result changes anticipated market share related syk compound goodwill excess consideration transferred fair values assigned assets acquired liabilities assumed million represents goodwill amount resulting cgi acquisition management believes goodwill mainly represents synergies expected combining rd operations well acquiring cgi 's assembled workforce intangible assets qualify separate recognition inventories inventories summarized follows thousands december raw materials work process finished goods total december joint ventures formed gilead bms see note included consolidated financial statements held billion million inventory respectively efavirenz active pharmaceutical ingredient purchased bms bms 's estimated net selling price efavirenz property plant equipment property plant equipment summarized follows thousands december property plant equipment net buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment capitalized leased equipment construction progress subtotal less accumulated depreciation amortization including relating capitalized leased equipment respectively subtotal land total november acquired land office building totaling approximately square feet located foster city california aggregate purchase price million construction progress increased million compared due primarily new lab building expected completed intangible assets goodwill following table summarizes carrying amount intangible assets goodwill thousands december indefinitelived intangible assets finitelived intangible assets total intangible assets goodwill total intangible assets goodwill indefinitelived intangible assets december indefinitelived intangible assets billion consisted primarily purchased iprd acquisition pharmasset see note december indefinitelived intangible assets million consisted million million purchased iprd acquisitions arresto calistoga respectively using probabilityweighted income approach estimate current fair value recorded million impairment charges related certain iprd assets acquired cgi impairment charges result changes anticipated market share related syk compound included rd expense consolidated statement income million purchased iprd project cv therapeutics inc completed reclassified finitelived intangible asset currently amortized estimated useful life finitelived intangible assets following table summarizes finitelived intangible assets thousands december december gross carrying accumulated gross carrying accumulated amount amortization amount amortization intangible asset ranexa intangible asset lexiscan total amortization expense related finitelived intangible assets included cost goods sold consolidated statement income totaled million million million years ended december respectively weightedaverage amortization period intangible assets approximately years december estimated future amortization expense associated intangible assets five succeeding fiscal years follows thousands fiscal year amount total goodwill following table summarizes changes carrying amount goodwill thousands balance december goodwill resulting acquisition pharmasset balance december collaborative arrangements time time result entering strategic collaborations may hold investments nonpublic companies review interests investee companies consolidation andor appropriate disclosure based applicable guidance variable interest entities vies may required consolidate entity contractual terms arrangement essentially provide us control entity even majority voting interest assess whether primary beneficiary vie based power direct activities vie significantly impact vie 's economic performance obligation absorb losses right receive benefits vie could potentially significant vie december determined certain investee companies vies however respect joint ventures bms primary beneficiary therefore consolidate investees bristolmyers squibb company north america entered collaboration arrangement bms united states develop commercialize single tablet regimen containing truvada bms 's sustiva efavirenz combination approved use united states sold brand name atripla bms structured collaboration joint venture operates limited liability company named bristolmyers squibb gilead sciences llc consolidate terms collaboration bms granted royalty free sublicenses joint venture use respective company owned technologies return granted license joint venture use intellectual property results collaboration bms amended joint venture 's collaboration agreement allow joint venture sell atripla canada economic interests joint venture held us bms including share revenues outofpocket expenses based portion net selling price atripla attributable efavirenz truvada since net selling price truvada may change time relative net selling price efavirenz bms 's respective economic interests joint venture may vary annually bms shared marketing sales efforts since second quarter except limited number activities jointly managed parties longer coordinate detailing promotional activities united states parties begun reduce joint promotional efforts since launched complera august stribild august parties continue collaborate activities manufacturing regulatory compliance pharmacovigilance daily operations joint venture governed four primary joint committees formed bms gilead responsible accounting financial reporting tax reporting manufacturing product distribution joint venture parties provide respective bulk active pharmaceutical ingredients joint venture approximate market values agreement continue terminated mutual agreement parties addition either party may terminate party 's participation collaboration within days launch least one generic version party 's single agent products double agent products nonterminating party right continue sell atripla obligated pay terminating party certain royalties threeyear period following effective date termination december joint venture held efavirenz active pharmaceutical ingredient purchased bms bms 's estimated net selling price efavirenz us market amounts included inventories consolidated balance sheets december total assets held joint venture billion consisted primarily cash cash equivalents million accounts receivable million inventories billion total liabilities billion consisted primarily accounts payable million accrued expenses million december total assets held joint venture billion consisted primarily cash cash equivalents million accounts receivable million inventories billion total liabilities billion consisted primarily accounts payable million accrued expenses million asset liability amounts reflect impact intercompany eliminations included consolidated balance sheets although consolidate joint venture legal structure joint venture limits recourse creditors general credit assets similarly assets held joint venture used settle obligations joint venture europe gilead sciences limited whollyowned subsidiary ireland bms entered collaboration agreement bms sets forth terms conditions bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory parties formed limited liability company consolidate manufacture atripla distribution european territory using efavirenz purchases bms bms 's estimated net selling price efavirenz european territory responsible product distribution inventory management warehousing local subsidiaries primary responsibility order fulfillment collection receivables customer relations handling sales returns territories bms promote atripla general parties share revenues outofpocket expenses proportion net selling prices components atripla truvada efavirenz starting first quarter except limited number activities jointly managed parties longer coordinate detailing promotional activities region responsible accounting financial reporting tax reporting collaboration december efavirenz purchased bms bms 's estimated net selling price efavirenz european territory included inventories consolidated balance sheets parties also formed limited liability company hold marketing authorization atripla europe primary responsibility regulatory activities major market countries parties agreed independently continue use commercially reasonable efforts promote atripla roche tamiflu entered development license agreement agreement roche develop commercialize therapies treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codeveloped us roche agreement roche exclusive right obligation manufacture sell tamiflu worldwide subject obligation pay us percentage net revenues roche generates tamiflu sales turn subject reduction certain defined manufacturing costs entered first amendment supplement agreement roche amended agreement provided formation joint manufacturing committee review roche 's manufacturing capacity tamiflu global plans manufacturing tamiflu us commercial committee evaluate commercial plans strategies tamiflu united states joint supervisory committee evaluate roche 's overall commercial plans tamiflu global basis case consisting representatives roche us amended agreement also option provide specialized sales force supplement roche 's marketing efforts united states tamiflu exercised date agreement roche 's obligation pay royalties us terminate countrybycountry basis patents providing exclusivity tamiflu countries expire roche may terminate agreement reason case rights tamiflu would revert us either party may terminate agreement response material breach party royalties payable us net sales tamiflu sold roche remain amended agreement follows first million worldwide net sales given calendar year b next million worldwide net sales calendar year c worldwide net sales excess million calendar year amended agreement revised provision agreement relating calculation royalty payments given calendar quarter roche pay royalties based actual royalty rates applicable quarter addition amended agreement royalties payable roche us longer subject cost goods sold adjustment provided agreement recorded total million million million tamiflu royalties respectively ranexa result acquisition cv therapeutics assumed rights agreement cv therapeutics roche exclusive worldwide license ranexa license agreement paid initial license fee obligated make certain payments roche upon receipt first second product approvals ranexa following major market countries france germany italy united states united kingdom received fda approval ranexa treatment chronic angina paid million roche accordance agreement received marketing authorization european medicines agency ema ranexa treatment chronic angina european union member states paid million roche related approval amount capitalized longterm asset consolidated balance sheet amortized useful us patent life approximately years expiring entered amendment agreement roche related ranexa amendment provided us exclusive worldwide commercial rights ranexa potential indications humans terms amendment made upfront payment roche obligated make royalty payments roche worldwide net product sales licensed products addition obligated make additional milestone payments upon achievement certain regulatory approvals japan tobacco inc japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco retained rights agreement responsible seeking regulatory approval territories required use diligent efforts commercialize product treatment hiv infection bear costs expenses associated commercialization efforts terms agreement incurred upfront license fee million included rd expenses future alternative use technology recorded million rd expenses related milestone incurred result dosing first patient phase clinical study recorded million rd expenses related milestone paid related dosing first patient phase clinical study december announced submitted marketing authorization application ema marketing approval stribild oncedaily single tablet regimen elvitegravir cobicistat tenofovir disoproxil fumarate emtricitabine recorded million rd expenses december related milestones incurred connection filings obligated make additional payments upon achievement milestones well pay royalties future product sales arising collaboration august capitalized million related milestone incurred connection fda approval stribild amortized useful us patent life approximately years expiring janssen rd ireland entered license collaboration agreement janssen rd ireland janssen formerly tibotec pharmaceuticals develop commercialize fixeddose combination truvada janssen 's nonnucleoside reverse transcriptase inhibitor rilpivirine combination approved united states european union sold trade name complera united states eviplera european union license collaboration agreement janssen granted exclusive license compleraeviplera administration adults oncedaily oral dosage form worldwide excluding certain middle income developing world countries japan neither party restricted combining drug products drugs accordance terms agreement obligated reimburse million approximately million development costs incurred janssen rilpivirine december recorded million approximately million million approximately million respectively reimbursable rd expenses incurred janssen development rilpivirine reimbursable rd expenses incurred janssen responsible manufacturing compleraeviplera lead role registration distribution commercialization combination product licensed countries janssen exercised right codetail combination product countries gilead selling party amended agreement include distribution compleraeviplera rest world right distribute product north america europe latin america except argentina mexico australia new zealand janssen right distribute product regions including japan russia price combination product sum prices truvada rilpivirine components cost rilpivirine purchased us janssen combination product approximates market price rilpivirine less specified percentage major markets longterm obligations financing arrangements following table summarizes carrying amount borrowings various financing arrangements thousands interest december type borrowing description issue date due date rate convertible senior may notes april may convertible senior may notes july may convertible senior may notes july may senior unsecured april notes march april senior unsecured december notes december december senior unsecured december notes december december senior unsecured december notes december december senior unsecured december notes december december credit facility fiveyear revolver january january variable total debt net less current portion total longterm debt net may convertible senior notes april issued million may notes private placement pursuant rule securities act amended portion may notes converted repaid million principal balance also paid million cash related conversion spread may notes represents conversion value excess principal amount received million cash convertible note hedges related may notes may notes issued par bear interest rates debt issuance costs million recorded longterm assets amortized interest expense contractual terms may notes initial conversion rate may notes shares per principal amount may notes represents initial conversion price approximately per share conversion rates subject customary antidilution adjustments may notes may converted subject adjustment following circumstances calendar quarter beginning september closing price common stock least trading days last consecutive trading day period previous quarter applicable conversion price per share make specified distributions holders common stock specified corporate transactions occur last month prior maturity applicable notes upon conversion holder would receive amount cash equal lesser principal amount note ii conversion value note conversion value exceeds principal amount may also deliver option cash common stock combination cash common stock conversion value excess principal amount may notes converted connection change control may required provide make whole premium form increase conversion rate subject stated maximum amount addition event change control holders may require us purchase portion notes purchase price equal principal amount plus accrued unpaid interest december ifconverted value may notes would exceed principal amount notes million concurrent issuance may notes purchased convertible note hedges private transactions cost million tax deductible life notes also sold warrants private transactions acquire million shares common stock received net proceeds million sale warrants convertible note hedges warrants intended reduce potential economic dilution upon future conversions notes effectively increasing conversion price per share may notes net cost million convertible note hedge warrant transactions recorded stockholders ' equity consolidated balance sheets addition contracts classified stockholders equity indexed common stock accounted derivatives convertible note hedges cover subject customary antidilution adjustments million shares common stock strike prices initially correspond initial conversion price may notes subject adjustments similar applicable conversion price related notes market value per share common stock time conversion may notes strike price applicable convertible note hedges entitled receive counterparties transactions shares common stock extent made corresponding election respect related convertible notes cash combination cash shares common stock option excess market value common stock strike price convertible note hedges convertible note hedges terminate upon maturity may notes none may notes remain outstanding due conversion otherwise million shares common stock underlying warrants subject customary antidilution adjustments warrants strike price per share exercisable expiration dates market value common stock time exercise applicable warrants exceeds strike prices required net settle cash shares common stock option counterparties value warrants excess warrant strike prices contemporaneously closing sale may notes portion net proceeds notes issuance proceeds warrant transactions used repurchase shares common stock current accounting guidance bifurcated conversion option may notes debt instrument classified conversion option equity accreting resulting debt discount interest expense contractual terms may notes following table summarizes information equity liability components may notes thousands carrying value net carrying amount unamortized discount equity component liability component liability component december december december may convertible senior notes years ended december recognized million million million respectively interest expense related contractual coupon rates amortization debt discount may notes effective interest rates liability components may notes may convertible senior notes july issued billion may notes billion may notes private placement pursuant rule securities act amended may notes may notes issued par bear interest rates respectively debt issuance costs million recorded longterm assets amortized interest expense contractual terms may notes may notes aggregate principal amount may notes may notes sold reflects full exercise initial purchasers option purchase additional notes cover overallotments initial conversion rate may notes shares per principal amount represents initial conversion price approximately per share initial conversion rate may notes shares per principal amount represents initial conversion price approximately per share conversion rates subject customary antidilution adjustments may notes may notes may converted prior april april respectively following circumstances calendar quarter commencing september closing price common stock least trading days whether consecutive period consecutive trading days ending last trading day preceding calendar quarter greater applicable conversion price applicable trading day five business day period measurement period ten consecutive trading days trading day period trading price per principal amount notes less product last reported sale price common stock applicable conversion rate trading day upon occurrence specified corporate transactions distribution certain stock rights cash amounts assets shareholders occurrence change control april case may notes april case may notes holders may convert notes time regardless foregoing circumstances generally upon conversion holder would receive amount cash equal lesser principal amount note ii conversion value note measured indenture governing relevant notes conversion value exceeds principal amount may also deliver option cash common stock combination cash common stock conversion value excess principal amount may notes may notes converted connection change control may required provide make whole premium form increase conversion rate subject stated maximum amount addition event change control holders may require us purchase portion notes purchase price equal principal amount plus accrued unpaid interest december ifconverted value may notes may notes would exceed principal amounts notes million million respectively concurrent issuance may notes may notes purchased convertible note hedges private transactions cost million tax deductible life notes also sold warrants private transactions acquire million shares common stock received net proceeds million sale warrants convertible note hedges warrants intended reduce potential economic dilution upon future conversions may notes may notes effectively increasing conversion price per share may notes per share may notes net cost million convertible note hedge warrant transactions recorded stockholders ' equity consolidated balance sheets addition contracts classified stockholders equity indexed common stock accounted derivatives convertible note hedges cover subject customary antidilution adjustments million shares common stock strike prices initially correspond initial conversion prices may notes may notes subject adjustments similar applicable conversion price related notes market value per share common stock time conversion may notes may notes strike price applicable convertible note hedges entitled receive counterparties transactions shares common stock extent made corresponding election respect related convertible notes cash combination cash shares common stock option excess market value common stock strike price convertible note hedges convertible note hedges terminate upon maturity may notes may notes none may notes may notes remain outstanding due conversion otherwise million shares common stock underlying warrants subject customary antidilution adjustments warrants strike prices per share warrants expiring per share warrants expiring exercisable respective expiration dates market value common stock time exercise applicable warrants exceeds respective strike prices required net settle cash shares common stock option respective counterparties value warrants excess warrant strike prices used net proceeds issuance convertible notes repurchase shares common stock repay existing indebtedness current accounting guidance bifurcated conversion option may notes may notes debt instrument classified conversion option equity accreting resulting debt discount interest expense contractual terms may notes may notes following table summarizes information equity liability components may notes may notes thousands carrying value net carrying amount unamortized discount equity component liability component liability component december december december may convertible senior notes may convertible senior notes total may convertible senior notes years ended december recognized million million million respectively interest expense related contractual coupon rates amortization debt discount may notes may notes effective interest rate liability components may notes may notes respectively april senior unsecured notes march issued april notes registered offering aggregate principal amount billion april notes mature april pay interest fixed annual rate debt issuance costs incurred connection issuance debt totaled approximately million amortized interest expense contractual term april notes years ended december recognized million million respectively interest expense related contractual coupon rates amortization debt discount april notes april notes may redeemed option time time time redemption price equal greater principal amount notes redeemed ii sum determined independent investment banker present values remaining scheduled payments principal interest notes redeemed exclusive interest accrued date redemption discounted redemption date semiannual basis treasury rate plus basis points plus case accrued unpaid interest notes redeemed date redemption time january may redeem notes whole part principal amount notes redeemed plus accrued unpaid interest date redemption addition event occurrence change control downgrade rating april notes investment grade rating standard poor 's ratings services moody 's investors service inc holders may require us purchase portion notes price equal principal amount plus accrued unpaid interest used net proceeds general corporate purposes include repayment existing indebtedness repurchases common stock december senior unsecured notes december issued december notes december notes december notes december notes december notes registered offering million million billion billion respectively aggregate principal amount billion notes mature december pay interest fixed annual rates respectively debt issuance costs incurred connection issuance debt totaled approximately million amortized interest expense contractual term respective notes years ended december recognized million million respectively interest expense related contractual coupon rates amortization debt discount december notes notes may redeemed option time time time redemption price equal greater principal amount notes redeemed ii sum determined independent investment banker present values remaining scheduled payments principal interest notes redeemed exclusive interest accrued date redemption discounted redemption date semiannual basis treasury rate plus basis points case december notes december notes basis points case december notes december notes plus case accrued unpaid interest notes redeemed date redemption time date three months prior maturity date december notes may redeem notes whole part principal amount notes redeemed plus accrued unpaid interest date redemption time date six months prior maturity date december notes may redeem notes whole part principal amount notes redeemed plus accrued unpaid interest date redemption event occurrence change control downgrade rating series notes investment grade rating standard poor 's ratings services moody 's investors service inc holders series notes may require us purchase portion notes series price equal aggregate principal amount notes repurchased plus accrued unpaid interest used net proceeds fund acquisition pharmasset completed january see note credit facilities eligible borrow aggregate billion revolving credit loans amended restated credit agreement entered credit agreement also included subfacility swingline loans letters credit december million letters credit outstanding credit agreement january fully repaid outstanding obligations credit agreement terminated credit agreement january conjunction acquisition pharmasset entered fiveyear billion revolving credit facility credit agreement five year revolving credit agreement million shortterm revolving credit facility credit agreement shortterm revolving credit agreement billion term loan facility term loan credit agreement borrowed million fiveyear revolving credit agreement million shortterm revolving credit agreement billion term loan credit agreement upon close acquisition fully repaid outstanding debt term loan credit agreement shortterm revolving credit agreement time agreements terminated fiveyear revolving credit agreement contains customary representations warranties affirmative negative financial maintenance covenants events default loan bears interest either eurodollar rate plus applicable margin ii base rate plus applicable margin defined credit agreement may reduce commitments may prepay loan whole part time without premium penalty required comply certain covenants credit agreement notes indentures december compliance covenants fiveyear revolving credit agreement inclusive million swing line loan subfacility million letter credit subfacility december million letters credit outstanding fiveyear revolving credit agreement fiveyear revolving credit agreement terminate amounts owed agreement shall due payable january commitments contingencies lease arrangements entered various longterm noncancelable operating leases equipment facilities lease facilities foster city fremont palo alto san dimas california branford connecticut princeton new jersey durham north carolina seattle washington dublin cork areas ireland london area united kingdom also operating leases sales marketing administrative facilities europe canada asia leases expire various dates many leases containing options renew certain facility leases also contain rent escalation clauses significant lease related facility seattle washington expires year term lease provides us three consecutive rights extend term lease contains annual three percent rent escalation clause lease also requires us pay additional amounts operating expenses maintenance also leases three corporate aircraft varying terms renewal options upon expiration lease terms lease expense operating leases approximately million million million years ended december respectively aggregate noncancelable future minimum rental payments operating leases follows thousands thereafter total legal proceedings department justice investigation june received subpoena us attorney 's office northern district california requesting documents related manufacture related quality distribution practices atripla emtriva hepsera letairis truvada viread complera cooperating continue cooperate governmental inquiry estimate possible loss range losses determined litigation generic manufacturers part approval process products fda granted new chemical entity nce exclusivity period manufacturers ' applications approval generic versions product granted generic manufacturers may challenge patents protecting products granted exclusivity one year prior end exclusivity period generic manufacturers sought may continue seek fda approval similar identical drug anda application form typically used manufacturers seeking approval generic drug received notices generic manufacturers submitted andas manufacture generic version atripla truvada viread hepsera ranexa tamiflu united states atripla truvada viread canada expect begin trial generic manufacturers february gilead teva reached agreement principle settle ongoing patent litigation concerning four patents protect tenofovir disoproxil fumarate viread truvada atripla products trial litigation adjourned pending completion activities necessary finalize settlement agreement teva allowed launch generic version viread december settlement agreement must filed federal trade commission department justice review final trial related ten patents associated ranexa scheduled begin april anticipate trial related two patents related hepsera begin mid trial related two patents protecting emtricitabine patent atripla scheduled begin october predict ultimate outcome actions may spend significant resources enforcing defending patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states atripla truvada viread canada could substantially shortened patents covering one products invalidated fda canadian ministry health could approve requests manufacture generic version products united states canada respectively prior expiration date patents sale generic versions products hepsera earlier patent expiration would significant negative effect revenues results operations matters party various legal actions arose ordinary course business believe legal actions material adverse impact consolidated business financial position results operations commitments normal course business enter various firm purchase commitments primarily related active pharmaceutical ingredients certain inventory related items december commitments next five years approximately billion million million million million amounts related active pharmaceutical ingredients represent minimum purchase requirements actual payments purchases related active pharmaceutical ingredients billion billion million years ended december stockholders ' equity stock repurchase programs january board authorized program repurchase common stock amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means completed plan may time board authorized threeyear billion stock repurchase program december repurchased billion common stock may program remaining authorized amount stock repurchases may made program billion spent total billion repurchase retire million shares common stock average purchase price per share january board authorized threeyear billion stock repurchase program initiated purchases program september upon completion may stock repurchase program december repurchased billion common stock january stock repurchase program remaining authorized amount stock repurchases may made plan billion spent total million repurchase retire million shares common stock average purchase price per share use par value method accounting stock repurchases par value method common stock first charged par value shares involved excess cost shares acquired par value allocated apic based estimated average sales price per issued share excess amounts charged retained earnings following table summarizes reduction common stock apic charge retained earnings result stock repurchases millions year ended december reduction common stock apic charge retained earnings preferred stock shares authorized preferred stock issuable series board authorized determine designation powers preferences rights series preferred stock outstanding december rights plan september terminated rights plan equity incentive plan may stockholders approved adopted gilead sciences inc equity incentive plan plan replaced existing equity plans prior plans remaining shares available future grants prior plans transferred plan additionally awards granted prior plans expire otherwise terminate without exercised shares common stock reserved awards added back pool available shares common stock plan plan broad based incentive plan provides grant equitybased awards including stock options restricted stock units restricted stock awards performance awards employees directors consultants plan authorized issue maximum shares fullvalue awards restricted stock restricted stock units performance shares performance units extent settled common stock phantom shares term plan plan authorizes issuance total shares common stock december shares remain available future grant plan stock options plan provides option grants designated either nonqualified incentive stock options prior january granted nonqualified incentive stock options stock options granted january nonqualified stock options plan employee stock options granted prior generally vest five years stock options granted starting generally vest four years options exercisable period exceed contractual term ten years date stock options issued granted prices less fair market value common stock grant date stock option exercises settled common stock plan 's previously authorized available pool shares connection acquisition arresto assumed arresto equity incentive plan arresto plan options issued outstanding arresto plan converted options purchase common stock effective january number converted options purchase common stock significant shares available future grant arresto plan following table summarizes activity stock option plans option grants presented table exercise prices less fair value underlying common stock grant date shares thousands weighted average shares exercise price outstanding december granted assumed forfeited expired exercised outstanding december exercisable end year total intrinsic value options exercised years ended december million million million respectively total fair value stock options vested years ended december million million million respectively weightedaverage grant date fair values stock options granted years ended december per share respectively december number options outstanding expected vest net estimated future option forfeitures weightedaverage exercise price per share aggregate intrinsic value million weightedaverage remaining contractual life years aggregate intrinsic value stock options outstanding stock options exercisable december billion billion respectively december weightedaverage remaining contractual life options outstanding options exercisable years respectively december million unrecognized compensation cost related stock options expected recognized estimated weightedaverage period years performance awards plan grant performancebased restricted stock units vest upon achievement specified market performance goals could include achieving total shareholder return compared predetermined peer group achieving revenue targets performance shares actual number common shares ultimately issued calculated multiplying number performance units payout percentage ranging performance shares vest committee subcommittee board determined specified market performance goals achieved january granted performance shares respectively awards generally vest period three years fair value performance share estimated date grant depending terms award fair value date grant determined based either monte carlo valuation methodology stock price date grant following table summarizes performance shares activity related information thousands except per share amounts weightedaverage grantdate shares fair value per share outstanding december granted vested forfeited outstanding december weightedaverage grant date fair values performance shares per share respectively recognized million million million stockbased compensation expenses respectively related performance shares december million unrecognized compensation costs related performance shares expected recognized estimated weightedaverage period years total fair value performance shares vested years ended december million million million respectively also granted performancebased restricted stock awards certain employees plan vesting awards subject achievement specified individual performance goals date number units granted fair value awards significant restricted stock units grant timebased restricted stock units rsus certain employees part annual employee equity compensation review program well new hire employees nonemployee members board rsus share awards entitle holder receive freely tradable shares common stock upon vesting awards granted prior rsus vest ratably annual basis five years date grant starting january rsus vest four years date grant fair value rsu equal closing price common stock grant date following table summarizes rsu activities related information thousands except per share amounts weightedaverage grantdate shares fair value per share outstanding december granted assumed vested forfeited outstanding december weightedaverage grant date fair values rsus granted years ended december per share respectively total fair value rsus vested years ended december million million million respectively december million unrecognized compensation cost related unvested rsus expected recognized weighted average period years employee stock purchase plan employee stock purchase plan amended international employee stock purchase plan together espp employees purchase shares common stock based percentage compensation subject certain limits purchase price per share equal lower fair market value common stock offering date purchase date espp offers twoyear lookback feature well automatic reset feature provides offering period reset new lowerpriced offering offering price new offering period less current offering period espp purchases settled common stock espp 's previously authorized available pool shares shares issued espp million total shares common stock reserved issuance espp shares available issuance espp december december million unrecognized compensation cost related espp expected recognized estimated weightedaverage period years stockbased compensation following table summarizes stockbased compensation expenses included consolidated statements income thousands year ended december cost goods sold research development expenses selling general administrative expenses stockbased compensation expense included total costs expenses income tax effect stockbased compensation expense net tax years ended december capitalized million million million stockbased compensation costs inventory respectively million million million remained inventory december respectively total stockbased compensation year ended december included million million rd sga expenses respectively related acceleration unvested stock options connection acquisition pharmasset closed first quarter stockbased compensation recognized expense requisite service periods consolidated statements income using graded vesting expense attribution approach unvested stock options granted prior january using straightline expense attribution approach stock options granted adoption new guidance sharebased payments employees directors january stockbased compensation expenses related stock options recognized adoption new guidance based awards ultimately expected vest gross expense reduced estimated forfeitures guidance requires forfeitures estimated time grant revised necessary subsequent periods actual forfeitures differ estimates estimated forfeitures based historical experience prior adoption guidance pro forma information required disclosed included forfeitures occurred result guidance adopted january recognize tax benefit stockbased compensation apic incremental tax benefit realized tax attributes currently available us utilized addition elected account indirect benefits stockbased compensation research tax credit extraterritorial income deduction consolidated statements income rather apic valuation assumptions fair values options granted plan purchases espp estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility expected award life used following assumptions calculate estimated fair value awards year ended december expected volatility stock options espp expected term years stock options espp riskfree interest rate stock options espp expected dividend yield fair value stock options granted calculated using single option approach use blend historical volatility along implied volatility traded options common stock determine expected volatility expected term stockbased awards represents weightedaverage period awards expected remain outstanding estimate weightedaverage expected term based historical cancellation historical exercise data related stock options well contractual term vesting terms awards riskfree interest rate based upon observed interest rates appropriate term stockbased awards dividend yield based history expectation dividend payouts segment information product sales operate one business segment primarily focuses development commercialization human therapeutics life threatening diseases products included one segment majority products similar economic characteristics including nature products production processes type customers distribution methods regulatory environment product sales consist following thousands year ended december antiviral products atripla truvada viread compleraeviplera stribild hepsera emtriva total antiviral products letairis ranexa ambisome products total product sales following table summarizes total revenues external customers collaboration partners geographic region thousands product sales productrelated contract revenue attributed regions based shipto location royalty nonproduct related contract revenue attributed regions based location collaboration partner year ended december revenues united states europe countries total revenues following table summarizes revenues customers individually accounted total revenues percentage total revenues year ended december cardinal health inc mckesson corp amerisourcebergen corp property plant equipment december net book value property plant equipment united states ireland canada million million million respectively comprised approximately total net book value property plant equipment december net book value property plant equipment united states ireland canada million million million respectively comprised approximately total net book value property plant equipment income taxes provision income taxes consists following thousands year ended december federal current deferred state current deferred foreign current deferred provision income taxes foreign pretax income million billion billion respectively cumulative unremitted foreign earnings considered indefinitely reinvested foreign subsidiaries us taxes provided approximately billion billion december respectively residual us tax liability amounts remitted would approximately billion billion december respectively difference provision income taxes amount computed applying us federal statutory income tax rate income provision income taxes follows thousands year ended december income provision income taxes tax federal statutory rate state taxes net federal benefit foreign earnings different rates research credits net unbenefitted stock compensation nondeductible pharmaceutical excise tax provision income taxes deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities follows thousands december deferred tax assets net operating loss carryforwards stockbased compensation reserves accruals currently deductible deferred revenue depreciation related research credit carryforwards net total deferred tax assets valuation allowance valuation allowance total deferred tax assets deferred tax liabilities intangibles unremitted foreign earnings total deferred tax liabilities net deferred tax assets valuation allowance increased million year ended december valuation allowance decreased million year ended december increased million year ended december concluded based standard set forth fasb accounting standards codification related income taxes likely realize benefit deferred tax assets related certain state net operating loss credit carryforwards december us federal net operating loss carryforwards approximately million federal net operating loss carryforwards start expire utilized also federal tax credit carryforwards approximately million start expire utilized addition state net operating loss tax credit carryforwards approximately billion million respectively state net operating loss tax credit carryforwards start expire utilized utilization net operating losses tax credits may subject annual limitation due ownership change limitations provided internal revenue code amended similar state provisions annual limitation may result expiration net operating losses credits utilization file federal state foreign income tax returns many jurisdictions united states abroad federal income tax purposes statute limitations open onwards certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years california income tax purposes statute limitations open onwards income tax returns audited federal state foreign tax authorities currently examination internal revenue service irs tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions december total federal state foreign unrecognized tax benefits million million respectively total unrecognized tax benefits million million december respectively recognized would reduce effective tax rate period recognition continued classify interest penalties related unrecognized tax benefits part income tax provision consolidated statements income december accrued interest penalties related unrecognized tax benefits million million respectively december believe reasonably possible unrecognized tax benefits significantly change next months expect clarification irs tax authorities regarding uncertain tax positions following rollforward total gross unrecognized tax benefit liabilities years ended december thousands december balance beginning period tax positions related current year additions reductions tax positions related prior years additions reductions settlements lapse statute limitations balance end period deferred compensation plans maintain retirement savings plan eligible employees may defer compensation income tax purposes section k internal revenue code gilead plan gilead plan employees may contribute eligible annual compensation subject irs plan limits make matching contributions gilead plan contributed employee 's contributions annual maximum match annual maximum match total matching contribution expense gilead plan years ended december million million million respectively maintain deferred compensation plan directors key employees may defer compensation income tax purposes deferred compensation plan nonqualified deferred compensation plan subject qualification requirements section internal revenue code compensation deferred december subject requirements section internal revenue code plan officers senior grade level employees may contribute annual salaries annual bonus directors may contribute annual retainer fee effective directors may also defer rsu awards amounts deferred participants deposited rabbi trust recorded longterm assets consolidated balance sheets beginning directors may also elect receive portion annual cash retainer phantom shares gives participant right receive amount equal value specified number shares specified period time payable shares common stock fractional shares paid cash established plan administrator december phantom shares outstanding participants elect one several distribution dates events available plan receive deferred compensation payment subsequent events acquisition ym biosciences inc december signed definitive agreement acquire ym biosciences inc ym usd per share cash approximately million transaction completed february time ym became whollyowned subsidiary quarterly results operations unaudited following amounts thousands except per share amounts st quarter nd quarter rd quarter th quarter total revenues gross profit product sales net income net income attributable gilead net income per share attributable gilead common stockholdersbasic net income per share attributable gilead common stockholdersdiluted total revenues gross profit product sales net income net income attributable gilead net income per share attributable gilead common stockholdersbasic net income per share attributable gilead common stockholdersdiluted net income per share periods presented reflect twoforone stock split effective january fourth quarter recorded million impairment charges rd expense related certain iprd assets acquired cgi gilead sciences inc schedule ii valuation qualifying accounts thousands balance beginning additionscharged balance end period expense deductions period year ended december accounts receivable allowances valuation allowances deferred tax assets year ended december accounts receivable allowances valuation allowances deferred tax assets year ended december accounts receivable allowances valuation allowances deferred tax assets allowances doubtful accounts sales returns cash discounts government chargebacks valuation allowance deferred tax assets includes million million december respectively related acquisitions